EP1353915A2 - Therapeutic chroman compounds - Google Patents

Therapeutic chroman compounds

Info

Publication number
EP1353915A2
EP1353915A2 EP02715919A EP02715919A EP1353915A2 EP 1353915 A2 EP1353915 A2 EP 1353915A2 EP 02715919 A EP02715919 A EP 02715919A EP 02715919 A EP02715919 A EP 02715919A EP 1353915 A2 EP1353915 A2 EP 1353915A2
Authority
EP
European Patent Office
Prior art keywords
sep
optionally substituted
piperazin
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02715919A
Other languages
German (de)
French (fr)
Inventor
Marc AstraZeneca Wilmington CHAPDELAINE
Timothy AstraZeneca Wilmington DAVENPORT
Markus Haeberlein
Carey AstraZeneca Wilmington HORCHLER
John AstraZeneca Wilmington MCCAULEY
Edward AstraZeneca Wilmington PIERSON
Daniel Sohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103646A external-priority patent/SE0103646D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1353915A2 publication Critical patent/EP1353915A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.

Description


  



   THERAPEUTIC CHROMAN COMPOUNDS
Field of the Invention
This invention relates to novel 8-amino derivatives, methods for their preparation, pharmaceutical compositions containing them and their use in therapy.



  Background of the Invention
Serotonin (5-HT) has been implicated in many psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. Furthermore serotonin has been implicated in gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. Serotonin receptors have been subdivided into at least 14 subtypes, see Barnes and Sharp,   Neuropharmacology,    1999,38,1083-1152, incorporated herein by reference.



  These various subtypes are responsible for serotonin's action in many pathophysicogical conditions. The   5-HTl    family of receptors has high affinity for serotonin and consists of five related receptors. This family includes the   5-HTiB    and   5-HT1D    receptor subtypes.



  Compounds that interact with the   5-HTl    family are known to have therapeutic potential in the above mentioned disorders and diseases. In particular, compounds that are 5HTIB and   5HTlD    antagonist have been known to be antidepressant and   anxiolytic    agents. Compounds that are   5HTIB    and   5HTlD    agonists have been used in the treatment of migraine.



  Summary of the Invention
Provided herein is a compound having the formula (I):
EMI1.1     
 wherein
   RI is,    at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl,,   thiomethoxy,-NHA,-NA2,-NHC    (=O) A, aminocarbonyl,   -C (=O)    NHA,-C (=O)   NA2,    halogen, hydroxy,-OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;

   
R2 is represented by (i), (ii), (iii), or (iv) below:
EMI2.1     
    - (i) (ii) (iii) (iv)   
R3 is independently at each position represented   by-H,    optionally substituted   Cl 6alkyl,    optionally substituted C2-6alkenyl, optionally substituted   C2-6alkynyl,    optionally substituted
C3 6cycloalkyl or AOH ; n is 2,3   or 4 ;   
P is a heterocyclic ring;   R6    is-H or methyl;
Y is-C (=O) NH-,-C (=O) NA-,-C (=O) N (A)-,-NHC   (=O)-,-C    (=S) NH-, -CH2NH-, -C (=O)-,   -C (=O)    CH2-,-CH2C   (=O)-,-C      (O)-piperazine-,,-NAC      (=O)-,-C    (=S) N   (A)-, CH2NA,   
NACH2 or a 5-membered heterocyclic.



  R7 is a monocyclic or bicyclic aromatic ring or a heterocycle optionally substituted by one or more substituents selected   from R8-R9 and Rl     ; wherein R7 is connected to Y either by a single bond or by a ring fusion ;
R8 is-CH2-,-C   (=O)-,-S02-,-S02NH-,-C    (=O)   NH-,-O-,-S-,-S    (=O)-, a single bond as tether from R7 to R9, or a five membered heterocyclic connected to R7 by either a single bond or by ring fusion;   R9    is optionally substituted heterocycle, optionally substituted aryl, optionally substituted   piperazinyl-Rl    1, optionally substituted morpholinyl-Rl 1 or optionally substituted thiomorpholinyl-or-C (=O)   A    ;

     Rl     is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen,-C (=O)   NH2-,      methylthio,-NHA,-NA2,-NHC    (=O) A, C (=O) NHA, C (=O) NA2, or
OA;
R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9,   -alkyl9,    C (=O) A, C (=O) NH2, C (=O) NHA, C (=O) NA2 or-C (=O) OA; or a pharmaceutically acceptable salt of said compound.



   The term"hydrocarbyl"refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms. 



   The term"alkyl"used alone or as a suffix or prefix, refers to straight or branched chain hydrocarbyl radicals comprising 1 to about 12 carbon atoms.



   The term"alkenyl"refers to straight or branched chain hydrocarbyl radicals having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.



   The   term"alkynyl"refers    to straight or branched chain hydrocarbyl radicals having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.



   The term"cycloalkyl"refers to ring-containing hydrocarbyl radicals comprising at least 3 up to about 12 carbon atoms.



   The term"cycloalkenyl"refers to ring-containing hydrocarbyl radicals having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.



   The   term"cycloalkynyl"refers    to ring-containing hydrocarbyl radicals having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.



   The term"aromatic"refers to hydrocarbyl radicals having one or more polyunsaturated carbon rings having aromatic character, (e.   g.,    4n + 2 delocalized electrons) and comprising 6 up to about 14 carbon atoms.



   The term"aryl"refers to aromatic radicals including both monocyclic aromatic radicals comprising 6 carbon atoms and polycyclic aromatic radicals comprising up to about 14 carbon atoms.



   The term"alkylene"refers to divalent alkyl moieties, wherein said moiety serves to link two structures together.



   The term"heterocycle"or"heterocyclic"or"heterocyclic moiety"refers to ringcontaining monovalent and divalent radicals having one or more heteroatoms, independently selected from N,   O    and S, as part of the ring structure and comprising at least 3 and up to about 20 atoms in the rings preferably 5 and 6 membered rings. Heterocyclic moieties may be saturated or unsaturated, containing one or more double bonds, and heterocyclic moieties may contain more than one ring.



   The term"heteroaryl"refers to heterocyclic monovalent and divalent radicals having aromatic character.



   Heterocyclic moieties include for example monocyclic moieties such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, dioxolane, sulfolan 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3 dioxane, dioxane, homopiperidine, 2,3,4, 7-tetrahydro-1H-azepine homopiperazine, 1,3dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

   In addition heterocyclic moieties include heteroaryl rings such as: pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4   oxadiazolyl.   



  Additionally, heterocyclic moieties encompass polycyclic moieties such as: indole, indoline,   quinoline,    tetrahydroquinoline,   isoquinoline, tetrahydroisoquinoline,    1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, 1,2-benzisoxazole, benzothiophene,   benzoxazole,    benzthiazole, benzimidazole, benztriazole, thioxanthine,   carbazole, carboline, acridine, pyrolizidine, and quinolizidine.   



   In addition to the polycyclic heterocycles described above, heterocyclic moieties include polycyclic heterocyclic moieties wherein the ring fusion between two or more rings comprises more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo [2.2.1] heptane and 7-oxabicyclo [2.2.1] heptane.



   The term"halo"or"halogen"refers to fluorine, chlorine, bromine and iodine radicals.



   The   term"alkoxy"refers    to radicals of the general formula-O-R, wherein R is selected from a hydrocarbyl radical. Alkoxy moieties include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.



   The term amine or amino refers to radicals of the general   formula-NRR',    wherein R and   R'are    independently selected from hydrogen or a hydrocarby radical.



  Detailed Description of the Invention
In a further aspect of the invention, A,   R'and R3,    each independently, as an alkyl, alkenyl, alkynyl and as a cycloalkyl, may optionally be substituted with halogen, nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carboxamido,   amidino,    carbamoyl, mercapto, sulfamoyl,   Cl 4 alkyl, C2 4 alkenyl, C24    alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl,   C1 4    alkoxy, Cl   4 alkanoyl, C14    alkanoyloxy, N- (C1-4 alkyl), N (CI alkyl) 2, Cl alkanoylamino,   (C 1-4    alkanoyl)   2amino, N- (1-4    alkyl) carbamoyl, N,   N- (C14 alkyl) 2carbamoyl, (C  4) S, (CI-4    alkyl) S (O),   (Cl 4alkyl ?    S   (O)    2, (C1-4)

   alkoxycarbonyl, N-(C1-4 alkyl) sulfamoyl,   N, N-CI 4    alkyl) sulfamoyl,   C 1-4 alkylsolfonylamino,    and heterocyclic.



   Examples of optional substituents for aryl and heterocyclic groups, when not otherwise defined, are halogen, nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carboxamido, amidino, carbamoyl, mercapto, sulfamoyl,   CI-4      alkyl, C24    alkenyl,   C24    alkynyl,
   C3-6    cycloalkyl, C3-6 cycloalkenyl,   C14    alkoxy, C1-4 alkanoyl, C1-4 alkanoyloxy, N-(C1-4 alkyl),
 N   (CI4    alkyl) 2,   Cl4    alkanoylamino,   (Cl4 alkanoyl) 2amino, N-(CI4    alkyl) carbamoyl, N, N-(C1-4 alkyl) 2carbamoyl,   (Cl4)      S,    (C1-4 alkyl) S (O), (C1-4alkyl) S   (0)    2,   (CI 4) alkoxycarbonyl, N- (C1-4    alkyl) sulfamoyl, N, N-C1-4 alkyl)

   sulfamoyl, C1-4 alkylsolfonylamino, and heterocyclic.



   A,   Rl and R3 each    independently as an alkyl, alkenyl or alkynyl may be straight or branched, preferably having 1-6 carbon atoms. A,   R'and R3    preferably have 3-6 atoms when each are independently a cyclic alkyl. Other preferable values for A,   Rl and R3    when each are an alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopentyl, neopentyl and cyclohexyl. Preferable values for R1 when R1 is a halogen are fluorine, chlorine, and bromine. Other preferable values for R1 when R1 is at position 6 on the bicyclic ring are methyl, ethyl, ethoxy and methoxy. Preferable values for   R'when R'is    at position 5 on the bicyclic ring are-H, methyl, ethyl and methoxy.

   When   R'is    at position   5-    on the bicyclic ring,   Rl is    more preferably-H. When   Rl is    at position 7-on the bicyclic ring,
 RI is preferably-H.



   R2 is preferably represented by Formula i. Preferably   R2    is represented by formula i, wherein n equals 2. Most preferably R2 is represented by N-methyl piperazinyl.



   R3 is preferably represented by hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl. R3 is most preferably represented by methyl.



   R4 is preferably represented by hydrogen, methyl, ethyl, n-propyl, isopropyl and
   trimethylsilanyl-ethoxymethoxy.    R4 is most preferably represented by methyl.



   R6 is preferably represented by H.



   Y represents a linking group. Y is preferably-C (=O) N (CH3)-, when Y is
   -C (=O)    N (A)-. Y may also be-C (=O)-piperazine. When Y represents a five-membered heterocyclic ring, Y may be represented by, for example, pyrrole, thiophene, furan, imidazole, thiazole, oxazole, pyrazole,   isothiazole,    isoxazole, 1,2,3-triazole, 1,2,3-thiadiazole, 1,2,3 oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole or 1,3,4-oxadiazole.



   More preferably, Y is-C (=O)   NH-.   



   Examples   of R7    that represent monocyclic or bicyclic aromatic ring or a heterocycle include, but are not limited to, phenyl; 1-and 2-naphthyl; 2-, 3-and 4-pyridyl; 2-and 3thienyl; 2-and 3-furyl ; 1-, 2-and 3-pyrrolyl; imidazolyl; thiazolyl; oxazolyl ; pyrazolyl; isothiazolyl; isoxazolyl; 1,2,3-triazolyl; 1,2,3-thiadiazolyl; 1,2,3-oxadiazolyl; 1,2,4-triazolyl; 1,2,4-thiadiazolyl; 1,2,4-oxadiazolyl; 1,3,4-triazolyl; 1,3,4-thiadiazolyl;   1,    3, 4 oxadiazolyl ; quinolyl; isoquinolyl; indolyl; benzothienyl; benzofuryl;   benzimidazolyl    ; benzthiazolyl; benzoxazolyl; or triazinyl.



  R7 may also be represented by the Formula (v):
EMI6.1     
   R7 may    further be represented by the Formula (vi):
EMI6.2     

When the values for R7 are as set forth above,   R8 may    be a single bond as tether,-C (=O)-,   - CH2-,-C (=O)-,-S02-,-S (=O)-,-S-,-O-,-C (=O) NH-,-S02NH-,    or a five membered heterocycle connected to   R    by single bond or by a ring fusion;

   and R9 may represent an aryl, heterocyclic or heteroaryl each independently optionally substituted with halogen, nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl,   C14    alkyl,   C2-4alkenyl, C24 alkynyl, C3-6 cycloalkyl, C3-6    cycloalkenyl, C1-4 alkoxy,   C14    alkanoyl, C1-4 alkanoyloxy,   N- (C14 alkyl),    N   (CI4    alkyl) 2,   C14    alkanoylamino, (C1-4 alkanoyl)2amino, N-(C14alkyl) carbamoyl, N, N-(C1-4)2carbamoyl, C1-4)S, C1-4S (O),   (Cl4alkyl)    S   (=0)    2, (C1-4) alkoxycarbonyl, N- (C1-4 alkyl) sulfamoyl, N, N-C1-4 alkyl) sulfamoyl,   Cl 4 alkylsolfonylamino,    or heterocyclic.

   Preferably R9 is an optionally substituted heterocyclic moiety.



   More preferably R9 represents piperazine, thiomorpholine or morpholine each independently optionally substituted on carbon with at least one substituent selected from A. may be a five membered heterocycle, incorporating at least one heteroatom selected from
N,   O,    or S and it may be connected to R7 by a ring fusion, preferably when   R    is phenyl.



  When   R8    is a single bond as tether,   R9    is preferably methoxy, cyano, a five-membered heterocycle optionally substituted with at least one substituent represented by A or   Rl l for    example compounds represented by the Formulas (vii), (viii) and (ix):
EMI6.3     
 
EMI7.1     
   (viii)   
EMI7.2     

When   R    is represented by a 5-membered heterocyclic comprising N and further when it is connected to   R7    by a ring fusion, R9 is preferably-C (=O) A attached at the nitrogen atom.



   R9 is most preferably-C (=O) CH2CH3.



   When R7 is phenyl or a 6-membered heterocyclic ring,   R9,    is attached via the R8 tether at the 2-, 3-or 4-position of the phenyl or a 6-membered heterocyclic ring. Preferably, R9 is attached via the   R8 tether    at the 3-or 4-position of the phenyl or a 6-membered heterocyclic ring. More preferably, R9 is attached via the R8 tether at the 4 position of the phenyl or a 6 membered heterocyclic ring.



   Rl  may be represented by alkyl or cycloalkyl each independently optionally substituted with halogen, nitro, cyano, hydroxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulfamoyl,   C14 alkyl, C24alkenyl, C24    alkynyl, C3-6 cycloalkyl,   C3-6    cycloalkenyl,
C1-4 alkoxy, C1-4 alkanoyl,   Ci-4    alkanoyloxy, N-(C1-4 alkyl), N   (C-l4    alkyl)   2,      C14    alkanoylamino, (C1-4 alkanoyl) 2amino, N- 4alkyl) carbamoyl, N, N-(C1-4)2carbamoyl, C1-4)S,
 C1-4S(O), (C1-4alkyl) S   (O)    2, (C1-4) alkoxycarbonyl,   N- (C14 alkyl)    sulfamoyl, N, N-C1-4 alkyl) sulfamoyl, C1-4 alkylsulfonylamino, or heterocyclic.

     RIO    is preferably a halogen, preferably chlorine or fluorine, cyano, or-OCH3. When   Rio ils    a halogen it is preferably chlorine or fluorine. When   R7is a phenyl    or 6-membered heteroaromatic ring, Rl  is attached at the 2-, 3-or 4-position of the phenyl or a 6-membered heterocyclic ring.



   Preferably,   Rl     is attached at the 2-or 3-position of the phenyl or a 6-membered heterocyclic ring when R9 is attached via the R8 tether at the 4-position of the phenyl or a 6-membered heterocyclic ring. More preferably,   Rl     is attached at the 3-position of the phenyl or a 6 membered heterocyclic ring when R9 is attached via the   R8    tether at the 4-position of the phenyl or a 6-membered heterocyclic ring. 



   When   R8    is represented by a single bond as tether,   R9    is preferably represented by an optionally substituted heterocyclic, optionally substituted on carbon with at least one substituent selected from A and further substituted on a heteroatom opposite to the heteroatom attached to the tether, with a substituent represented by R11 (see e.

   g., Formulas (vii), (viii) and   (ix)).    The preferred heterocyclic compounds for R8 are piperazine, morpholine, or thiomorpholine    When Rl l represents SO2A    it is preferably represented by an alkylsufonyl, more   preferably-SO2CH3,-S02CH2CH3,    SO2-n-C3H7, SO2-i-C3H7,   S02-n-C4Hlo,-S02-i-C4Hlp,    or  S02-t-C4Hlo.    When   Rl l represent    C (=O) A, it is preferably represented by an alkylcarbonyl more preferably-C (=O) CH3,-C (=O) CH2CH3, C (=O)-n-C4H10, -C   (=O)-i-C4H, o,-C (=O)-t-      C4Hio,    or -C(=O)C3H7.- When R11 is represented by C (=O) NHA or C (=O) NA2 it is preferably an alkyl or dialkyl carbamoyl more preferably C (=O) NCH2CH3, C (=O)   NH-cycloC6HI2,    or
C (=O)

   NH-cycloC5H10, When R11 is represented by C (=O) R9 it is preferably-C (=O)pyrrolidine, or-C (=O)-morpholine. When   Rl l is    represented by   S02NA2    it is preferably   S02N    (CH3)   2,. When R"is    represented by AOH, it is preferably represented by,   CH2CH20H    or-C (=O)   CH2CH20H. Rll may    also be represented by-C (=O)   OC4Hlo.   



   In preferred embodiments, when Y is represented   by-C    (=O) NH:  (a) RI is halogen or methoxy, most preferably fluorine, at the 6th position of the bicyclic ring, and is preferably hydrogen, methyl, ethyl or methoxy at the   5th    position of the bicyclic ring, and is hydrogen at the 7th position on the bicyclic ring ;  (b)   R2    is methyl piperazine;  (c) R6 is hydrogen;  (d)   R    is phenyl substituted with R8-R9  (e)   R8    is a single bond as tether;  (f) R9 is a heterocyclic moiety, preferably morpholine or piperazine attached to R8 by nitrogen and optionally substituted on the other nitrogen (for piperazine) with   Rl 9    or optionally substituted on the oxygen with   R''when R''is morpholine    ;

    (g)   Ri l    is AOH   or-SO2A    wherein A is represented by methyl or ethyl.



   The compounds provided herein are useful in the form as a free base, but may also be provided in the form of a pharmaceutically acceptable salt, and/or in the form of a pharmaceutically acceptable hydrate. For example pharmaceutically acceptable salts of compounds of Formula I, include those derived from mineral acids such as for example: hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, and phosphorous acid. Pharmaceutically acceptable salts may also be developed with organic acids including aliphatic mono and dicarboxylates and aromatic acids.



  Other pharmaceutically-acceptable salts of compounds of the present invention include for example hydrochloride, sulfate, pyrosulfate, bisulfate, bisulfite, nitrate, and phosphate.



   Processes for the manufacture of the compounds of Formula I are provided as further features of the invention. Many of the Compounds described herein can be made by processes known in the chemical arts for the production of structurally analogous compounds.



  Accordingly, the compounds of this invention may be prepared by employing procedures known in the literature starting from known compounds or readily prepared intermediates. For example, the core bicyclic, heterocyclic structure may be made by first preparing a chromone, quinolone or quinoline. For compounds of the present invention that have Y as an amide linker, the compounds are preferably made by the general procedure for amide coupling, that is by coupling an anime with an acid hydrochloride. The amines used in the current invention if not commercially available may be made by known techniques. For example as a first step in the process of making compound of Formula   I,    a nitro compound may be reduced to an amine. The nitro compound may be a nitrophenyl compound.

   The resulting amines may be reacted with an acid hydrochloride
Provided herein is a process for preparation of a precursor compound or use in practicing aspects of the present invention by reacting a compound of Formula   (VIa)    :
EMI9.1     

Vla   (Rl, R2, R3,    and R7 are as defined for Formula I unless otherwise specified and X is represented by 0), with for example a compound represented by::   R'O C CO R'     , wherein R'is represented by alkyl, preferably lower alkyl (e. g.,   Ci-C6)    most preferably methyl or ethyl, to form a precursor compound of Formula   (VIb)    : 
EMI10.1     

RI is preferably fluorine, chlorine, methyl, methoxy, ethoxy or hydrogen. The Halogen is preferably Chlorine or Bromine.

   The reaction may be carried out in the presence of a catalyst such as   tetrabultyammonium    fluoride in THF. The reaction may be stirred for example at room temperature and refluxed with heat.



   Further provided herein is a process for the preparation of a precursor compound comprising hydrolyzing the esters of compound   (VIb)    to form intermediate   (VIc)    :
EMI10.2     
    vlc-   
This reaction may be carried our for example by reacting a compound of Formula (VIb) with a base such as sodium hydroxide (aqueous). Also provided here is a process for the preparation of an intermediate by the cyclization of compound   (VIc)    to form intermediate (VId) 
EMI11.1     

Intermediate compound   (VId)    may be formed by refluxing a compound of Formula (VIc) with a strong acid (e. g.,   H2SO)    and further refluxed with heat and an alkyl alcohol for example R"OH wherein R"is   Cl-C4    alkyl, preferably ethyl.



   In an additional aspect of the invention, a process is provided for the preparation of an intermediate by reacting a compound of Formula   (VId)    with an amine of Ra in the presence of   a    catalyst and a base to form intermediate Formula   (VIe)    :
EMI11.2     

Vle
In a further embodiment of the invention, a compound of Formula   (VId)    is reacted with a catalyst selected from the group consisting of nickel and palladium. Preferably the palladium is provided in the presence of a phosphine ligand for example 2,2'-bis (diphenylphosphino)1,1'-binapthyl. The palladium may be provided as tris (dibenzylideneacetone) dipalladium.



  The base is preferably selected from the group consisting of potassium carbonate, sodium carbonate, cesium carbonate and triethylamine and mixtures thereof.



   Further provided herein is an acid hydrochloride of a compound of Formula   (VIe)    which is intermediate Formula   (VIf)    : 
EMI12.1     

HCI  . Vif
The intermediate Formula   (VIf)    may be formed for example by heating a compound of
Formula (VIe) in the presence of an acid and water (e. g.,   HCL/H20).   



  In another aspect of the invention provided is intermediate Formula   (VIg)    :
EMI12.2     
 
Thus, in another aspect of the invention, a leaving group is added to the carboxylate of a compound of Formula (VIf). L is a leaving group. This intermediate is useful in that the acid is activated to provide an electrophile. L is preferably represented by chlorine in intermediate Formula   (VIg)    which is prepared by reacting a compound of Formula (VIf) with thionyl chloride   (SOC12).   



  Provided herein is a compound of Formula   (VIh)    :
EMI13.1     
   Vlh   
Methods for reacting amines with acid chlorides may be used to prepare compounds of formula I such as a compound of Formula   (VIh)    For example, a method for the preparation of   (VIh)    may include reacting a compound of Formula   (VIg)    with   H2N-R7    in the presence of
DIPEA.



   Alternatively, compounds of Formula   (VIh)    may also be prepared by reacting a compound of Formula   (VIf)    with   H2N-R7    in the presence for example 1hydroxybenzotriazole (HOBT),   O- (1H-Benzotriazol-1-yl)-N, N, N'N'-pentamethylene-    uronium tetrafluorborate (TBTU), and (dimethylamino) pyridine, preferably in that order.



   Compounds of Formulas   (VIe),    (VIf), and   (VIg),    and (VIh) may also comprise a pharmaceutically acceptable salt of said compounds.



   The compounds and processes above may also be used to prepare the chroman derivatives of Formula (I) via the saturation of the double bond (4H-chromene) in the bicyclic compound. Depending on the reduction conditions, the 4-oxo derivative may or may not be obtained.



   Provided herein is a process for preparation of a precursor compound or use in practicing aspects of the present invention by reacting a compound of Formula   (VIa)    :
EMI14.1     

Via   (R',      R2, R3,    and R7 are as defined for Formula I unless otherwise specified and X is represented by 0), with for example a compound represented by::
EMI14.2     
 wherein R'is represented by alkyl, preferably lower alkyl (e. g.,   C-C6)    most preferably methyl or ethyl, to form a precursor compound of Formula (VIb):
EMI14.3     

Vib
RI is preferably fluorine, chlorine, methyl, methoxy, ethoxy or hydrogen. The Halogen is preferably Chlorine or Bromine. The reaction may be carried out in the presence of   a    catalyst such as tetrabultyammonium fluoride in THF.

   The reaction may be stirred for example at room temperature and refluxed with heat.



   Further provided herein is a process for the preparation of a precursor compound comprising hydrolyzing the esters of compound   (VIb)    to form intermediate (VIc) : 
EMI15.1     
    Vlc   
This reaction may be carried our for example by reacting a compound of Formula   (VIb)    with a base such as sodium hydroxide (aqueous).

   Also provided here is a process for the preparation of an intermediate by the cyclization of compound   (VIc)    to form intermediate   (VId)   
EMI15.2     
    Vld   
Intermediate compound   (VId)    may be formed by refluxing a compound of Formula   (VIc)    with a strong acid (e. g.,   H2SO)    and further refluxed with heat and an alkyl alcohol for example R"OH wherein R"is   Cx-C4 alkyl,    preferably ethyl.



   In an additional aspect of the invention, a process is provided for the preparation of an intermediate by reacting a compound of Formula   (VId)    with an amine   of R2    in the presence of a catalyst and a base to form intermediate Formula (VIe) : 
EMI16.1     

In a further embodiment of the invention, a compound of Formula   (VId)    is reacted with a catalyst selected from the group consisting of nickel and palladium. Preferably the palladium is provided in the presence of a phosphine ligand for example 2,2'-bis (diphenylphosphino)1,1'-binapthyl. The palladium may be provided as tris (dibenzylideneacetone) dipalladium.



  The base is preferably selected from the group consisting of potassium carbonate, sodium carbonate, cesium carbonate and triethylamine and mixtures thereof.



   Further provided herein is an acid hydrochloride of a compound of Formula   (VIe)    which is intermediate Formula   (VIf)    :
EMI16.2     
 
The intermediate Formula   (VIf)    may be formed for example by heating a compound of
Formula (VIe) in the presence of an acid and water (e. g., HCL/H20).



  In another aspect of the invention provided is intermediate Formula   (VIg)    :
EMI17.1     
    HCI
Vlg   
Thus, in another aspect of the invention, a leaving group is added to the carboxylate of a compound of Formula (VIf). L is a leaving group. This intermediate is useful in that the acid is activated to provide an electrophile.

   L is preferably represented by chlorine in intermediate Formula (VIg) which is prepared by reacting a compound of Formula (VIf) with thionyl chloride   (SOc12)-   
Provided herein is a compound of Formula   (VIh)    : 
EMI18.1     

Vlh
Methods for reacting amines with acid chlorides may be used to prepare compounds of formula I such as a compound of Formula (VIh) For example, a method for the preparation of   (VIh)    may include reacting a compound of Formula   (VIg)    with   H2N-R7    in the presence of
DIPEA.



   Alternatively, compounds of Formula   (VIh)    may also be prepared by reacting a compound of Formula   (VIf)    with   H2N-R7    in the presence for example   1-    hydroxybenzotriazole (HOBT),   0-      Benzotriazol-1-yl)-N,    N, N'N'-pentamethyleneuronium tetrafluorborate (TBTU), and   (dimethylamino)    pyridine, preferably in that order.



   Compounds of Formulas   (VIe),      (VIf),    and   (VIg),    and   (VIh)    may also comprise a pharmaceutically acceptable salt of said compounds.



   The compounds and processes above may also be used to prepare the chroman derivatives of Formula (I) via the saturation of the double bond (4H-chromene) in the bicyclic compound. Depending on the reduction conditions, the 4-oxo derivative may or may not be obtained.



   A method for preparing the acid hydrochlorides useful in synthesis of a chromone is set forth in Scheme 1 below: A method for preparing the acid hydrochlorides useful in synthesis of a chromone is set forth in Scheme 1 below : 
EMI19.1     


<tb>  <SEP> C R'Cp2R'
<tb>  <SEP> 1
<tb>  <SEP> /OH <SEP> Br <SEP> R <SEP> i
<tb>  <SEP> R <SEP> I"I. <SEP> I <SEP> I
<tb>  <SEP> 3 <SEP> 2 <SEP> 5 <SEP> Hal gen
<tb> Halogen= <SEP> Cl, <SEP> Br <SEP> Halogen
<tb> (R) <SEP> q <SEP> =-OCH3, <SEP> F, <SEP> CH3. <SEP> Cl, <SEP> OEt, <SEP> H. <SEP> Vlb
<tb>  <SEP> Via <SEP> NaOH
<tb>  <SEP> 0
<tb>  <SEP> O'
<tb>  <SEP> 1.

   <SEP> H2SO4
<tb>  <SEP> R'
<tb>  <SEP> 0 <SEP> OEt <SEP> 10"1 <SEP> 1 <SEP> (C02H
<tb>  <SEP> Hal gen <SEP> OHHaI 9 <SEP> n
<tb>  <SEP> Hat S <SEP> 0 <SEP> Hg, <SEP> ogen
<tb>  <SEP> Vld
<tb>  <SEP> Vlc
<tb>  <SEP> (CH2) <SEP> n <SEP> (Or <SEP> precursor <SEP> amines <SEP> for <SEP> (ii) <SEP> or <SEP> (iii)
<tb>  <SEP> 2
<tb>  <SEP> N <SEP> structural <SEP> variations <SEP> of <SEP> R2
<tb>  <SEP> 3
<tb>  <SEP> R
<tb>  <SEP> Pd <SEP> catalyst
<tb>  <SEP> phosphine <SEP> ligand
<tb>  <SEP> cesium <SEP> carbonate
<tb>  <SEP> 0. <SEP> 0
<tb>  <SEP> HCI/H20 <SEP> 1
<tb>  <SEP> -AO
<tb>  <SEP> 0 <SEP> OEt <SEP> I <SEP> OH
<tb>  <SEP> / <SEP> 0 <SEP> M <SEP> 
<tb>  <SEP> N, <SEP> N <SEP> HCI
<tb>  <SEP> N. <SEP> O <SEP> N. <SEP> II
<tb>  <SEP> cl2) <SEP> n <SEP> (CHC) <SEP> n
<tb>  <SEP> CI
<tb>  <SEP> R3 <SEP> N\R3
<tb>  <SEP> Vie <SEP> Vif
<tb> 
Scheme 1:

   Preparation of chromone-2-carboxylic acids as intermediates in the synthesis of compounds of the present invention.



   Alternatively, the chromone-2-carboxylic acid may be converted to the acid chloride and reacted immediately with an appropriate amine, as depicted in Scheme 2, below: 
EMI20.1     

Scheme 2. Amide synthesis via acid chloride intermediate.



   Additional functional group manipulations include, but are not limited to,   O-    dealkylation and N-dealkylation (Scheme 3). 
EMI21.1     


<tb>



   <SEP>   <SEP> o
<tb>  <SEP> i  <SEP> Ho
<tb>  <SEP> Ber3 <SEP> w
<tb>  <SEP> 85%
<tb>  <SEP> N) <SEP> a <SEP> I <SEP> I
<tb>  <SEP> C <SEP> 
<tb>  <SEP> ) <SEP> Example <SEP> 310 <SEP> 0
<tb>  <SEP> N <SEP> Example <SEP> 86
<tb>  <SEP> CH3 <SEP> CH3
<tb>  <SEP> I-chloroethylchloroformate
<tb>  <SEP> 64%
<tb>  <SEP> zu
<tb>  <SEP> 0
<tb>  <SEP> H
<tb>  <SEP> N
<tb>  <SEP> N <SEP> 0 <SEP> 0'aN
<tb> H3CZ <SEP> X <SEP> 9 <SEP> CNNX
<tb>  <SEP> Example <SEP> 85
<tb>  <SEP> N
<tb>  <SEP> H
<tb> 
Scheme 3: Functional group manipulation with compounds of the present invention includes, but is not limited to, N-and   0-dealkylation   
Quinoline and quinolone compounds of the present invention are prepared and derivatized via synthetic routes similar to those employed for synthesis of the chromone-2carboxamides described above and in Schemes 1-3.

   These synthetic routes to quinoline and quinolone compounds of the present invention are depicted in Scheme 4, infra.
EMI22.1     


<tb>



   <SEP> MeO <SEP> O <SEP> O
<tb>  <SEP> methanol
<tb>  <SEP> R <SEP> + <SEP> reflux <SEP> Rl <SEP> ? <SEP> OMe
<tb>  <SEP> NH <SEP> I <SEP> /NJOMe
<tb>  <SEP> Y
<tb>  <SEP> Br <SEP> MeO <SEP> 0 <SEP> Br <SEP> 0
<tb> R'= <SEP> OCH3 <SEP> or <SEP> F <SEP> I <SEP> 230 C
<tb>  <SEP> 1
<tb>  <SEP> oAo¯si <SEP> (CH3) <SEP> 3 <SEP> 0
<tb>  <SEP> 1 <SEP> 
<tb>  <SEP> Ra <SEP> 2-imethylsilyl) <SEP> ethoxy- <SEP> N
<tb>  <SEP> N <SEP> methyl <SEP> chloride <SEP> Br <SEP> H <SEP> O
<tb>  <SEP> Ber <SEP> 0
<tb>  <SEP> amine, <SEP> Pd <SEP> +
<tb>  <SEP> O <SEP> o¯Si <SEP> (CH3)

   <SEP> 3 <SEP> 0 <SEP> R1 <SEP> o
<tb>  <SEP> R <SEP> \ <SEP> amine
<tb>  <SEP> 1 <SEP> l
<tb>  <SEP> /OMe <SEP> LiOH <SEP> ( <SEP> N <SEP> I <SEP> OH <SEP> N <SEP> NHAr
<tb>  <SEP> R2 <SEP> O <SEP> THF/MeOH/H2O <SEP> R2 <SEP> H <SEP> 0 <SEP> R2 <SEP> H <SEP> O
<tb>  <SEP> ORME
<tb>  <SEP> Lu
<tb>  <SEP> w <SEP> W <SEP> w <SEP> W <SEP> R <SEP> CH3I
<tb>  <SEP> JOH <SEP> -.-I
<tb>  <SEP> LiOH <SEP> NOMe <SEP> amine, <SEP> Pd <SEP> i <SEP> pMe
<tb>  <SEP> R <SEP> O <SEP> THF/MeOH/Ha0 <SEP> R2 <SEP> N <SEP> Y
<tb>  <SEP> Br <SEP> 0
<tb>  <SEP> amine
<tb>  <SEP> TBTU <SEP> LiOH
<tb>  <SEP> HOBS <SEP> CI <SEP> O <SEP> THF/MeOH/H20
<tb>  <SEP> OMe
<tb>  <SEP> R <SEP> 1 <SEP> ci <SEP> oxalyl <SEP> chloride-I <SEP> OH
<tb>  <SEP> NHAR <SEP> (N- <SEP> N
<tb>  <SEP> Br <SEP> O <SEP> Br <SEP> H <SEP> O
<tb>  <SEP> 1) <SEP> amine
<tb>  <SEP> CI <SEP> RvN. <SEP> R4, <SEP> RvN.

   <SEP> R4
<tb>  <SEP> amine, <SEP> Pd/
<tb>  <SEP> Rs, <SEP> %, <SEP> NHAr <SEP> amine <SEP> YNX <SEP> R <SEP> XN'b, <SEP> NHAr
<tb>  <SEP> , <SEP> 60 <SEP> psi <SEP> gr <SEP> O
<tb>  <SEP> amine
<tb>  <SEP> amine
<tb>  <SEP> 0'0 <SEP> HOBT
<tb>  <SEP> R <SEP> NaH <SEP> R
<tb>  <SEP> NaH <SEP> ¯
<tb>  <SEP> l <SEP> v <SEP> II
<tb>  <SEP> j <SEP> NJ/NHAr <SEP> I/NJ/NHAr
<tb>  <SEP> Pd
<tb>  <SEP> 2 <SEP> H <SEP> s <SEP> N <SEP> 2-(trimethylsilyl) <SEP> ethoxy-H
<tb>  <SEP> Br <SEP> O <SEP> methyl <SEP> chloride <SEP> Br <SEP> O
<tb>  
It will be appreciated by those skilled in the art that certain compounds of the present invention contain for example asymmetrically substituted carbon   and/or    sulfur atoms, and accordingly may exist in and be isolated in, optically-active and racemic forms.

   It will be appreciated by those skilled in the art that certain compounds of the present invention contain for example asymmetrically substituted carbon   and/or    sulfur atoms, and accordingly may exist in and be isolated in,   optically-active and    racemic forms. Some compounds may exhibit polymorphism, thus it is to be understood that the present invention encompasses racemic, optically-active, polymorphic or stereoisomeric forms, or mixtures thereof, which forms possess properties useful in the treatment of the disorders set forth below.

   Preparation of optically active forms is well known in the art how (for example by resolution of racemic forms by   recrystallization    techniques, synthesis from optically-active starting materials, chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the treatment of the disorder described above.



   Compounds of Formula I have been found to be   5-HTIB    and 5HTID agonists. The compounds of Formula I, and their pharmaceutically acceptable salts, may also be used in a method for the treatment of migraine. The treatment of this disorder comprises administering to a warm-blooded animal, preferably a mammal, more preferably a human, in need of such treatment, an effective amount of a compound of Formula I or a pharmaceutically acceptable salt of said compound.



   Further provided is the use of a compound of Formula I in the preparation of a medicament for the treatment of a disorder such as migraine in a warm-blooded animal, preferably a mammal, more preferably a human, suffering from such disorder.



   The invention further provides a pharmaceutical composition suitable for the treatment of the above describe disorders comprising administering to a warm-blooded animal having such disorder an effective amount of a pharmaceutical composition of a compound of
Formula I, or a pharmaceutically acceptable salt.



   The invention also provides a pharmaceutical composition comprising a compound of
Formula I, as defined herein, or a pharmaceutically acceptable salt, in combination with a pharmaceutically acceptable carrier. Preferred compounds of Formula I, for use in the compositions of the invention are as described above.



   All compounds described herein demonstrate binding affinities (observed Ki values), in an assay described below, of less than about   1 O, uM.    Further, compounds of the present invention not only demonstrate   SHTIB    antagonist activity by reversing   5HTlB    agonist-induced hypothermia in the guinea pig, these compounds are considered to be orally active, and hence, they are the preferred compounds. Examples 1,10,11,31,32,34,44,55,56,57,71 and 72, infra, demontrate   5HTIB    antagonist activity in a dosage range of 0.006-5.5 mg/kg. In addition, compounds described herein demonstrate activity in the learned helplessness assay for antidepressant/antianxiety activity. Examples 31,44,71 and 72, infra, demonstrate activity in the learned helplessness assay.

   In addition, compounds were tested for maximal intrinsic activity (IA), and were found to have measured IA's of negative 50% to positive 150% in the   GTPyS    assay described below, thus demonstrating a range of response from agonism (low percentages) to antagonism (high percentages).



   The compounds described herein may be provided or delivered in a form suitable for oral use, for example in a tablet, lozenge, hard and soft capsule, aqueous solution, oily solution, emulsion, and suspension. The compounds may be also be provided for topical administration, for example, as a cream, ointment, gel, spray, or aqueous solutions, oily solutions, emulsions or suspensions. The compounds described herein may also be provided in a form suitable for nasal administration for example, as a nasal spray, nasal drops, or dry powder. The compositions may also be administered to the vagina or rectum in the form of a suppository. The compounds described herein may also be administered parentally, for example by intravenous, intravesicular, subcutaneous, or intramuscular injection or infusion.



  The compounds may be administered by insufflation (for example as a finely divided powder). The compounds may also be administered transdermally or sublingually.



   The compounds of the invention may accordingly be obtained by conventional. procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.



   The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I, will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

   Various assays and in vivo tests are known for determining the utility of the compounds in the disorders noted above and specifically as agonists and antagonists   of SHTzB and SHTlD    
The utility of the compounds for example to treat depression may be shown via a learned helplessness test in guinea pigs, which is used extensively as correlative to antidepressant activity in humans. The learned helplessness test may be carried out as follows:
Seventy male Hartley guinea pigs, each weighing about 350-425 gm are fed ad lib, and are housed under a 12-hour   light/dark    cycle. The procedure consists of two phases: The induction phase and the avoidance training phase. In the induction phase, subjects are placed into standard shuttle cages (20 L   X 16 W X 21    centimeters H) which are fitted with a grid floor.



  Electrical stimulation (1.25 mA, 10 sec duration) is delivered to the floor of the cage every 90-sec during 1 hour daily sessions. Subjects have no opportunity to escape or to avoid shocks. Induction is conducted for 2 consecutive days.



   In avoidance training, testing is also conducted in the shuttle cages, except that the subjects are not returned to the same chamber in which induction had occurred. Additionally, all cages are fitted with a partition with an arch in the center of the cage, through which animals can pass between the left and right halves of the cage. The procedure employed is a standard shuttle avoidance procedure in which a compound, conditioned stimulus (a 10-sec presentation of a tone and turning on of a lamp on the side of the cage that the guinea pig was occupying) serves to indicate presentation of electrical current to the floor of the cage. Shock is presented for a 5 sec period, 5 sec after initiation of the conditioned stimulus. Entry into the opposite side of the shuttle cage via the arched partition prior to shock onset results in the end of the trial (avoidance response).

   If shock is delivered, entry into the opposite side of the cage results in termination of the shock and CS (escape). Reversal of learned helplessness in the induction subjects correlates to antidepressant activity of the test compound.



   Avoidance training, 45-min in duration, is conducted on 2 consecutive days, beginning 48 hr after the final induction session. Seventy subjects are assigned to 1 of 6 groups of 11-12 animals. The groups are as follows:
1) No induction group. The subjects are placed into the shuttle cages but are not given inescapable shock, the animals are subsequently trained in the avoidance procedure and the vehicle is administered;
2) Induction vehicle control group;
3)   Imipramine 17. 8 mg/kg    ;
4) 0.3 mg/kg compounds;    5)    1 mg/kg compounds; and
6) 5 mg/kg compounds. 



   Groups 2-6 are given induction and avoidance training sessions. Injections are administered immediately following induction sessions and 1 hour prior to avoidance training sessions. A second injection is administered 7-8 hours following the first injection, for a total of 9 injections administered over 5 days. No injections are administered following the final avoidance training session.



   Compounds of the present invention may be administered in a volume of   1mL/kg    bwt.



  Imipramine is dissolved in DI water. The compounds are dissolved in DI water, to which was added   a    few drops of lactic acid (pH 5.5). The vehicle control is DI water prepared with lactic acid to the same pH as the-treated groups.



   The primary dependent variable is escape failure during avoidance training. 2-way analysis of variance (ANOVA) is used to assess overall treatment effect, with Dunn's post hoc analysis used to compare the vehicle-treated group with the drug-treated groups. The noinduction group is used to gauge whether learned helplessness is established, by comparison to the vehicle treated group.



   Other assays that may be used to measure for example affinity of compounds of the present invention for   SHTIB    and   5HTiD    receptors are described in J. Med. Chem 41: 12181235,1228 (1998) and J. Med. Chem 42: 4981-5001, (1999) and incorporated by reference herein. These assays may be used with some modifications: Frozen membrane preparations of a stably transfected chinese hamster ovary (CHO) cell line expressing 5-HTIB receptors and   5-HTID    receptors are thawed rapidly, briefly vortexed, and diluted in assay buffer (AB) containing 50 mM   Tris-HCI,    4 mM   MgCl2,    4mM   CaCl2,      1    mM EDTA, and adjusted to pH 7.4 with NaOH.

   Final protein concentrations are-0. 185   mg/ml    for   5-HTIB,    and 0.4 mg/ml for 5
HTID membranes. Test compounds are evaluated in competition assays using   [3H]-GR125743    (Amersham). The ligand concentration in both assays was 0.27nM. Kd for   [3H]-GR125743    may vary from 0.15 nM to 0.25 nM. The   5-via    and   5-HTID    assays are performed simultaneously on one 96-well assay plate, one drug/compound per plate. Ten serial dilutions   (1    uM to 4 pM, final concentration) of compound are prepared in DMSO from 10 mM stock solutions. Incubation mixtures are prepared in quadruplicate in 96-deep well assay plates (Matrix 1 ml).

   Final assay volumes per well are   10 u, l compound/nonspecific    ;   100      jil    membranes;   100, ul [3H]-GR125743    ; and 790   gl    AB. Specific binding is defined by using 10 uM Methiothepine. The assay plates are shaken for 5 min., and then incubated for an additional 55 min. Then the assay plates are filtered through Beckman GF/B filters (soaked  >  2 hrs. in   PEI)    using a Packard   Filtermate    196. Filters are washed 2x with 1 ml ice-cold wash buffer (5 mM   Tris-HCl-pH7.    4 with   NaOH).    After the filters are dried, 35   p1 of Microscint20    is added to each well.

   The plates are then counted on a Packard TopCount to determine
 CPM's per well. Ki values are determined for each test compound utilizing the graphic and analytical software package, GraphPad Prism. Compounds are then ranked in order of potency, and selectivity for   5-HTIB    over   5-HTjD    receptors.



   A method that may be used to determine a compound's affinity for   5-HTzB    and   5HTID    receptors is a guinea pig cortical test. This assay is described in detail by Roberts, et   al,    Br. J.



   Pharmacol., 1996,117,384-388, which is incorporated by reference herein. The test is carried out as follows: Guinea pigs are decapitated and the cortici is dissected out, weighed and homogenized in 50 mM Tris-HCl, pH 7.7 with an Ultra-Turrax followed by centrifugation for 10 min at 48000 x g and   5 C.    The pellet is resuspended and recentrifuged.



  The final pellet is suspended in 0.32 M sucrose buffer to a concentration   of 0. 5g    original wet weight per mL and stored frozen   at-70 C.    The radioligand binding assay is carried out as follows:   [3HJGR125743    saturation studies are tested in duplicate with 3-4 mg w. w. per tube in 5 mL buffer (50 mM Tris, 4 mM   CaC12,    4 mM   MgC12    and 1 mM EDTA at pH 7.7), and a concentration range of 0.012-2 nM (10-12 concentrations) for the radioligand. Non-specific binding is determined in the presence of 10 mM methiothepin. In competition experiments 4
8 mg w. w. per tube and a radioligand concentration of 0.2 nM are used with 10-12 concentrations of the competing drug.

   The assays are run for   2-4    hours at   30 C    and terminated by rapid filtration through Whatman GF/B filters (pretreated with 0.1 % polyethyleneimine) using a Brandel cell harvester. Bovine serum albumin (0.1%) is added to the washing buffer to reduce non-specific binding. Data from the experiments may be analyzed using the iterative non-linear curve-fitting program LIGAND. The   Kd    values obtained from the saturation studies are used in the calculation of the Ki values by the LIGAND program. The
 Kd value of   [3H]    GR125743 may result in a measurement of 46       4 pM and the Bmax in a measurement of 4.9       0.2 pmol/g w. w.



   A   GTPzS    binding assay may used to determine whether   a    compound is a   5HTia    or
   5HTiD    agonist or antagonist. One assay available measures agonist stimulated GTP binding for example as set forth by Lazareno, S. (1999) Methods in Molecular Biology 106:   231-245.   



   Membrane preparations of a stably transfected CHO cell line expressing human   5-HTlB    receptors are purchased for example from Unisyn, Hopkinton, MA. Frozen membranes are thawed, briefly sonicated, and diluted to   167, ug/ml    protein in assay buffer containing 20 mM
 HEPES, 100 mM NaCl,   1mM      MgCL2    and   l, uM    GDP, pH adjusted to 7.4 with   NaOH.    



  Diluted membranes are briefly homogenized with a Polytron and allowed to equilibrate at room temperature for at least 15 minutes before use. Serial dilutions (10 RM to 1 pM, final concentration) of test compounds are prepared in buffer with and without 100 nM 5-HT (final concentration) from 10 mM DMSO stock solutions. Incubation mixtures are prepared in quadruplicate in 96-well, deep-well plates and consisted of   180 fol    of membranes   (30 gag    protein) and   40 gel    of compound with or without 5-HT. After an incubation period of 15 minutes at room temperature, 20   gL    of [35S]   GTPzS    (NEN; 100 pM final concentration) is added to begin the assay. Mixtures are shaken for 2 minutes and incubated at room temperature for an additional 28 minutes.

   The reaction is stopped by rapid filtration through
Beckman GF/B glass fiber filters using a 96-well Packard cell harvester. Filters are washed four times with 1 mL ice-cold water. The filter plates are nominally dried and 30   RL    of scintillation cocktail (MicroScint 40, Packard) is added to each well. CPMs for each well is determined using a TopCount Scintillation Counter (Packard). Maximum stimulation of   [35S] GTPyS    binding is defined in the presence of   100nM    5-HT. Basal   [35S] GTPyS    binding is defined in buffer alone. IC50 values are defined as the concentration of compound at which 50% of the   100nM    5-HT response [was] obtained.

   Maximal intrinsic activity (IA) of a compound is defined as the percent maximal 5-HT-induced stimulation by 10   RM    compound in the absence of 5-HT. As an inter-assay standard, a concentration response curve of 5-HT (1  M to   1pM    final) in the absence of compounds was included in each assay and an   EC50    was determined.



   Preferred compounds of the present invention include, but are not limited to, the following compositions listed in Table 1 on the following pages. 



  Table 1: Compounds.
EMI29.1     


<tb>  <SEP> a.
<tb>



   <SEP> Eam <SEP> e,: <SEP> Strizcture:: <SEP> N <SEP> me
<tb>  <SEP> 1 <SEP> 8- <SEP> (4-methyl-1-piperazinyl)-N <SEP> [4- <SEP> (4
<tb>  <SEP> w <SEP> morpholinyl) <SEP> phenyl]-4-oxo-4H
<tb>  <SEP> chromene-2-carboxamide
<tb>  <SEP> r <SEP> co
<tb>  <SEP> ce
<tb>  <SEP> 0
<tb>  <SEP> o <SEP> i <SEP> 2-f <SEP> 1- <SEP> [4- <SEP> (2-Methoxy-phenyl)
<tb>  <SEP> piperazin-1-yl]-methanoyl}-8- <SEP> (4
<tb>  <SEP> methyl-piperazin-1-yl)-chromen-4
<tb>  <SEP> N <SEP> O
<tb>  <SEP> nu.
<tb>



   <SEP> N
<tb>  <SEP> 0 <SEP> 2-f <SEP> 1- <SEP> [4- <SEP> (l-Acetyl-2, <SEP> 3-dihydro-lH
<tb>  <SEP> indol-6-yl)-piperazin-1-yl]
<tb>  <SEP> methanoyl}-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> (o <SEP> 1-yl)-chromen-4-one
<tb>  <SEP> gNo <SEP> O.
<tb>



   <SEP> N
<tb>  <SEP> 0 <SEP> c <SEP> I <SEP> 2-Chloro-5- <SEP> (4-f <SEP> 1- <SEP> [8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> N <SEP> C <SEP> N <SEP> 2-yl]-methanoyl <SEP> I-piperazin-I-yl)
<tb> \owN <SEP> benzonitrile
<tb>  <SEP>  
<tb>  <SEP> N <SEP> O
<tb>  <SEP> gNn <SEP> O.
<tb>



   <SEP> 0/  <SEP> 2-f <SEP> 1- <SEP> [4- <SEP> (4-Methoxy-phenyl)
<tb>  <SEP> piperazin-1-yl]-methanoyl}-8- <SEP> (4
<tb>  <SEP> methyl-piperazm-1-yl)-chromen-4
<tb>  <SEP> one
<tb>  <SEP> . <SEP> zNX <SEP> O
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> w <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (5
<tb>  <SEP> furan-2-yl-lH-pyrazol-3-yl)-amide
<tb>  <SEP> po
<tb>  <SEP> N <SEP> 8 <SEP> non
<tb>  <SEP> N
<tb>  
EMI30.1     


<tb> xample.'6tn.

   <SEP> icture <SEP> Naz'ne
<tb>  <SEP> amp <SEP> ire
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> imidazol-1-yl-phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> po
<tb>  <SEP> 0 <SEP> O <SEP> Nn
<tb>  <SEP> N
<tb>  <SEP> o <SEP> s-N <SEP> - <SEP> (4-Methyl-piperazin-l-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> N <SEP> [1, <SEP> 2,3] <SEP> thiadiazol-5-yl-phenyl)
<tb>  <SEP> 0 <SEP> amide
<tb>  <SEP> po
<tb>  <SEP> N
<tb>  <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> 4
<tb>  <SEP> i <SEP> S <SEP> [1, <SEP> 2,3] <SEP> thiadiazol-5-yl-benzylamide
<tb>  <SEP> .

   <SEP> N <SEP> o <SEP> tN"N
<tb>  <SEP> zon
<tb>  <SEP> , <SEP> N
<tb>  <SEP> 10 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin- <SEP> 1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> [4
<tb>  <SEP> (4-acetyl-piperazin-1-yl)-phenyl]
<tb>  <SEP> amide
<tb>  <SEP> N <SEP> o <SEP> Ny
<tb>  <SEP> ce
<tb>  <SEP> '0
<tb>  <SEP> 0
<tb>  <SEP> 11 <SEP> 8-(4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> 4
<tb>  <SEP> XoXNA <SEP> (4-methanesulfonyl-piperazin-1-yl)
<tb>  <SEP> 0 <SEP> phenyl]-amide
<tb>  <SEP> (N) <SEP> o <SEP> N
<tb>  <SEP> N <SEP> ON.,, <SEP> S
<tb>  <SEP> ! <SEP> ou
<tb>  <SEP> 1 <SEP> a <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (2
<tb>  <SEP> N <SEP> methoxy-4-morpholin-4-yl-phenyl)

  
<tb>  <SEP> amide
<tb>  <SEP> N <SEP> 0 <SEP> I/N^
<tb>  <SEP> ' 
<tb>  
EMI31.1     


<tb> St. <SEP> ructur'e*'N
<tb>  <SEP> aras
<tb>  <SEP> 13 <SEP> o <SEP> 8- <SEP> (4-Methyl-piperazin-l-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (3
<tb>  <SEP> chloro-4-morpholin-4-yl-phenyl)
<tb>  <SEP> amide
<tb>  <SEP> IN <SEP> T <SEP> ! <SEP> ! <SEP> ! <SEP> amide
<tb>  <SEP> N
<tb>  <SEP> 
<tb>  <SEP> 14 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> N <SEP> thiomorpholin-4-yl-phenyl)-amide
<tb>  <SEP> . <SEP> CND <SEP> O <SEP> Nn
<tb>  <SEP> o
<tb>  <SEP> C
<tb>  <SEP> N
<tb>  <SEP> 15 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid
<tb>  <SEP> o <SEP> (2, <SEP> 5-diethoxy-4-morpholin-4-yl
<tb>  <SEP> CN <SEP> o <SEP> :

   <SEP> Co
<tb>  <SEP> N <SEP> 0
<tb>  <SEP> C <SEP> zu <SEP> aN
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 16 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> cyanomethyl-phenyl)-amide
<tb>  <SEP> Con
<tb>  <SEP> o
<tb>  <SEP> N
<tb>  <SEP> 17 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid
<tb>  <SEP> N.

   <SEP> (lH-indol-5-yl)-amide
<tb>  <SEP> (N) <SEP> o
<tb>  <SEP> ?
<tb>  <SEP> 18 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> [4
<tb>  <SEP> (l <SEP> JJX <SEP> N <SEP> (l-morpholin-4-yl-methanoyl)  <SEP> T <SEP> ro <SEP> phenyl]-amide
<tb>  <SEP> N <SEP> O <SEP> 9Af <SEP> N
<tb>  <SEP> N
<tb> I
<tb>  
EMI32.1     


<tb> Exarnple <SEP> Striteture"Nare
<tb>  <SEP> 9 <SEP> 1 l <SEP> 8-(4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> [4
<tb>  <SEP> N <SEP> (2, <SEP> 6-dimethyl-morpholin-4-yl)
<tb>  <SEP> phenyl]-amide
<tb>  <SEP> N <SEP> O
<tb>  <SEP> S'-T
<tb>  <SEP> 20o8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo-.
<tb>



   <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> [4
<tb>  <SEP> oXNu <SEP> xF <SEP> (4-fluoro-phenoxy)-phenyl]-amide
<tb>  <SEP> o <SEP> w <SEP> i
<tb>  <SEP> N
<tb>  <SEP> 0
<tb>  <SEP> N
<tb>  <SEP> 21 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-2- <SEP> (6
<tb>  <SEP> o <SEP> morpholin-4-yl-benzooxazol-2-yl)  <SEP> 0
<tb>  <SEP> 1t-Js <SEP> j/chromen-4-one
<tb>  <SEP> 0 <SEP> 0
<tb>  <SEP> N <SEP> O
<tb>  <SEP> v
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP>  <  <SEP> OH <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (2
<tb>  <SEP> fi! <SEP> H
<tb>  <SEP> OH <SEP> hydroxy-4-morpholin-4-yl-phenyl)
<tb>  <SEP> \ <SEP> \N. <SEP> .. <SEP> j. <SEP> 
<tb>



   <SEP> 0 <SEP> amide
<tb>  <SEP> r <SEP> o <SEP> L
<tb>  <SEP> N
<tb>  <SEP> 23 <SEP> o <SEP> 8-(4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (5
<tb>  <SEP> ethoxy-benzothiazol-2-yl)-amide
<tb> I <SEP> 11 <SEP> X <SEP> A
<tb>  <SEP> (N) <SEP> N
<tb>  <SEP> r <SEP> oa
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> .

   <SEP> bromo-phenyl)-amide
<tb>  <SEP> CND <SEP> O <SEP> Nn
<tb>  <SEP> (NI)
<tb>  <SEP> c <SEP> o
<tb>  <SEP> N
<tb>  
EMI33.1     


<tb>  <SEP> N
<tb>  <SEP> 25 <SEP> 0 <SEP> 8- <SEP> (4-Methylpiperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid
<tb>  <SEP> N <SEP> methyl- <SEP> (4-morpholin-4-yl
<tb>  <SEP> , <SEP> phenyl) <SEP> amide
<tb> cNa <SEP> o <SEP> N
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 26 <SEP> o <SEP> 8- <SEP> (4-Methyl-piperazm-l-yl)-4-oxo
<tb>  <SEP> ru <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (3
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> N <SEP> O
<tb>  <SEP> .
<tb>  <SEP> r
<tb>  <SEP> 27 <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (3
<tb>  <SEP> cyano-4-morpholin-4-yl-phenyl)

  
<tb>  <SEP> amide
<tb>  <SEP> po
<tb>  <SEP> f <SEP> Na <SEP>   <SEP> vNn
<tb>  <SEP> N
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (3
<tb>  <SEP> N <SEP> F <SEP> fluoro-4-morpholin-4-yl-phenyl)
<tb>  <SEP> amide
<tb>  <SEP> N <SEP> ou
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 29 <SEP> o. <SEP> 4-[4-({1-[8-(4-Methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromen-2-yl]
<tb>  <SEP> methanoyl}-amino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid <SEP> tert
<tb>  <SEP> t <SEP> 9 <SEP> n <SEP> butylester
<tb>  <SEP> N <SEP> O
<tb>  <SEP> (
<tb>  <SEP> 0
<tb>  <SEP> 30 <SEP> 0 <SEP> 8- <SEP> (4-Methyl-piperazin-l-yl)-4-oxo
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> N <SEP> piperazin-1-yl-phenyl)-amide
<tb>  <SEP> Nl <SEP> NH
<tb>  <SEP> (N) <SEP> NH
<tb>  <SEP> c <SEP> N.
<tb>



   <SEP> NH
<tb>  <SEP> N
<tb>  
EMI34.1     


<tb> N
<tb>  <SEP> 31 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> i  <SEP> 1.-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> N <SEP> N <SEP> O
<tb>  <SEP> c <SEP> 
<tb>  <SEP> N
<tb>  <SEP> I
<tb>  <SEP> 32 <SEP> o <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4  <SEP>   <SEP> methanesulfonyl-piperazin-1-yl)
<tb>  <SEP> o <SEP> PP <SEP> Y)
<tb>  <SEP> N <SEP> phenyl]-amide
<tb>  <SEP> N <SEP> NSz
<tb>  <SEP> N <SEP> os
<tb>  <SEP> 33 <SEP> o <SEP> 6-Methoxy-8- <SEP> (4-Methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (3-chloro-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> . <SEP> t <SEP> C .
<tb>



   <SEP> CN) <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 34 <SEP> o <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> N <SEP> F <SEP> carboxylic <SEP> acid <SEP> (3-fluoro-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> .
<tb>



   <SEP> N
<tb>  <SEP> 35 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (2-methoxy-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> N <SEP> O <SEP> I/N^.
<tb>



   <SEP> N
<tb>  <SEP> 36 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-thiomorpholin-4
<tb>  <SEP> yl-phenyl)-amide
<tb>  <SEP> N <SEP> o <SEP> (i
<tb>  <SEP> IN <SEP> os
<tb>  <SEP> N
<tb>  
EMI35.1     


<tb>  <SEP> nase <SEP> :

  
<tb>  <SEP> 37 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> / \ve <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (2, <SEP> 6-dimethyl
<tb>  <SEP> morpholin-4-yl)-phenyl]-amide
<tb>  <SEP> N <SEP> N-y
<tb>  <SEP> c
<tb>  <SEP> 0
<tb>  <SEP> N
<tb>  <SEP> I
<tb>  <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP>   >  <SEP> 1-yl)-4-oxo-4H-chromene-2  <SEP> ,.

   <SEP> N <SEP> NJ <SEP> carboxylic <SEP> acid <SEP> (3-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> N
<tb>  <SEP> 39 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (2-hydroxy
<tb>  <SEP> o <SEP> ( <SEP> ethyl)-piperazin-1-yl]-phenyl}
<tb>  <SEP> amide
<tb>  <SEP> aN <SEP> eN <SEP> OH
<tb>  <SEP> OH
<tb>  <SEP> 40 <SEP> 6-Methoxy-S- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (l-morpholin-4  <SEP> .. <SEP> N <SEP> ° <SEP> XNS <SEP> yl-methanoyl)-phenyl]-amide
<tb> .

   <SEP> N <SEP> O <SEP> I/NJ
<tb>  <SEP> N
<tb>  <SEP> 1
<tb>  <SEP> 41 <SEP> 0 <SEP> 6-Methoxy-8= <SEP> (4-methyl-piperazin
<tb>  <SEP> , <SEP> o <SEP> I-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (3-cyano-4  <SEP> "rt-" <SEP> T. <SEP> r <SEP> 1 <SEP> i <SEP> 1-j
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb> .

   <SEP> C) <SEP> T, <SEP> NX
<tb>  <SEP> N <SEP> O <SEP> I/N.,
<tb>  <SEP> CNJ
<tb>  <SEP> 4a <SEP> 4- <SEP> [4- <SEP> ( <SEP> { <SEP> 1- <SEP> [6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> i <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-amino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid <SEP> tert
<tb>  <SEP>   <SEP> butyl <SEP> ester
<tb>  <SEP> gN <SEP> Zozo
<tb>  <SEP> kYo
<tb>  <SEP> o
<tb>  
EMI36.1     

  <SEP> 
<tb>  <SEP> Eacarrx <SEP> le'Btzucture <SEP> Narn
<tb>  <SEP> 43 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-piperazin-1-yl
<tb>  <SEP> . <SEP> 1 <SEP> Ï, <SEP> phenyl)-amide
<tb>  <SEP> .

   <SEP> C) <SEP> N)
<tb>  <SEP> (N) <SEP> 0
<tb> 44 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-10 <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-propionyl
<tb>  <SEP> ! <SEP>   <SEP> piperazin-1-yl)-phenyl]-amide
<tb>  <SEP> .. <SEP> IN <SEP> oNv.
<tb>



   <SEP> N
<tb>  <SEP> o
<tb>  <SEP> 45 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> w-l-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> N <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-ethane
<tb>  <SEP> tND <SEP> O <SEP> WN) <SEP> sulfonyl-piperazin-l-yl)-phenyl]
<tb>  <SEP> amide <SEP> ¯
<tb>  <SEP> N
<tb>  <SEP> ou
<tb>  <SEP> 46 <SEP> o <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> v <SEP>  l <SEP> l-yl)-4-oXo-4H-chromene-2
<tb>  <SEP> N <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-dimethyl
<tb>  <SEP> tND <SEP>   <SEP> W\N) <SEP> sulfamoyl-piperazin-l-yl)-phenyl]  <SEP> o <SEP> Y) <SEP> P <SEP> Y
<tb>  <SEP> amide
<tb>  <SEP> N <SEP> N <SEP> /
<tb>  <SEP> .
<tb>



   <SEP> 47 <SEP> o <SEP> 4- <SEP> [4- <SEP> (11- <SEP> [6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-amino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid
<tb>  <SEP> C <SEP> NtN <SEP> dimethylamide
<tb>  <SEP> zu
<tb>  <SEP> 0
<tb>  <SEP> 48 <SEP> o <SEP> 4- <SEP> [4- <SEP> ( <SEP> {l- <SEP> [6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-arriino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid
<tb>  <SEP> ethylamide <SEP> ¯
<tb>  <SEP> N
<tb>  <SEP> N <SEP> N
<tb>  <SEP> 0
<tb>  
EMI37.1     


<tb>  <SEP> c <SEP> urne
<tb>  <SEP> 49 <SEP> 0 <SEP> 4- <SEP> [4- <SEP> ( <SEP> { <SEP> 1- <SEP> [6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-amino)

  -phenyl]
<tb>  <SEP> 0 <SEP> piperazine-l-carboxylic <SEP> acid
<tb>  <SEP> cyclohexylamide
<tb>  <SEP> IN <SEP> l\/NX
<tb>  <SEP> o
<tb>  <SEP> 50 <SEP> 0 <SEP> 4- <SEP> [4- <SEP> ( <SEP> {l- <SEP> [6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-amino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid
<tb>  <SEP> cyclopentylamide
<tb> WVJ <SEP> XNX
<tb>  <SEP> o
<tb>  <SEP> 51 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-10 <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> , <SEP> I <SEP> N) <SEP> carboxylic <SEP> acid <SEP> 14- <SEP> [4- <SEP> (l-pyrrolidin
<tb>  <SEP> 1-yl-methanoyl)-piperazin-1-yl]
<tb>  <SEP> phenyl}-amide
<tb>  <SEP> N <SEP> OU
<tb>  <SEP> 0
<tb>  <SEP> 0
<tb>  <SEP> 52 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)

  -4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (propane-2
<tb>  <SEP> sulfonyl)-piperazin-1-yl]-phenyl}
<tb>  <SEP> amide
<tb>  <SEP> CNJ <SEP> N,
<tb>  <SEP> IS
<tb>  <SEP> 00
<tb>  <SEP> 53 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (2-methyl
<tb>  <SEP> propanoyl)-piperazin-l-yl]-phenyl}
<tb>  <SEP> amibe
<tb>  <SEP> IN <SEP> o <SEP> N
<tb>  <SEP> S <SEP> 
<tb>  <SEP> 0
<tb>  <SEP> 54 <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (1-morpholin
<tb>  <SEP> 4-yl-methanoyl)

  -piperazin-1-yl]
<tb>  <SEP> phenyl}-amide
<tb>  <SEP> N <SEP> O
<tb>  <SEP> ?
<tb>  
EMI38.1     


<tb>  <SEP> E
<tb>  <SEP> amer
<tb>  <SEP> sample
<tb>  <SEP> 55 <SEP> 0 <SEP> 6-Fluoro-8- <SEP> (4-methyl-pip <SEP> erazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> I <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> o <SEP> i  <SEP> (N) <SEP> 0
<tb>  <SEP> r-4/ 
<tb>  <SEP> 56 <SEP> 0 <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-l
<tb>  <SEP> F <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4
<tb>  <SEP> methanesulfonyl-piperazin-1-yl)
<tb>  <SEP> cN) <SEP> O <SEP> WNX <SEP> phenyl]-amide
<tb>  <SEP> o <SEP> o
<tb> l <SEP> o//ssio <SEP> + <SEP> J
<tb>  <SEP> o.

   <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> N! <SEP> r <SEP> N
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-acetyl
<tb>  <SEP> piperazin-1-yl)-phenyl]-amide
<tb>  <SEP> r <SEP>   <SEP> 
<tb> r <SEP> o
<tb>  <SEP> 1 <SEP> 0
<tb>  <SEP> 5 <SEP> 8 <SEP> 6-Fluoro-8-(4-methyl-piperazin-1
<tb>  <SEP> F <SEP> yl)-4-oxo-4H-chromene-2  <SEP> N <SEP> cl <SEP> carboxylic <SEP> acid <SEP> (3-chloro-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> tv <SEP> o <SEP> i
<tb>  <SEP> C <SEP> Co
<tb>  <SEP> N
<tb>  <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2  <SEP> t <SEP>   <SEP> 10A <SEP> N <SEP> F <SEP> carboxylic <SEP> acid <SEP> (3-fluoro-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> I <SEP> 0 <SEP> N
<tb>  <SEP> .,

   <SEP> c <SEP> o
<tb>  <SEP> 1
<tb>  <SEP> 60 <SEP> 0 <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> F <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> t <SEP> N <SEP> CN <SEP> carboxylic <SEP> acid <SEP> (3-cyano-4
<tb>  <SEP> T <SEP>   <SEP> ° <SEP> X <SEP> morpholin-4-yl-phenyl)-anXide'
<tb>  <SEP> (N) <SEP> 0 <SEP> N
<tb>  <SEP> N <SEP> 00
<tb>  
EMI39.1     


<tb> F, <SEP> kample' <SEP> S <SEP> e,
<tb>  <SEP> u
<tb>  <SEP> am
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (l-morpholin-4
<tb>  <SEP> yl-methanoyl)-phenyl]-amide
<tb>  <SEP> N <SEP> O/NJ
<tb>  <SEP> N <SEP> O
<tb> l <SEP> X
<tb>  <SEP> 62 <SEP> ¯ <SEP> 0 <SEP> 6-Methyl-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> t <SEP> oso.
<tb>



   <SEP> (N) <SEP> 0
<tb>  <SEP> N <SEP> 00
<tb>  <SEP> r
<tb>  <SEP> 63 <SEP> o <SEP> 6-Methyl-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> t <SEP> N <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (1-morpholin-4
<tb>  <SEP> yl-methanoyl)-phenyl]-amide
<tb>  <SEP> N <SEP> 0 <SEP> I/N
<tb>  <SEP> N <SEP> O
<tb>  <SEP> lu <SEP> o
<tb>  <SEP> N
<tb>  <SEP> 64 <SEP> o <SEP> 6-Methyl-8- <SEP> (4-methyl-piperazin-l
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (3-fluoro-4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> . <SEP> N <SEP> o <SEP> i
<tb>  <SEP> C <SEP> v. <SEP> o.
<tb>



   <SEP> N
<tb>  <SEP> 65 <SEP> 0 <SEP> 6-Chloro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> o <SEP> i
<tb>  <SEP> N <SEP> 01.
<tb>



   <SEP> N
<tb>  <SEP> 66 <SEP> CH3 <SEP> 0 <SEP> 5-Methyl-8-(4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> 'n" <SEP> t. <SEP> 
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> o <SEP> i
<tb>  <SEP> Nl <SEP> D <SEP> 40
<tb>  <SEP> N
<tb>  
EMI40.1     

  <SEP> -E, <SEP> xample <SEP> N'
<tb>  <SEP> Stuc <SEP> urne
<tb>  <SEP> amie
<tb>  <SEP> 67 <SEP> 0 <SEP> 5-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> T <SEP>   <SEP> Y <SEP>  < N <SEP> phenyl)-amide
<tb>  <SEP> .

   <SEP> trX <SEP> t0
<tb>  <SEP> o
<tb>  <SEP> N
<tb>  <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (3-hydroxy
<tb>  <SEP> propanoyl)-piperazin-1-yl]-phenyl}
<tb>  <SEP> (N) <SEP> 0 <SEP> amide
<tb>  <SEP> N
<tb>  <SEP> N <SEP> OH
<tb>  <SEP> I
<tb> S.

   <SEP> l
<tb>  <SEP> 69 <SEP> 0 <SEP> 4- <SEP> [4- <SEP> (11- <SEP> [6-Fluoro-8- <SEP> (4-methyl
<tb>  <SEP> piperazin-1-yl)-4-oxo-4H-chromen
<tb>  <SEP> 2-yl]-methanoyl}-amino)-phenyl]
<tb>  <SEP> 0 <SEP> piperazine-1-carboxylic <SEP> acid <SEP> tert  <SEP> tND <SEP>   <SEP> WNn <SEP> butyl <SEP> ester
<tb>  <SEP> N
<tb>  <SEP> 1 <SEP> 0
<tb>  <SEP> I
<tb>  <SEP> 0
<tb>  <SEP> 70 <SEP> 0 <SEP> 4- <SEP> [4- <SEP> ( <SEP> {l- <SEP> [6-Fluoro-8- <SEP> (4-methyl
<tb>  <SEP> F <SEP> piperazin-1-yl)-4-oxo-4H
<tb>  <SEP> chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> piperazin-1-yl-phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> C) <SEP> INn
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 71 <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-ethane
<tb>  <SEP> sulfonyl-piperazin-1-yl)-phenyl]
<tb>  <SEP> (N)

   <SEP> 0 <SEP> amide
<tb>  <SEP> L, <SEP> J <SEP> s  <SEP> N
<tb>  <SEP> 0 <SEP> 0
<tb>  <SEP> 72 <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-propionyl
<tb>  <SEP> piperazin-1-yl)-phenyl]-amide
<tb>  <SEP> o <SEP> 
<tb>  <SEP> r <SEP> k, <SEP> N
<tb>  <SEP> N
<tb>  
EMI41.1     


<tb> Exanaple <SEP> Struature <SEP> Name.
<tb>



   <SEP> ,..... <SEP> ....-." <SEP> :.,,-,.-.. <SEP> a <SEP> :,.-v <SEP> :..' <SEP> ,. <SEP> ; <SEP> ;..- <SEP> :
<tb>  <SEP> 73 <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-l
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> {4- <SEP> [4- <SEP> (3-hydroxy
<tb>  <SEP> propanoyl)-piperazin-I-yl]-phenyl}
<tb>  <SEP> tND <SEP>   <SEP> wNn <SEP> amide
<tb>  <SEP> N
<tb>  <SEP> 0
<tb>  <SEP> 74 <SEP> R <SEP> N-[8-(4-Methyl-piperazin-1-yl)-4
<tb>  <SEP> oxo-4H-chromen-2-yl]-4
<tb>  <SEP> morpholin-4-yl-benzamide
<tb>  <SEP> . <SEP> ! <SEP> 0 <SEP> 11
<tb>  <SEP> N <SEP> N <SEP> 0
<tb>  <SEP> . <SEP> c <SEP> o.
<tb>



   <SEP> N
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)
<tb>  <SEP> chroman-2-carboxylic <SEP> acid
<tb>  <SEP> 0O) <SEP> r
<tb>  <SEP> (4-morpholin-4-yl-phenyl)-amide
<tb>  <SEP> CN) <SEP> 0 <SEP> N
<tb>  <SEP> N
<tb>  <SEP> racemic
<tb>  <SEP> 76 <SEP> (+)-8- <SEP> (4-Methyl-piperazin- <SEP> I-yl)
<tb>  <SEP> chroman-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> 0 <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> N <SEP> oe
<tb>  <SEP> N <SEP> 00
<tb>  <SEP> (-)-8- <SEP> (4-Methyl-piperazin-l-yl)
<tb>  <SEP> chroman-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> , <SEP> oNw <SEP>   <SEP>   <SEP> nNn <SEP> morpholin-4-yl-phenyl)-amide,
<tb>  <SEP> N <SEP> O/N/'.
<tb>



   <SEP> N <SEP> IN <SEP> 0
<tb>  <SEP> N
<tb>  <SEP> 78 <SEP> 0 <SEP> racemic-8- <SEP> (4-methyl-piperazin-l
<tb>  <SEP> yl)-4-oxo-chroman-2-carboxylic
<tb>  <SEP> acid <SEP> (4-morpholin-4-yl-phenyl)
<tb>  <SEP> .
<tb>  <SEP> amide
<tb>  <SEP> N <SEP> Na <SEP>   <SEP> vNX
<tb>  <SEP>  
<tb>  <SEP> Nô
<tb>  <SEP> 0
<tb>  
EMI42.1     


<tb> Example. <SEP> Structiue, <SEP> : <SEP> Nai <SEP> :

   <SEP> e
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> chroman-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> (faster <SEP> running <SEP> isomer)
<tb>  <SEP> o
<tb>  <SEP> N <SEP>  
<tb>  <SEP> N
<tb>  <SEP> 8- <SEP> (4-Methyl-piperazin-1-yl)-4-oxo
<tb>  <SEP> chroman-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> N <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> (slower <SEP> running <SEP> isomer).
<tb>  <SEP> o <SEP> I <SEP> 
<tb>  <SEP> e <SEP> Y <SEP> Co
<tb>  <SEP> 81[4- <SEP> ( <SEP> {1- <SEP> [6-Fluoro-- <SEP> (4-methyl
<tb>  <SEP> F <SEP> piperazin-1-yl)-4-oxo-4H-chromen  <SEP> t <SEP> N <SEP> 2-yl]-methanoyl}-amino)-phenyl]
<tb>  <SEP> piperazine-1-carboxylic <SEP> acid
<tb>  <SEP> ethylamide
<tb>  <SEP> N <SEP> OO
<tb>  <SEP> Tu
<tb>  <SEP> 82 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> [1,

   <SEP> 4] <SEP> diazepan-1-yl)-4-oxo-4H
<tb>  <SEP> N <SEP> chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> r) <SEP> ' <SEP> i <SEP> i <SEP> i <SEP> L <SEP> .]
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> o <SEP> i
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> 83 <SEP> 6-Èthoxy-8-(4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> Ws <SEP> Ws <SEP> N <SEP> carboxylicacid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> N
<tb>  <SEP> * <SEP> l
<tb>  <SEP> N
<tb>  <SEP> 84 <SEP> 6-Ethoxy-8-(4-methyl-piperazin-1
<tb>  <SEP> yl)-4-oxo-4H-chromene-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-propionyl
<tb>  <SEP> piperazin-1-yl)-phenyl]-amide
<tb>  <SEP> o
<tb>  <SEP> r <SEP> CN <SEP> il.
<tb>



   <SEP> N
<tb>  
EMI43.1     


<tb> 'ex
<tb>  <SEP> ample-Name
<tb>  <SEP> 6-Methoxy-4-oxo-8-piperazin-1-yl
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> morpholin-4-yl-phenyl)-amide
<tb> tND <SEP>   <SEP> NX
<tb>  <SEP> o
<tb>  <SEP> 0
<tb>  <SEP> (N)
<tb>  <SEP> 6-Hydroxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> 1-yl)-4-oxo-4H-chromene-2
<tb>  <SEP> H <SEP> f <SEP> H
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> * <SEP> o
<tb>  <SEP> C <SEP> o.
<tb>



   <SEP> N
<tb>  <SEP> 6-Methoxy-8- <SEP> (4-methyl
<tb>  <SEP> H <SEP> [1, <SEP> 4] <SEP> diazepan-1-yl)-4-oxo-1, <SEP> 4
<tb>  <SEP> I <SEP> dihydro-quinoline-2-carboxylic <SEP> acid
<tb>  <SEP> 4-mo <SEP> holin-4-1-hen <SEP> 1-amide
<tb>  <SEP> N <SEP> H <SEP> I <SEP> \ <SEP> Y <SEP> P <SEP> Y)
<tb>  <SEP> . <SEP> N <SEP> Wo0
<tb>  <SEP> N <SEP> H
<tb>  <SEP> /
<tb>  <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> o
<tb>  <SEP>  \ <SEP> 1-yl)-4-oxo-1, <SEP> 4-dihydro-quinoline
<tb>  <SEP> . <SEP> 11.

   <SEP> 2-carboxylic <SEP> acid <SEP> (4-morpholin-4
<tb>  <SEP> 1-hen <SEP> 1-amide
<tb>  <SEP> N <SEP> H <SEP> I <SEP> \ <SEP> Y <SEP> P <SEP> Y)
<tb>  <SEP> o
<tb>  <SEP> N <SEP> Zu
<tb>  <SEP> 89 <SEP> o <SEP> 6-Methoxy-8- <SEP> (4-methyl-piperazin
<tb>  <SEP> o
<tb>  <SEP> 1-yl)-4-oxo-1, <SEP> 4-dihydro-quinoline
<tb>  <SEP> 2-carboxylic <SEP> acid <SEP> [4- <SEP> (4-propionyl
<tb>  <SEP> N
<tb>  <SEP> N <SEP> H <SEP> \-piperazin-1-yl)-phenyl]-amide
<tb>  <SEP> (N <SEP> H
<tb>  <SEP> 0"  <SEP> WoNTo.
<tb>



   <SEP> 90 <SEP> o <SEP> 6-Fluoro-8- <SEP> (4-methyl-piperazin-l
<tb>  <SEP> yl)-4-oxo-1, <SEP> 4-dihydro-quinoline-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> rNa  <SEP> WNa
<tb>  <SEP> N <SEP> 0
<tb>  
EMI44.1     


<tb> 91 <SEP> 1 l <SEP> 6-Fluoro-8-(4-methyl-piperazin-1
Ef <SEP> e <SEP> ructure"
<tb>  <SEP> fuzz <SEP> yl)-4-oxo-1, <SEP> 4-dihydro-quinoline-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> [4- <SEP> (4-propionyl
<tb>  <SEP> piperazin-l-yl)-phenyl]-amide
<tb>  <SEP> N <SEP> r. <SEP>  < 
<tb>  <SEP> N
<tb>  <SEP> 0
<tb>  <SEP> 92 <SEP> 0 <SEP> 8- <SEP> [ <SEP> (2-Dimethylamino-ethyl)
<tb>  <SEP> methyl-amino]-6-methoxy-4-oxo
<tb>  <SEP> i.

   <SEP> 1, <SEP> 4-dihydro-quinoline-2-carboxylic
<tb>  <SEP> PIN
<tb>  <SEP> acid <SEP> (4-morpholin-4-yl-phenyl)  <SEP> N <SEP> H <SEP> p <SEP> amide
<tb>  <SEP> N
<tb> 93 <SEP> o <SEP> 8- <SEP> [ <SEP> (3-Dimethylamino-propyl)
<tb>  <SEP> methyl-amino]-6-methoxy-4-oxo
<tb>  <SEP> W <SEP> N <SEP> 1, <SEP> 4-dihydro-quinoline-2-carboxylic
<tb>  <SEP> N <SEP> N
<tb>  <SEP> I <SEP> acid <SEP> (4-morpholin-4-yl-phenyl)
<tb> , <SEP> Na <SEP> H <SEP> o <SEP>  >  <SEP> 9 <SEP> amide
<tb> NS <SEP> X, <SEP> 0
<tb>  <SEP> amide
<tb>  <SEP> N
<tb>  <SEP> ..
<tb>



  94o8- <SEP> ( <SEP> (3R)- <SEP> (+)-3-Dimethylammo
<tb>  <SEP> /\ <  <SEP> H <SEP> pyrrolidin-l-yl)-6-methoxy-4-oxo
<tb>  <SEP> 1, <SEP> 4-dihydro-quinoline-2-carboxylic
<tb>  <SEP> N <SEP> N
<tb>  <SEP> acid <SEP> (4-morpholin-4-yl-phenyl)
<tb>  <SEP> amide
<tb>  <SEP> - <SEP> N <SEP> O
<tb> Nx
<tb> 95 <SEP> 8-((3 <SEP> S)-(-)-3-Dimethylamino
<tb>  <SEP> pyrrolidin-l-yl)-6-methoxy-4-oxo
<tb>  <SEP> .

   <SEP> 1, <SEP> 4-dihydro-quinoline-2-carboxylic
<tb>  <SEP> I <SEP> acid <SEP> (4-morpholin-4-yl-phenyl)  <SEP> N <SEP> t <SEP> H <SEP> o <SEP> vNX <SEP> amide
<tb>  <SEP> - <SEP> N
<tb> 96 <SEP> 0 <SEP> 6-Methoxy-8- <SEP> [methyl- <SEP> (l-methyl
<tb>  <SEP> pyrrolidin-3-yl)-amino]-4-oxo-1, <SEP> 4
<tb>  <SEP> dihydro-quinoline-2-carboxylic <SEP> acid
<tb>  <SEP> ( <SEP> (4-morpholin-4-yl-phenyl)-amide
<tb>  <SEP> H <SEP> N
<tb>  <SEP> N
<tb>  
EMI45.1     


<tb>  <SEP> Exainple
<tb>  <SEP> 9o8- <SEP> [Ethyl- <SEP> (l-ethyl-pyrrolidm-3-yl)
<tb>  <SEP> 8- <SEP> [Ethyl- <SEP> ( <SEP> 1-ethyl-pyrrolidin-3-yl)
<tb>  <SEP> amino]-6-methoxy-4-oxo-1,

   <SEP> 4
<tb>  <SEP> dihydro-quinoline-2-carboxylic <SEP> acid
<tb>  <SEP> 4-mo <SEP> holin-4-1-hen <SEP> 1-amide
<tb>  <SEP> N <SEP> l\/o
<tb>  <SEP>  < 
<tb>  <SEP> O
<tb>  <SEP> 98
<tb>  <SEP> 4-dimethylamino-6-methoxy-8- <SEP> (4
<tb>  <SEP> methyl-piperazin-1-yl)-quinoline-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> N <SEP> N <SEP> phenyl)-amide
<tb> . <SEP> C <SEP> 3 <SEP> NX
<tb>  <SEP> N <SEP> \
<tb>  <SEP> 99
<tb>  <SEP> 0
<tb>  <SEP> 99 <SEP> N/6-methoxy-4-methylamino-8- <SEP> (4
<tb>  <SEP> methyl-piperazin-1-yl)-quinoline-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> N <SEP> N <SEP> phenyl)-amide
<tb>  <SEP> N <SEP> o <SEP> I <SEP> i
<tb>  <SEP> N <SEP> 0
<tb>  <SEP> Lj
<tb>  <SEP> 100,.

   <SEP> 6-fluoro-4-methoxy-8-(4-methyl
<tb>  <SEP> piperazin-l-yl)-quinoline-2
<tb>  <SEP> carboxylic <SEP> acid <SEP> (4-morpholin-4-yl
<tb>  <SEP> N <SEP> phenyl)-amide
<tb>  <SEP> o
<tb>  <SEP> N
<tb>  <SEP> I
<tb>  <SEP> 101 <SEP> 6-Fluoro-4-oxo-8-piperazin-1-yl
<tb>  <SEP> 4H-chromene-2-carboxylic <SEP> acid <SEP> (4
<tb>  <SEP> N <SEP> morpholin-4-yl-phenyl)-amide
<tb>  <SEP> .
<tb>  <SEP> CN) <SEP> 0 <SEP> N
<tb>  <SEP> 0
<tb> 
Also provided herein are the pharmaceutically acceptable salts of the compounds set forth in Table   1.    



   The following reference examples illustrate the making of intermediates in the synthesis of the compounds of the present invention, and are not intend to limit the invention in any manner.



   Reference Example 1
 Preparation of Reference Example 1:   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-   
2-carboxylic acid hydrochloride.



  Reference Example la: (E,   Z)-2-(2-Bromo-phenoxy)-but-2-enedioic    acid diethyl ester.



   Diethyl acetylenedicarboxylate (20 ml, 0.162 mol) was added to 2-bromophenol   (28    g, 0.162 mol), in anhydrous 2-propanol   (60      ml)    followed by the addition of a catalytic amount of tetrabutylammonium fluoride (0.5 ml, 1.0 M in THF). The solution was stirred at room temperature four hours and was then heated to reflux for one hour. The mixture was cooled to room temperature, then concentrated under vacuum to an oil   (51    g =   91%).   



  Reference Example lb : (E,   Z)-2- (2-Bromo-phenoxy)-but-2-enedioic    acid.



   (E,   Z)-2- (2-Bromo-phenoxy)-but-2-enedioic    acid diethyl ester (51 g, 148 mmol) as prepared in Reference Example la was suspended in ethanol (95 ml) and a solution of sodium hydroxide (12.9   g,    0.323 mol) in water (95 ml) was added. The solution was refluxed for 1 h to give a clear orange solution. The mixture was cooled to room temperature and acidified with 6 M   HC1    (50 ml). The mixture was then concentrated under vacuum and the residue azeotroped   (4x) with    ethanol. The solid was filtered, washed with water and dried to give   (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioic    acid as a light orange solid (24.3 g, 88 % yield). This crude product was used without further purification.



  Reference Example le : Ethyl-8-Bromo-4-oxo-4H-chromene-2-carboxylate.



   Sulfuric acid (95mL) was added to crude (E,   Z)-2- (2-Bromo-phenoxy)-but-2-enedioic    acid as prepared in Reference Example lb. After heating the mixture with a heat gun for 45 min an orange milky solution was obtained. This solution was slowly added to refluxing absolute ethanol (500 mL). After the addition, the reaction was refluxed for 30 min. then allowed to cool. Crystals started to form after 20 min and the reaction was put in the refrigerator overnight. The solid was filtered, washed with cold   ethanol/water    9: 1 and dried to give ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate as an off-white solid   (11.    7 g, 24 % yield, mp 124-126    C).    



  Reference Example ld : Ethyl-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromenec-2carboxylic acid.



     Ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate    as prepared in Reference Example   lc (Davies,    Stephen et al., J. Chem. Soc. Perkin Trans I p 2597,1987) (3.0 g, 10.1 mmol) was azeotroped with anhydrous toluene then the white solid was dissolved in 100 mL anhydrous toluene and transferred to the reaction vessel. The. mixture was subjected to vacuum/argon (x2) and the following were added in order (positive argon pressure): N-methylpiperazine (1.3 ml, 11.   1    mmol), 2,2'-bis (diphenylphosphino)-1,   l'-binaphthyl    (0.75 g, 1.2 mmol,), tris (dibenzylideneacetone) dipalladium   (0)    (0.48 g, 0.5 mmol) then cesium carbonate (4.6 g, 14.1 mmol).

   The mixture was again subjected to   vacuum/argon    and was heated at   80  C    overnight.



   The cooled reaction mixture was filtered through diatomaceous earth and the toluene solution was applied directly to a 600   ml    filter funnel (silica 230-400 mesh ASTM packed in ethyl acetate) and then washed with ethyl acetate   (2 1).    The product was eluted with 5-8 % methanol/chloroform and the desired was collected to give 2.5 g of a slightly impure orange yellow solid (mp   120-123  C).    The impure product was chromatographed on a Waters Delta
Prep 4000 using 1 PrepPak cartridge (Porasil   37-55, um 125 )    eluting with 3-5 % methanol/ chloroform.

   The product was collected and dried to give ethyl   8- (4-methyl-l-piperazinyl)-4-      oxo-4H-chromene-2-carboxylate    as a yellow solid (2.25 g, 70 % yield mp   124-125  C).   



  GC/MS   (EI,    M+) m/z 316.



  Reference Example le :   8- (4-methyl-1-piperazinyl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride.



   Ethyl   8- (4-methyl-1-piperazinyl)-4-oxo-4H-chromene-2-carboxylate    as prepared in
Reference Example ld (1.01 g. 3.19 mmol) was suspended in 6 M   HC1    (60 ml) and to reflux for 1.5 h (after 20 min a clear solution was obtained).



  The reaction was allowed to cool. The solution was concentrated in vacuo and anhydrous toluene was added (x3) and the solution was again concentrated in vacuo to give   8- (4-methyl-      l-piperazinyl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride as a yellow powder (1.02 g, quantitative yield). LC/MS   (M+1)    m/z 289. 



  Reference Example 2
EMI48.1     

Preparation   of 6-Methoxy-8-(4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride.



  Reference Example 2a: Diethyl   (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioate.   



   Ethyl acetylenedicarboxylate (17.8 ml, 0.145 mol) was added to 2-bromo-4methoxyphenol (Synlett   pl241,    1997) (27.3 g, 0.134 mol), in anhydrous 2-propanol   (55 ml)    followed by the addition of a catalytic amount of tetrabutylammonium fluoride (0.4 ml, 1.0 M in THF). The solution was stirred at room temperature overnight and was then heated to reflux for 30 min. Upon cooling a precipitate   formed, the    solution was cooled and filtered to give diethyl (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioate as a yellow solid (29.9 g, 62 % yield). Note: the solid contains 10 % of diethyl   (2E)-2- (2-bromo-4-methoxyphenoxy)-2-    butenedioate. GC/MS   (EI,    M+)   m/z    344 and 346.



  Reference Example 2b:   (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioic    acid.



   Diethyl (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioate (29. 9 g, 86.6 mmol) as prepared in Reference Example 2a was suspended in ethanol (55 ml) and a solution of sodium hydroxide (7.0 g, 0.175 mol) in water (55 ml) was added. The solution was refluxed for 1 h to give a clear orange solution. Most of the ethanol was removed in vacuo then 6 M   HC1    (50 ml) was added. The solid was filtered, washed with water and dried to give (2Z)-2- (2-bromo4-methoxyphenoxy)-2-butenedioic acid as a light orange solid (24.3 g, 88 % yield).



  Reference Example   2c    : Ethyl-6-methoxy-8-bromo-4-oxo-4H-chromene-2-carboxylate.



   Sulfuric acid   (SOml)    was added to (2Z)-2- (2-bromo-4-methoxyphenoxy)-2-butenedioic acid (24.3g, 86.6 mmol; as prepared in Reference Example 2b above). After heating the mixture with a heat gun for   5-10    min a clear deep brown solution was obtained. This solution was slowly added to refluxing absolute ethanol (250 ml). After the addition the reaction was refluxed for 30 min then allowed to cool. Crystals started to form after 20 min and the reaction was put in the refrigerator overnight. The solid was filtered, washed with cold ethanol/water 9: 1 and dried to give ethyl 8-bromo-6-methoxy-4-oxo-4H-chromene-2-carboxylate as an offwhite solid (12.3 g, 50 % yield, mp 159-161    C).   



  Reference Example   2d    : Ethyl-6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene2-carboxylate.



   Ethyl 8-bromo-4-oxo-4H-chromene-2-carboxylate (9.2 g, 28.1 mmol), as prepared in
Example 2c above, was azeotroped with anhydrous toluene then the white solid was dissolved in 300 ml anhydrous toluene in a 500 mL single-neck round bottom flask.. The mixture was degassed by alternating argon sparge and vacuum (3x), and the following were added in order: N-methylpiperazine (4.0 ml, 35.1   mmol),    2,2'-bis   (diphenylphosphino)-l,      l'-binaphthyl    (1.05 g, 1.69 mmol,), tris (dibenzylideneacetone) dipalladium   (0)    (0.50 g, 0.56 mmol) then cesium carbonate (12.8 g, 39.3 mmol). The mixture was again degassed via alternating argon sparge and vacuum and was heated at 80    C    for 17 h.

   Additional tris (dibenzylideneacetone) dipalladium   (0)    (0.10 g, 0.11 mmol) and 2,2'-bis (diphenylphosphino)-1,   l'-binaphthyl    (0.20 g, 0.32 mmol,) was added and the reaction was stirred at 80  C for another 55 h at which time the conversion was essentially complete.



   The cooled reaction mixture was diluted with tetrahydrofuran (250 mL), filtered and concentrated under vacuum. The residue was purified by chromatography on a silica column eluted with 2-5 % methanol/chloroform and the desired fractions were collected and concentrated under vacuum and the residue triturated with methylene chloride to give 7.4 g   (76%)    of a yellow powder.



  Reference Example 2e:   6-Methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid.



     Ethyl-6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylate    (1.0 g.



  2.89 mmol), as prepared in Reference Example 2d above, was suspended in 6 M   HC1    (60 ml) and methanol (10 mL) and warmed to reflux for 3.0 h. The reaction was allowed to cool. The solution was concentrated in vacuo and anhydrous toluene was added (x3) and the solution was again concentrated in vacuo. The residue was dried under vacuum (17 h) to yield 6  methoxy-8- (4-methyl-1-piperazinyl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride as a yellow powder (1.0 g, quantitative yield).



  Reference Example 3 
EMI50.1     
    6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid    hydrochloride.



  Reference Example 3a: Diethyl   (EZ)-2- (2-bromo-4-fluorophenoxy)-2-butenedioate.   



   This compound was synthesized from 2-bromo-4-fluorophenol and diethylacetylenedicarboxylate, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example la above.



  Reference Example 3b:   (EZ)-2-(2-Bromo-4-fluorophenoxy)-2-butenedioic    acid.



   This compound was synthesized from diethyl (EZ)-2- (2-bromo-4-fluorophenoxy)-2butenedioate, as prepared in Reference   Example 3 a    above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example lb above.



  Reference Example 3c: Ethyl-6-fluoro-8-bromo-4-oxo-4H-chromene-2-carboxylate.



   This compound was synthesized from (EZ)-2- (2-bromo-4-fluorophenoxy)-2butenedioic acid, as prepared in Reference Example 3b above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example   lc    above.



  Reference Example 3d: Ethyl-6-fluoro-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2carboxylate.



   This compound was synthesized from ethyl-6-fluoro-8-bromo-4-oxo-4H-chromene-2carboxylate, as prepared in Reference Example 3c above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example   ld    above.



  Reference Example 3e:   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid hydrochloride.



   This compound was synthesized starting from   ethyl-6-methoxy-8- (4-Methyl-      piperazin-l-yl)-4-oxo-4H-chromene-2-carboxylate,    as prepared in Example 3d, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example le above. 



  Reference Example 4
EMI51.1     
   Preparation 6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid    hydrochloride.



  Reference Example 4a: Diethyl (E, Z)-2- (2-bromo-4-methylphenoxy)-2-butenedioate.



  2-Bromo-4-methyl phenol (10 mL, 83mmol) was dissolved in diethyl ether (90 mL). To this was added dropwise triethyl amine (13.7 mL, 98mmol) followed by dimethyl acetylene dicarboxylate (11.2 mL,   91mmol).    The resulting mixture was stirred overnight at room temperature. The reaction was worked up by adding diethyl ether (200 mL) and tetrahydrofuran (50 mL) and washing the resulting   mixture with 1N HC1    (200 mL), water (200 mL) and brine (100 mL). The organic phase was then dried   (Na2S04),    filtered and concentrated to a red-brown oil which was used without further purification.



  Reference 4b: (2E, Z)-2- (2-Bromo-4-fluorophenoxy)-2-butenedioic acid.



   This compound was synthesized from diethyl   (E,    Z)-2- (2-bromo-4-methylphenoxy)-2butenedioate, as prepared in Reference Example 4a above, using the same synthetic procedures and the same stoichiometry as demonstrated in Example lb above.



  Reference Example   4c    :   Ethyl-6-methyl-8-bromo-4-oxo-4H-chromene-2-carboxylate.   



   This compound was synthesized from (2Z)-2- (2-bromo-4-methylphenoxy)-2butenedioic acid, as prepared in Reference Example 4b above, and using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example   1 c above.,   
Reference Example 4d:   Ethyl-6-methyl-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylate.



   This compound was synthesized from   ethyl-6-methyl-8-b. romo-4-oxo-4H-chromene-2-    carboxylate, as prepared in Reference Example 4c above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example   ld    above. 



  Reference Example 4e:   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid hydrochloride.



   This compound was synthesized   starting with ethyl-6-methyl-8- (4-Methyl-piperazin-      l-yl)-4-oxo-4H-chromene-2-carboxylate,    as prepared in Reference Example 4d, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example le above.



  Reference Example 5
EMI52.1     

Preparation   of 6-Chloro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride.



  Reference Example 5a : Diethyl (E,   Z)-2- (2-bromo-4-chlorophenoxy)-2-butenedioate.   



  This compound was prepared from 2-bromo-4-chloro phenol and dimethyl acetylenedicarboxylate by the same synthetic procedures and in the same stoichiometry as the preparation described in Reference Example 4a.



  Reference Example 5b : (2E,   Z)-2-(2-Bromo-4-chlorophenoxy)-2-butenedioic acid..   



  This compound was synthesized from diethyl   (E,    Z)-2- (2-bromo-4-chlorophenoxy)-2butenedioate, as prepared in Reference Example Sa above, as using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example lb above.



  Reference Example 5c : Ethyl-6-chloro-8-bromo-4-oxo-4H-chromene-2-carboxylate.



   This compound was synthesized from   (2E',      Z)-2- (2-bromo-4-chlorophenoxy)-2-    butenedioic acid, as prepared in Reference Example 5b above, using the same synthetic procedures and the same stoichiometry   as.    demonstrated in Example lc above.



  Reference Example 5d :   Ethyl-6-chloro-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylate. 



   This compound was synthesized from ethyl-6-chloro-8-bromo-4-oxo-4H-chromene-2carboxylate, as prepared in Reference Example 5c above, using the same synthetic procedures and the same stoichiometry as demonstrated in Example 1 d above.



  Reference Example 5e : 6-Chloro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2carboxylic acid hydrochloride.



   This compound was synthesized starting with   ethyl-6-chloro-8- (4-methyl-piperazin-1-    yl)-4-oxo-4H-chromene-2-carboxylate, prepared in Reference Example Sd above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example le above.



  Reference Example 6
EMI53.1     
    Preparation of 5-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride
Reference Example 6a: Diethyl (E,   Z)-2- (2-chloro-5-methylphenoxy)-2-butenedioate.   



   This compound was prepared from 2-chloro-5-methylphenol and dimethyl acetylenedicarboxylate by the same synthetic procedures and in the same stoichiometry as the. preparation described in Reference Example 1 a.



  Reference Example 6b: (2E,   Z)-2- (2-chloro-5-methylphenoxy)-2-butenedioic    acid.



   This compound was synthesized from diethyl (E, Z)-2- (2-chloro-5-methylphenoxy)-2butenedioate, as prepared in Reference Example 6a above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example lb above.



  Reference Example 6c : Ethyl-5-methyl-8-chloro-4-oxo-4H-chromene-2-carboxylate.



  * This compound was synthesized from   (2Z)-2- (2-chloro-5-methylphenoxy)-2-    butenedioic acid, as prepared in Reference example 6b, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example 1 c above. 



  Reference Example 6d : Ethyl-5-methyl-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2carboxylate.



   Ethyl 5-methyl-8-chloro-4-oxo-4H-chromene-2-carboxylate (1.0 g, 3.6 mmol) as prepared in Reference Example 6c above, was azeotroped with anhydrous toluene then the white solid was dissolved in 100 ml anhydrous toluene in a 250 mL single-neck round bottom flask.. The mixture was degassed by alternating argon sparge and vacuum (3x), and the following were added'in order:   N-methylpiperazine    (0.6'ml, 5.37 mmol), (2'  dicyclohexylphosphanyl-biphenyl-2-yl)-dimethyl-amine    (JACS 1998,120, p9722) (40 mg, 0.1 mmol,), tris (dibenzylideneacetone) dipalladium   (0)    (66 mg, 0.072 mmol) then cesium carbonate (1.6 g, 5.37 mmol). The mixture was again degassed via alternating argon sparge and vacuum and was heated at   80  C    for 17 h.

   Additional tris (dibenzylideneacetone) dipalladium   (0)    (66 mg, 0.072 mmol) and   (2'-dicyclopentylphosphanyl-biphenyl-2-yl)-    dimethyl-amine (40 g, 0.1 mmol,) were added and the reaction was stirred at   80  C    for another four days at which time the conversion was still only about 50% complete by HPLC.



  Tetrahydrofuran (100 mL) was added, and the combined mixture was filtered, concentrated under vacuum and purified by chromatography on silica eluted with 2.5% methanol in chloroform. The desired fractions were concentrated under vacuum to yield a yellow powder   (250 mg = 21%).   



  Reference Example 6e:   5-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid hydrochloride.



   This compound was synthesized starting with   ethyl-5-methyl-8- (4-methyl-piperazin-1-.    yl)-4-oxo-4H-chromene-2-carboxylate, as prepared in Reference Example 6d, and using the same synthetic procedures and the same stoichiometry as demonstrated in Example le above.



  Reference Example 7
EMI54.1     
 
Preparation   of 5-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride.



  Reference Example 7a:   (E,      Z)-2- (2-Bromo-5-methoxyphenoxy)-2-butenedioate.   



   This compound was prepared from 2-bromo-5-methoxyphenol and dimethyl   acetylenedicarbbxylate    by the same synthetic procedures and in the same stoichiometry as the preparation described in Reference Example la.



  Reference Example 7b: (E,   Z)-2-(2-Bromo-5-methoxyphenoxy)-2-butenedioic    acid.



   This compound was synthesized from diethyl (E, Z)-2-   (2-bromo-5-methoxyphenoxy)-    2-butenedioate, as prepared in Reference Example 7a, using the same synthetic procedures and the same stoichiometry as demonstrated in   Reference Example lb above.   



  Reference Example 7c: Ethyl-5-methoxy-8-bromo-4-oxo-4H-chromene-2-carboxylate.



  This compound was synthesized from (E, Z)-2- (2-bromo-5-methoxyphenoxy)-2-butenedioic acid, as. prepared in Reference Example 7b above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example lc above.



  Reference Example 7d:   Ethyl-5-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylate.



   This compound was synthesized from ethyl-5-methoxy-8-bromo-4-oxo-4H-chromene2-carboxylate, as prepared in Reference Example 7c above, using the same synthetic procedures and the same stoichiometry as demonstrated in Reference Example   ld    above.



  Reference Example 7e:   5-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid hydrochloride.



   This compound was prepared from   cthyl-5-methoxy-8- (4-Methyl-piperazin-l-yl)-4-    oxo-4H-chromene-2-carboxylate, as prepared in Reference Example 7d above, using the same method as the preparation in   le.   



  Reference Example 8
EMI55.1     

Preparation of   1- (6-Piperazin-1-yl-2, 3-dihydro-indol-1-yl)-ethanone   
Reference Example 8a:   1- [5- (4-Benzyl-piperazin-1-yl)-2, 3-dihydro-indol-1-yl]-ethanone.   



     1-acetyl-5-bromoindoline    (3.0 g,   12.      5mmol)    was dissolved in toluene (60 mL). To this was added, sodium t-butoxid (1.68 g,   17.      5mmol),    N-benzylpiperazine (2.4 mL, 13.8mmol), S-BINAP (0.93 g,   1.      5mmol)    and Pd2 (dba) 3 (0.46 g,   O.      5mmol).    The mixture was degassed via three cycles of vacuum and nitrogen sparge and then stirred at   95 C    until
GC analysis confirmed that the reaction was complete   (1 h).    The mixture was diluted with ethyl acetate (150 mL), washed with water and extracted with 2N   HC1    (2 x 100 mL).

   The combined aqueous extract was basified with concentrated ammonium hydroxide and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was dried   (MgS04)    and concentrated to yield a solid (2.7 g) which was purified by chromatography to yield a white solid (1.81 g, 43%). Mp   = 150.    5-152.8 C.



  Reference Example 8b:   1- (6-Piperazin-1-yl-2,    3-dihydro-indol-1-yl)-ethanone.



     1- [5- (4-Benzyl-piperazin-1-yl)-2, 3-dihydro-indol-1-yl]-ethanone    (0.37 g,   l.    lmmol), as prepared in Reference Example 8a above, was dissolved in methanol (5 mL). Pd/C (90 mg, 10%) and ammonium formate (0.9 g,   14mmol)    was added and the resulting mixture was heated to   65 C    for two hours. The mixture was filtered and the filter cake washed with hot methanol. The combined filtrate was concentrated to yield the desired product (0.26 g, 90%).



  Reference Example 9
EMI56.1     
    Preparation of 2-chloro-5-piperazin-1-yl    benzonitrile.



  Reference Example 9a: 3-Cyano-4-chloroaniline.



   2-Chloro-5-nitrobenzonitrile (25 g,   137mmol)    was dissolved in ethanol (275 mL).



     Stannous    chloride dihydrate (154.5 g,. 685 M) was added and the mixture stirred at   70 C    for 30 min. The mixture was then cooled to room temperature and poured into crushed ice. The mixture was made basic with solid sodium hydroxide. This mixture was extracted with ethyl acetate (3 x 100 mL). The extracts were combined, washed with brine, dried   (MgS04),    concentrated and the residue dried under vacuum and recrystallized from ethanol to yield light brown needles (10.6 g,   51%).   



  Reference Example 9b: 2-chloro-5-piperazin-1-yl benzonitrile.



   3-Cyano-4-chloroaniline (10.1 g, 66mmol), as prepared in Reference Example 9a, was dissolved in n-butanol (300 mL)   bis- (2-chloroethyl)    amine hydrochloride (23.2 g, 130mmol) and potassium iodide (50 mg, catalytic) were added. The mixture was heated at reflux for three days, then cooled in a refrigerator overnight. A solid precipitate was collected by filtration, washed with cold n-butanol and dried. The crude product was distributed between methylene chloride and 2N ammonium hydroxide. The organic layer was separated, dried   (Na2S04)    and concentrated to yield a light yellow solid (9.1 g, 59%) which gave a single peak by GC and TLC analysis.



  Reference Example 10
EMI57.1     

Preparation of   4- [1,    2,3] thiadiazol-5-yl-phenylamine.



     SnC12 H20    (3.21 g, 5   eq)    was added to a slurry of   (5- (4-Nitrophenyl)-1,    2,3thiadiazole (Lancaster Synthesis) (0.59 g, 2.8 mmol) in absolute   EtOH    (50 mL) and the reaction heated to   70  C    for 2 h. The reaction was allowed to cool to room temperature and pour into saturated   NaHC03    and ice. The product was extracted with EtOAc (2X) the solution dried   (MgS04)    and evaporated to dryness in vacuo to yield 0.47 g of a light yellow solid mp   126-128  C.   



  Reference Example 11
EMI57.2     

Preparation of   1- [4- (4-Amino-phenyl)-piperazin-1-yll-ethanone.-   
Reference Example lla:   4- (4-Nitrophenyl)-1-acetylpiperazine.   



   1- (4-Nitrophenyl) piperazine (2.5 g, 12.1 mmol) was dissolved in dichloromethane (100 ml). Triethylamine (2.0 ml, 14.5 mmol) was added and the reaction was cooled to 0 C.



  Acetic anhydride (1.25 ml, 13.3 mmol) was added dropwise and the reaction was stirred at   0       C    for 1 h. Saturated sodium bicarbonate was added and the reaction was extracted (x3) with dichloromethane, dried   (MgS04),    filtered and concentrated in vacuo to give   4- (4-      nitrophenyl)-l-acetylpiperazine    as a yellow solid (3.01 g,). GC/MS (EI, M+)   m/z = 249.   



  Reference Example llb :   1- [4- (4-Amino-phenyl)-piperazin-1-yl]-ethanone.   



  4- (4-Nitrophenyl)-l-acetylpiperazine (3.0 g, 12.0 mmol), as prepared in Reference Example   1 la    above, was mixed in methanol (100 ml) and 2 M ammonia in methanol (50 ml) and 10 % palladium on carbon (300 mg) was added. The mixture was hydrogenated on a Paar apparatus (50 psi) for 1. 5 h.



   The reaction was allowed to cool, the catalyst was filtered and the solution was concentrated in vacuo.. The crude solid was recrystallized from ethyl acetate to give   4- (4-    acetyl-l-piperazinyl) benzenamine as a light purple solid (1.86 g, 70 % yield, mp 149.5-150.5    C).    GC/MS (EI, M+) m/z = 219
Reference Example 12
EMI58.1     

Preparation of   4- (4-methanesulfonyl-piperazin-1-yl)-phenylamine   
Reference 12a: 4- (4-Nitrophenyl)-1-methylsulfonylpiperazine.



   1- (4-Nitrophenyl) piperazine (2.79 g, 13.5 mmol) was dissolved in dichloromethane (100 ml). Triethylamine (2.25 ml, 16.2 mmol) was added and the reaction was cooled to   0       C.   



  Methanesulfonyl chloride (1.15 ml, 14.9 mmol) was added dropwise and the reaction was stirred at   0  C    for 1 h. Saturated sodium bicarbonate was added and the reaction was extracted (x3) with dichloromethane, dried   (MgS04),    filtered and concentrated in vacuo to give 4- (4-nitrophenyl)-1-methylsulfonylpiperazine as a yellow solid (3.83 g, quantitative yield).   GC/MS      (EI,    M+)   m/z = 285.   



  Reference Example   12b    :   4- (4-methanesulfonyl-piperazin-1-yl)-phenylamine.   



     4- (4-Nitrophenyl)-l-methylsulfonylpiperazine (3. 83    g, 13.4 mmol), as prepared in
Reference Example   12a    above, was mixed in methanol (100 ml) and 2 M ammonia in methanol (50 ml) and 10 % palladium on carbon (400 mg) was added. The mixture was hydrogenated on a Paar apparatus (50 psi) for 3 h.



  The reaction was allowed to cool, the catalyst was filtered, washed with methanol then washed with chloroform. The chloroform portion contained a minor amount of the desired but looked purer. The chloroform portion was concentrated in vacuo and was recrystallized ethyl acetate to give   4- [4- (methylsulfonyl)-1-piperazinyl]    benzenamine as a shiny brown solid (0.94 g, 27 % yield, mp 192-193    C).    GC/MS   (EI,    M+) m/z = 255.



  Reference Example 13
EMI58.2     

Preparation of   4-Thiomorpholin-4-yl-phenylamine    :   Reference Example 13a    :   4- (4-Nitro-phenyl)-thiomorpholine.   



  4-Fluoronitrobenzene (3.0 g, 21.3 mmol) was dissolved in toluene (25 mL). Thiomorpholine (2.4 mL, 23.4 mmol) was added and the mixture stirred overnight at   100  C.    At 17 h, the mixture was distributed between ethyl acetate (100 mL) and saturated sodium bicarbonate   (50    mL). The organic layer was separated, dried   (Na2S04),    filtered and concentrated under vacuum. The residue was triturated with hexane to yield a bright yellow solid.



  Reference Example 13b: 4-Thiomorpholin-4-yl-phenylamine.



     4- (4-Nitro-phenyl)-thiomorpholine    (3.0g, 13.4 mmol), as prepared in Reference
Example 13a above, was dissolved in ethanol (250 mL) and 10% palladium on carbon (250 mg) was added. This mixture was shaken on a Parr   hydrogenator    for 3 h. The reaction mixture was then filtered through diatomaceous earth and concentrated under vacuum. The residue was triturated with hexane to yield an gray solid (2.1 g).



  Reference Example 14
EMI59.1     

Preparation of   1- (4-Amino-phenyl)-l-morpholin-4-yl-methanone.   



  Reference Example 14a: 1-Morpholin-4-yl-1- (4-nitro-phenyl)-methanone :
4-Nitrobenzoyl chloride (5 g, 27 mmol) in tetrahydrofuran (10 mL) was added slowly to a solution of morpholine (Sg, 88 mmol) and triethylamine (2.7 g, 27 mmol) in tetrahydrofuran (50 mL), and stirred at room temperature for four hours. Ethyl acetate (200 mL) was added to the mixture and the combined mixture was washed with water (25 mL), IN   HC1    (25 mL), water (25 mL), saturated sodium bicarbonate (25 mL), water (25 mL) and brine (25 mL). The mixture was dried   (Na2S04),    filtered and concentrated under vacuum and the residue used without further purification.



  Reference Example 14b:   1- (4-Amino-phenyl)-1-morpholin-4-yl-methanone.   



   This compound was prepared from   1-morpholin-4-yl-1- (4-nitro-phenyl)-methanone    as prepared in Reference Example   13b.   



  Reference Example'15
EMI59.2     

Preparation of   5-Amino-2-morpholin-4-yl-benzonitrile   
Reference Example 15a: 2-Morpholin-4-yl-5-nitro-benzonitrile.



   3-Cyano-4-fluoronitrobenzene (3.3 g, 19.9 mmol) was dissolved in ethyl acetate (10 mL). Morpholine (2.2 mL, 25 mmol),   and N, N-diisopropylethylamine    (3.5 mL, 20 mmol) were added and the mixture stirred overnight at room temperature. At 17 h, additional ethyl acetate (150 mL) was added and the combined mixture was washed with water   (50    mL) and brine (50 mL) ; dried   (Na2S04),    filtered and concentrated under vacuum. The residue was used without further purification.



  Reference Example 15b: 5-Amino-2-morpholin-4-yl-benzonitrile
This compound was prepared from 2-Morpholin-4-yl-5-nitro-benzonitrile (as prepared in Reference Example   15a    above), as prepared in Reference Example   13b.   



  Reference Example 16
EMI60.1     

Preparation of 3-Fluoro-4-morpholin-4-yl-phenylamine
Reference Example 16a :   4-(2-Fluoro-4-nitro-phenyl)-morpholine.   



   3,4-Difluoronitrobenzene (3.7 g, 23.2 mmol) was dissolved in ethyl acetate (10 mL).



  Morpholine (2.2 mL, 25 mmol), and N, N-diisopropylethylamine (4 mL, 23 mmol) were added and the mixture stirred overnight at room temperature. At 17 h, additional ethyl acetate (150 mL) was added and the combined mixture was washed with water (50 mL) and brine (50 mL), dried   (Na2S04),    filtered and concentrated under vacuum. The residue was used without further purification.



  Reference Example 16b: 3-Fluoro-4-morpholin-4-yl-phenylamine.



  This compound was prepared from 4- (2-Fluoro-4-nitro-phenyl)-morpholine, (as prepared in
Reference Example 16a above) as prepared in Reference Example   13b.   



  Reference Example 17
EMI60.2     

Preparation   of 4- (4-Amino-phenyl)-piperazine-l-carboxylic    acid tert-butyl ester:
Reference Example 17a:   4- (4-Nitro-phenyl)-piperazine-l-caxboxylic    acid tert-butyl ester.



  4-Fluoronitrobenzene (4.8 g, 34 mmol) was dissolved in ethyl acetate (25 mL).   Piperazine-l-    carboxylic acid tert-butyl ester (6.7 g, 36 mmol) and N, N-diisopropylethylamine (6.3 mL, 36 mmol) were added and the mixture was stirred at   65  C    for five days and cooled to room temperature. Ether (100 mL) was added and the combined mixture was washed with water  (25 mL) and brine (25 mL), dried   (Na2S04),    filtered and concentrated under vacuum. The residue was triturated with hexane to yield a bright yellow solid (8 g, 77%).



  Reference Example 17b:   4- (4-Amino-phenyl)-piperazine-l-carboxylic    acid tert-butyl ester.



     4- (4-Amino-phenyl)-piperazine-l-carboxylic acid tert-butyl    ester was prepared from   4- (4-Nitro-phenyl)-piperazine-1-carboxylic    acid tert-butyl ester, (as prepared in Reference
Example   17a)    as prepared in Reference Example   13b.   



  Reference Example 18
EMI61.1     

Preparation   of 3-Morpholin-4-yl-phenylamine   
Reference Example 18a:   4- (3-Nitro-phenyl)-morpholine.   



     3-Fluoronitrobenzene    (10 g, 71 mmol) was dissolved in   acetonitrile    (100 mL).



  Morpholine (30 mL, 350 mmol) was added and the mixture was reacted 18 h at   150  C/80psi    in a pressure reactor. The reaction was cooled to room temperature, concentrated under vacuum and   5g    of the total mixture was purified by column chromatography on silica eluted with   CH2C12.    The product (3.6 g) was isolated as a bright yellow oil.



  Reference Example 18b: 3-Morpholin-4-yl-phenylamine
3-Morpholin-4-yl-phenylamine was prepared from   4- (3-Nitro-phenyl)-morpholine,    (as prepared in Reference Example   18a),    as prepared in Reference Example   13b.   



  Reference Example 19
EMI61.2     

Preparation of   2- [4- (4-amino-phenyl)-piperazin-1-yl]-ethanol.   



  Reference Example 19a : 2   [4- (4-nitrophenyl) piperazine-1-yl]-ethanol.   



   2   [4- (4-nitrophenyl) piperazine-1-yl]-ethanol    is prepared from commercially available 4-fluoronitrobenzene (Aldrich) and commercially available N- (2-hydroxyethyl) piperazine (Aldrich) via the same procedure as described in Reference Example 13a above.



  Reference Example   19b    :   2- [4- (4-amino-phenyl)-piperazin-1-yl]-ethanol.   



     2- [4- (4-amino-phenyl)-piperazin-1-yl]-ethanol    is prepared by catalytic hydrogenation of 2   [4- (4-nitrophenyl) piperazine-1-yl]-ethanol    (prepared as in Reference Example   19a)    as described in Reference Example 13b 
Reference Example 20
EMI62.1     

Preparation of   4-Morpholin-4-yl-phenylamine.   



     4- (4-Nitrophenyl)    morpholine (10.3 g, 49.5 mmol;) (Lancaster Synthesis) was suspended in methanol (130 ml) and 2 M ammonia in methanol (70 mL) and 5 % palladium on carbon (100 mg) was added. The mixture was hydrogenated on a Paar apparatus   (50    psi) for 1 h. The reaction was allowed to cool, the catalyst was filtered and the solution was concentrated   in vacuo.    The crude solid was recrystallized from ethyl acetate hexane to give   4- (4-morpholinyl)    aniline as a light purple solid (6.2 g, 70 % yield, mp 132-133    C).   



     GC/MS      (EI,    M+) m/z = 178.



  Reference Example 21
EMI62.2     

Preparation of 4-Amino-3-hydroxyphenylmorpholine
4-Nitro-3-hydroxyphenylmorpholine (Maybridge Chemical) (3.34 g, 14.9mmol) was dissolved in 59 ml of ethanol at   30 C.    The mixture was stirred at   25 C    and treated with tin (II) chloride dihydrate (16.8 grams, 74.5mmol) with stirring. The yellow suspension was heated to reflux over a 30 minute period. TLC showed reaction progress over several hours.



  The mixture was refluxed for 18 hours, cooled to room temperature, and concentrated to remove most of the ethanol to give a yellow slurry. The mixture was treated with saturated aqueous sodium bicarbonate until it was basic. The mixture was extracted with ethyl acetate, filtered, and the organic layer was separated. The aqueous layer was extracted twice more with ethyl acetate. The extracts were combined, dried over magnesium sulfate, filtered, and concentrated to give 1.02 grams of a purple solid. Proton NMR and CI mass spectral analyses were consistent for the desired product (m/z   = 195    base peak by positive ion CI and m/z   =193    base peak by negative ion CI). 



  Reference Example 22
EMI63.1     

Preparation of   6-Methoxy-8- (4-methyl- [1,    4]   diazepan-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid
Reference Example 22a:   6-Methoxy-8- (4-methyl- [1,4] diazepan-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid ethyl ester.



   Into a 250 mL 3 neck round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is placed 1.5 g (4.59 mmol, 1.0 equiv.) of 8-Bromo-6-methoxy-4  oxo-4H-chromene-2-carboxylic    acid ethyl ester (Reference Example 2c), 84 mg (0.092 mmol, 0.02 equiv.) of tris dibenzylidineacetone dipalladium, 342 mg (0.55 mmol, 0.12 equiv.) of racemic 2,2'-bis   (diphenylphosphino)-1, 1'-binapthyl    and 2 g of 4 A molecular sieves. To this suspension is added 150 mL of dry toluene. To the stirred suspension is then added 628 mg, 684   gL,    (5.50 mmol, 1.2 equiv.) of   1-methylhomopiperazine,    followed by 2.05 g (6.3 mmol, 1.4 equiv.) of cesium carbonate. The mixture is then heated to 80    C    for 3 days.

   At the end of this time completion was monitored by LC/MS analysis of an aliquot. When the reaction was determined to be complete it was cooled to room temperature then filtered through a plug of diatomaceous earth with toluene washing to remove solid by products. Purification by flash chromatography, using   a    gradient of 5 to 20% methanol in methylene chloride as eluent, yielded 1.0 g, (60%) of the desired product.



  Mass Spec.: calc. for   [Cl9H24N205+Hl+ Theor.. m/z    = 361; Obs. = 361
Reference Example 22b:   6-Methoxy-8- (4-methyl- [l, 4] diazepan-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid.



   Into a 125 mL   erlenmeyer    equipped with a magnetic stirrer is placed 319 mg (0.89 mmol, 1.0 equiv.)   of 6-Methoxy-8-(4-methyl-[1,    4]   diazepan-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid ethyl ester. This material is dissolved in 30 mL of THF, then 30 mL of methanol are added. To this stirring solution is added 30 mL of a water containing 41 mg (0.97 mmol, 1.1 equiv.) of lithium hydroxide. This mixture is stirred at room temperature for 2 hr. Completion of the reaction is monitored by LC/MS, then 10 mL   of 2N HC1    is added.



  This mixture is then concentrated, dried and triturated with ether to give the product as the hydrochloride salt in quantitative yield.



  Mass Spec.: calc. for   [Ci7H2oN205+H]    Theor.   m/z    = 333 ; Obs. = 333
Reference Example 23
EMI64.1     

Preparation of   6-Ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carbonyl    chloride
Reference Example 23a :   8-Bromo-6-hydroxy-4-oxo-4H-chromene-2-carboxylic acid    ethyl ester:
The hydroxy compound,   8-Bromo-6-hydroxy-4-oxo-4H-chromene-2-carboxylic    acid ethyl ester, is formed as a side product during the synthesis of 8-Bromo-6-methoxy-4-oxo-4Hchromene-2-carboxylic acid ethyl ester. It can be separated from the crude methoxy compound by flash chromatography using a step gradient of 20% ethyl acetate in methylene chloride to the same solvent containing 2% methanol. The hydroxy compound, which elutes last, is concentrated to give the pure compound.

   Mass Spec.: calc. for   [Cl2H9BrO5+H]    +
Theor.   m/z=    313,315;   Obs. = 313,    315
Reference Example 23b:   8-Bromo-6-ethoxy-4-oxo-4H-chromene-2-carboxylic    acid ethyl ester:
Into a 100 mL 3 neck round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is added 700 mg (2.24 mg, 1.0 equiv.)   of 8-Bromo-6-hydroxy-4-      oxo-4H-chromene-2-carboxylic    acid ethyl ester (Reference Example   23a).    This material is dissolved in 50 mL of toluene, then 689 mg,   586 gel    (4.47 mmol, 2.0 equiv.) of diethyl sulfate and 309 mg (2.24 mmol, 1.0 equiv.)   of K2CO3    were added. The reaction was then heated to reflux for 24 hr.

   At the end of this time, monitoring by LC/MS reveals that the reaction is  > than 95% complete. The reaction is then cooled, 100 mL of ethyl acetate is added and the organic layer is washed with   O.    5N   HC1    solution, dried over   Na2S04,    filtered and concentrated.



  The residues were subjected to flash chromatography, using 40% ethyl acetate in hexane as eluent. The purified fractions were concentrated to yield 500 mg (65%) of a colorless solid.



  Mass Spec.: calc. for   [Cl4Hl3BrOs+H]    + Theor. m/z = 341,343; Obs. = 341,343
Reference Example 23c:   6-Ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid ethyl ester:
Into a 1 OOmL, 3 neck round bottom flask equipped with a reflux condenser, magnetic stirrer and nitrogen inlet is added 350 mg (1.03 mmol, 1.0 equiv.) of 8-Bromo-6-ethoxy-4  oxo-4H chromene-2-carboxylic    acid ethyl ester (Reference Example 23b), 18.9 mg (0.02 mmol, 0.02 equiv.) of tris dibenzylidineacetone dipalladium, 77 mg (0.123 mmol, 0.12 equiv.) of racemic 2,2'-bis (diphenylphosphino)-1,   1'-binapthyl    and   lg of 4    A molecular sieves and 60 mL of dry toluene.

   To the stirred suspension is then added 113 mg, 1255   pL,    (1.13 mmol,   1.      1    equiv.) of   1-methylpiperazine,    followed by 470 mg (1.44 mmol, 1.4 equiv.) of cesium carbonate. The mixture is then heated to   80  C    for 3 days. At the end of this time completion was monitored by LC/MS analysis of an aliquot. When the reaction was determined to be complete it was cooled to room temperature then filtered through a plug of diatomaceous earth, with toluene washing to remove solid by products. Purification by flash chromatography, using a gradient of 5 to 40% methanol in methylene chloride as eluent, yielded 350 mg (75%) of the desired product as   a    yellow solid.

   Mass Spec.: calc. for [Ci9H24N20s+H] + Theor. m/z = 361 ; Obs. = 361
Reference Example 23d:   6-Ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carboxylic acid   :   
Into a 125 mL   Erlenmeyer    equipped with a magnetic stirrer is placed 500 mg (1.39 mmol, 1.0 equiv.)   of 6-Ethoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid ethyl ester (Reference Example 23c). This material is dissolved in 30 mL of THF, then 30 mL of methanol are added. To this stirring solution is added 30 mL of a water containing 64.2 mg (1.53 mmol, 1.1 equiv.) of lithium hydroxide. This mixture is stirred at room temperature for 2 hr.

   Completion of the reaction is monitored by   LC/MS,    then 10 mL   of 2N      HC1    is added. This mixture is then concentrated, dried and triturated with ether to give the product as the hydrochloride salt in quantitative yield.



  Mass Spec.: calc. for   [Cl7H20N2os+H]    + Theor.   m/z 333    ; Obs. = 333
Reference Example 23e :   6-Ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-    carbonyl chloride:
Into a 100 mL round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is placed 250 mg (0.68 mmol, 1.0 equiv.)   of 6-Ethoxy-8-(4-methyl-piperazin-    1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride salt (Reference Example 23d) and 20 mL of methylene chloride. To the stirring suspension is then added 129.5 mg, 164
 L   (1.    02 mmol, 1.5 equiv.) of oxalyl chloride followed by addition of one drop of DMF from a 50 microliter syringe to act as catalyst.

   The mixture is stirred. for 2 hours, then concentrated to dryness on a rotary evaporator under a nitrogen atmosphere, followed by drying under high vacuum. The completeness of the reaction was ascertained by analysis of an aliquot, which was quenched with a THF solution of methylamine, by LC/MS. The crude material was used as obtained in the subsequent amidation reaction.



  Reference Example 24
EMI66.1     

 Preparation of   8-Bromo-6-methoxy-4-(2-trimethylsilanyl-ethoxymethoxy)-quinoline-2-    carboxylic acid methyl ester.



  Reference Example 24a: 2- (2-Bromo-4-methoxy-phenylamino)-but-2-enedioic acid dimethyl ester.



   A   solution of 2-bromo-4-methoxy aniline    (6.02 g, 29.8 mmol) in 125 mL anhydrous methanol was treated with dimethyl acetylenedicarboxylate   (3.    70 mL, 30.2 mmol) and the solution was heated at reflux under nitrogen for 8 hours. The reaction mixture was cooled, concentrated, and   redissolved    in hot methanol. Yellow crystals were obtained by filtration (6.93 g, 68%). A second crop of crystals was obtained from ethanol (0.942 g, 9%). The filtrates were combined and purified by flash chromatography on silica gel using 4: 1 hexanes: ethyl acetate to afford an additional 1.63 g (16%) for a total yield of   93%.

   IH    NMR (300 MHz, DMSO, d6)   8    9.60 (s, 1 H, NH), 7.26 (d,   1    H,   Jm=    2.7 Hz, ArH), 6.93 (dd, 1 H,
Jo=   8h7n Jm=    2.7 Hz,   ArH),    6.87 (d, 1 H,   Jo=      8. 7    Hz,   ArH6),    5.34 (s,   1    H, C=CH), 3.76 (s, 3
H,   OC¯3),    3.68 (s, 3 H,   CHCO2C¯3),    3.66 (s, 3 H,   CNCO2CH3)    ; Mass Spec.: calc. for   [Cl3Hl4BrNO5+H] + Theor.    m/z = 344,346; Obs. 344,346.



  Reference Example 24a:   8-Bromo-6-methoxy-4-oxo-1,      4-dihydro-quinoline-2-carboxylic    acid methyl ester.



   Dow-Therm (175 mL) was heated to   244  C    and the 2- (2-bromo-4-methoxyphenylamino)-but-2-enedioic acid dimethyl ester (9.50 g, 27.6 mmol) was added as a solid in portions over 7 minutes while maintaining a temperature of   230-240  C.    The brown reaction mixture was heated at   240-245  C    for 45 minutes and then cooled to room temperature. A yellow precipitate formed upon cooling.

   Approximately 100 mL of hexanes were added to the mixture and the solids were isolated by filtration, washed with additional hexanes, and dried under high vacuum to afford the product as a yellow solid (6.73 g, 78%). 1H NMR (300
MHz, DMSO, d6) 8 12.01 (s, 1 H,   NH),    7.86 (d,   1    H,   Jm=      2.    7 Hz, ArH5), 7.52 (s,   1    H,   C=CH),    7.48 (d, 1 H, Jm= 2. 7 Hz, ArH7), 3.93 (s, 6 H,   OC¯3    and   CO2CH3)    ; Mass Spec.: calc. for [C12H10BrNO4+H]+ Theor. m/z = 312, 314; Obs. 312,314.



  Reference Example 24c:   8-Bromo-6-methoxy-4- (2-trimethylsilanyl-ethoxymethoxy)-    quinoline-2-carboxylic acid methyl ester.



   A brown solution of 8-bromo-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2carboxylic acid methyl ester (6.73 g, 21.6 mmol) in 100 mL N-methyl pyrolidinone was treated with sodium hydride (60% dispersion in oil, 1.028 g, 25.7 mmol). Gas evolution and warming were observed. The reaction was stirred for 10 minutes at room temperature under nitrogen. Addition of2- (trimethylsilyl) ethoxymethyl chloride (5.00 mL, 28.3 mmol) resulted in a slightly cloudy, light brown solution. After 2.5 hours at room temperature, the reaction mixture was poured into 800 mL water and stirred for 15 minutes. The resulting cream colored precipitate was isolated by filtration, washed with water, and dried under high vacuum to afford the product as a cream colored solid (9.70 g, quantitative   yield).

   IH    NMR (300 MHz, DMSO, d6)   8    7.976 (d,   1    H,   Jm=    2.7 Hz,   ArH7),    7.79 (s, 1 H, C=CH), 7.53 (d, 1 H,   Jm=      2. 7    Hz, ArH5), 5.70 (s, 2 H,   OCH O),    3.99 (s, 6 H,   OC¯3    and   C02CH3),    3. 88   (t,    2 H,   J=    8.0 Hz,   OCH2CH2Si),    0.97 (t, 2 H,   J= 8.    0 Hz,   OCH2CH Si),),-0.    04 (s, 9 H, Si (C H3) 3; Mass
Spec.: calc. for [C18H24BrNO5Si+H]+ Theor. m/z =   442,    444; Obs. 442,444.



  Reference Example
EMI67.1     

Preparation of   6-Methoxy-8- (4-methyl- [1,    4] diazepan-1-yl)-4-oxo-1, 4-dihydro-quinoline
2-carboxylic acid. 



   Reference Example 25a: 6-Methoxy-8- (4-methyl- [1, 4]   diazepan-1-yl)-4- (2-trimethylsilanyl-    ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester.



   To a clear, light brown solution of 2-bromo-6-methoxy-4- (2-trimethylsilanyl
   ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (1.01 g, 2.28   mmol),    N methylhomopiperazine (0.32 mL, 2.57 mmol), and   4    A sieves in 30 mL anhydrous toluene was added Pd2 (dba) 2 (43.8-mg, 0.048 mmol) and BINAP   (169. 8,    mg, 0.27 mmol). The resulting wine colored solution was treated with cesium carbonate (1.124 g, 3.45 mmol). The reaction mixture was heated at reflux under nitrogen for 21 hours. The pea green reaction mixture was cooled to room temperature and concentrated.

   The crude mixture was purified by flash chromatography on silica gel using a gradient of 95: 5 to 40: 60 methylene chloride: methanol to afford the desired product as a yellow foam (1.004 g,   92%).'H    NMR (300 MHz,
 DMSO, d6)   5    7.67 (s, 1 H,   ArH3),    6.94 (d,   1    H,   Im 2.    4 Hz, ArH5), 6.66 (d,   1    H, Jm=   2.    4 Hz,
   Ar¯7),    5.60 (s, 2 H,   OCH O),    3.94 (s, 3 H,   C02CH3),    3.88 (s, 3 H, OCH3), 3.82 (t, 2 H,   J= 8.    0
 Hz,   OCH CH2Si),    3.75 (bs,.

   4 H, ArNCH2CH2CH2NCH3  &    ArNCH CH2N-CH3),    3.45 (bs, 2
 H, ArNCH2CH2NCH3), 3.31 (bs, 2   H,      ArNCH2CH2CH H     (bs, 2 H ArNCH2CH2 CH2NCH3), 0.92 (t, 2   H,      J=    8.0 Hz,   OCH2CH7Si),-0.    04 (s, 9 H, Si (C
   H3)    3 ; Mass Spec.: calc. for [C24H37N3O5Si+H]+ Theor. m/z = 476; Obs. 476.



   Reference Example   25b    :   6-Methoxy-8- (4-methyl- [1,    4] diazepan-1-yl)-4-oxo-1,4-dihydro quinoline-2-carboxylic acid.



   To a light brown solution of 6-methoxy-8-(4-methyl-[1, 4] diazepan-1-yl)-4-(2
   trimethylsilanyl-ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (1.00 g, 2.10 mmol) in 18 mL 3: 1: 1 tetrahydrofuran: methanol: water was added lithium hydroxide monohydrate (0.267 g, 6.35 mmol). The reaction mixture was stirred at room temperature for
5 hours, acidified to pH 4 with 1 N   HC1,    and stirred an additional 20 minutes.

   The reaction mixture was concentrated and dried under high vacuum to afford an orange   foam. 1H    NMR  (300 MHz, DMSO, d6) 8 11.06 (s,   1    H, NH), 7.53 (s,   1    H, C=CH), 7.00 (d,   1    H, Jm= 2.4 Hz,
 ArH5), 6. 70 (d,   1    H, Jm= 2.4 Hz, ArH7), 4.05-3.99 (m, 2 H, ArNCH2CH2CH2NCH3), 3. 87 (s,
3 H, OCH3), 3.68-3.60   (m,    2 H, ArNCH2CH2NCH3), 3.54-3.47 (m, 2 H,   ArNCH2CH2NCH3),   
3.41-3.26 (m, 2 H,   ArNCH2CH2CH2NCH3),    2.82 (d, 3 H,   J= 4.    8 Hz,   NCH),    2.46-2.41 (m, 1
 H ArNCH2CH2CH2NCH3), 2.30-2.25 (m,   1    H   ArNCH2C¯2CH2NCH3)    ; Mass Spec.: calc. for  [C17H21N3O4+H]+ Theor. m/z = 332;

   Obs. 332. 



  Reference Example 26
EMI69.1     

Preparation of   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-1, 4-dihydro-quinoline-2-    carboxylic acid.



  This compound was prepared via the same procedure described for preparation of Reference
Example 25.



  Reference Example 27
EMI69.2     
    Preparationof 6-Methoxy-8- (4-methyl- [1,    4] diazepan-1-yl)-4- (2-trimethylsilanyl    ethoxymethoxy)-quinoline-2-carboxylic acid    (4-morpholin-4-yl-phenyl)-amide.



  Reference Example 27a:   8-Bromo-6-methoxy-4-oxo-1,    4-dihydro-quinoline-2-carboxylic acid.



   To a light brown solution of 8-bromo-6-methoxy-4- (2-trimethylsilanylethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example 24c) (4.98 g, 11.3 mmol) in 75 mL 3: 1: 1 tetrahydrofuran: methanol: water was added lithium hydroxide monohydrate (1.367 g, 32.6 mmol). The reaction was stirred at room temperature for 5 hours.



  The reaction mixture was concentrated and then poured into water. The solution was acidified to pH 2 with 1 N   HC1    and the resulting solids were isolated by filtration. The solids were then suspended in methanol and filtered to afford the desired product (2.6732 g, 80%).



  An additional 0.5768 g (17%) of product was obtained from the methanol filtrates. IH NMR (300 MHz, DMSO, d6, TFA Shake)   8    7.86 (d, 1 H, Jm=   2. 7    Hz,   Ar),    7.55 (d, 1 H, Jm=   2.    7   H-z, ArH7),    7.32 (s,   1    H, C=CH), 3.94 (s, 3 H,   OCH)    ; Mass Spec.: calc. for   [CllH8BrNO4+H] +    Theor. m/z = 298,300; Obs.   = 298,    300.



  Reference Example 27b: 8-Bromo-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid   (4-morpholin-4-yl-phenyl)-amide.   



   To a yellow suspension of 8-bromo-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2carboxylic acid (Reference Example   27a)    (3.446g, 11.56   mmol),    TBTU (9.039 g, 28.15 mmol), and HOBt   (3.    757 g, 27.8 mmol) in 100 mL   dimethylformamide    was added 4morpholinoaniline (2. 733 g, 15.3 mmol) and diisopropylethyl amine (8.2 mL, 50.2 mmol).



  The resulting marroon solution was stirred at room temperature under nitrogen for 16 hours during which time the reaction became greenish brown and formed a large amount of precipitate. The reaction mixture was filtered and the solids washed with dimethylformanide, water, and methanol. Drying under high vacuum afforded the desired product as a yellow solid (3.09 g, 58%). 1H NMR (300 MHz, DMSO, d6) 8 12.13 (s, 1 H, NH), 10. 18 (s,   1      H,   
C (O)   NH),    7.90 (d,   1    H, Jm=2. 7 Hz, ArH5), 7.68 (d, 2 H, Jo=   9. 0    Hz,   Ar¯2  &  H6),    7.63 (s,   1   
H, C=CH), 7.51 (d, 1 H, Jm 2. 7 Hz, ArH7), 7.00 (d, 2 H, Jo=9.

   0 Hz, Art    & LHJ,),    3.94 (s, 3
H,   OC¯3),    3.75 (t, 4 H,   J= 4. 8    Hz,   OCH2CH2N),    3.10 (t, 4 H,   J= 4.    8 Hz,   OC, H2CH9N)    ; Mass
Spec.: calc. for   [C2lH2oBrN304+H] + Theor.    m/z = 458,460; Obs. = 458,460.



  Reference Example 27c:   8-Bromo-6-methoxy-4- (2-trimethylsilanyl-ethoxymethoxy)-    quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   A yellow suspension   of 8-bromo-6-methoxy-4-oxo-1,    4-dihydro-quinoline-2carboxylic acid (4-morpholin-4-yl-phenyl)-amide (Reference Example 27b) (3.092 g, 6.75 mmol) in 40 mL   N-methylpyrolidinone    was treated with sodium hydride (60% dispersion in oil, 0.410 g, 10.24 mmol). Gas evolution and warming were observed and the suspension became light brown and almost clear. The reaction was stirred for 10 minutes at room temperature under nitrogen. Addition of the 2- (trimethylsilyl) ethoxymethyl chloride (1.6 mL, 9.1 mmol) resulted in a slightly cloudy, lighter brown solution. After 4.5 hours at room temperature, the reaction mixture was poured into 300 mL water, stirred for 15 minutes and then stored at   0  C    overnight.

   The solids were isolated by filtration, suspended in methanol, filtered again, and dried under high vacuum to afford the product as a yellow solid (3.190 g, 80%).'H NMR (300 MHz, DMSO, d6) 8 10.18 (s,   1    H, C (O) NH), 7.95 (d, 1 H,   Jm=    2.4 Hz,   Ar),    7.83 (s, 1 H, ArH3), 7.69 (d, 2 H, Jo=9. 0 Hz, ArH2' &  H6'), 7.51 (d, 1 H, Jm= 2.7 Hz,
ArH5), 7.00 (d, 2 H, Jo=9.0 Hz, ArH3, &  H5'), 5.69 (s, 2 H, OCH20), 3.95 (s, 3 H, OCH3), 3.85 (t, 2 H,   J= 8.    0 Hz, OCH2CH2Si), 3.75 (t, 4 H,   J= 4.    7 Hz, OCH2CH2N), 3.10 (t, 4 H,   J= 4.    7
Hz, OCH2CH2N), 0.94 (t, 2 H,   J= 8.    0 Hz,   OCH2CH Si),-0.    04 (s, 9 H, Si   (C H3)    3;

   Mass Spec.: calc. for [C27H34BrN3O5Si+H]+ Theor. m/z =   588,    590; Obs. = 588,590.



  Reference Example 27d: 6-Methoxy-8- (4-methyl- [1, 4]   diazepan-1-yl)-4- (2-trimethylsilanyl-    ethoxymethoxy)-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



     To'a    yellow-green suspension of 8-bromo-6-methoxy-4- (2-trimethylsilanylethoxymethoxy)-quinoline-2-carboxylic acid (Reference Example 27c) (4-morpholin-4-ylphenyl)-amide (1.155 g, 1.96 mmol), N-methyl homopiperazine (0.39   mL,    3.14 mmol), and 4
A sieves in 30 mL anhydrous toluene was added Pd2 (dba)   2    (90.0 mg, 0.098 mmol) and
BINAP (0.358 g, 0.58 mmol). The resulting reddish brown mixture became lighter in color upon treatment with cesium carbonate (2.544 g, 7.81   mmol).    The reaction mixture was heated at reflux under nitrogen for 17 hours.

   The clear brown solution was cooled to room temperature, concentrated, and then purified by flash chromatography on silica gel using a slow gradient of 95: 5 to 50: 50 methylene chloride: methanol to afford the desired product (0.989 g, 81%).'H NMR (300 MHz, DMSO, d6) 8 9.88 (s, 1 H,   NE),    7.73 (s,   1    H,   ArH3),      7.    68 (d, 2 H, Jo= 8.9 Hz, ArH2' &  H6'), 7.00 d, 2 H, Jo= 8.9 Hz, ArH3' &  H5'), 6.94 (d, 1 H,
Jm= 2.7 Hz, ArH5), 6.66 (d, 1 H, Jm= 2.7 Hz, ArH7), 5.62 (s, 2 H, OCH2O), 3.87   (s,    3   H,      OCH3),    3.80 (t, 2 H,   J= 8.    0 Hz, OCH2CH2Si), 3.

   73 (t, 4 H,   J=    4.7 Hz, OCH2CH2N), 3.63 (t, 2
H,   J= 5.    9 Hz,   ArNCH2CH2CH2NCH3),    3.33 (bs, 2 H,   ArNCH2CH2NCH3),    3.09 (t, 4 H,   J=    4.7 Hz,   OCH2CH2N),    2.97 (bs, 2 H,   ArNCH2CH2NCH3),    2.69 (bs, 2 H,   ArNCH2CH2CH2NCH3),    2.35 (s, 3 H, NCH3), 2. 09 (bs, 2 H ArNCH2CH2CH2NCH3), 0. 94 (t, 2 H,   J= 8.    0 Hz,   OCH2CH Si),-0.    03 (s, 9 H, Si (C H3) 3; Mass Spec.: calc. for [C33H47N5O5Si=H]+ Theor. m/z = 622; Obs. = 622.



  Reference Example 28
EMI71.1     
 
Preparation of   8-Bromo-4-dimethylamino-6-methoxy-quinoline-2-carboxylic    acid (4 morpholin-4-yl-phenyl)-amide.



  Reference Example 28a: 8-Bromo-4-chloro-6-methoxy-quinoline-2-carboxylic acid (4morpholin-4-yl-phenyl)-amide.



   A   suspension of 8-bromo-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2-carboxylic    acid (Reference Example 27b) (1.75 mmol) in 20 mL methylene chloride was treated with oxalyl chloride (1.5 mL, 17.2 mmol) and catalytic   dimethylformamide    (3 drops). The reaction mixture bubbled vigorously and became clearer. The reaction was heated at reflux for 2 hours, cooled to room temperature, and concentrated to a pale yellow solid (kept under nitrogen).'
To a yellow solution of the acid chloride in 20 mL methylene chloride was added 4morpholinoaniline (0.347 g, 1.94 mmol) and diisopropylethyl amine (1.0 mL, 6.1 mmol). The solution became orange and gas evolution was observed. Within 30 minutes, solids began to precipitate from the solution. The reaction was stirred at room temperature for 1 hour.

   The solids were isolated by filtration and dried under high vacuum to afford the desired product (0.406   g,    49%). 1H NMR (300 MHz, DMSO,   d6)    8 10.15 (s, 1 H, C (O) NH), 8.33 (s, 1 H,   Ar ; 3),    8.10 (d, 1 H, Jm= 2.7 Hz, ArH7), 7.70 (d, 2 H, Jo=   9. 0    Hz,   Ar¯2  &  H6),    7.56   (du 1    H,
Jm= 2.7 Hz, ArH5), 7.01 (d, 2 H, Jo=9.0 Hz, ArH3' &  H5'), 4.06 (s, 3 H, OCH), 3.75 (t, 4 H, J= 4.8 Hz, OCH2CH2N), 3.11 (t, 4 H,   J= 4.    8 Hz,   OCH2CH2N)    ; Mass Spec.: calc. for.



     [C21HIgBrClN303+H] +    Theor.   milz =    476,478; Obs. = 476,478.



  Reference Example 28b: 8-Bromo-4-dimethylamino-6-methoxy-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   A solution of   8-bromo-4-chloro-6-methoxy-quinoline-2-carboxylic    acid (4-morpholin4-yl-phenyl)-amide (Reference Example 28a)   (0.    1512 g, 0.317 mmol) in 100 mL 2.0 M dimethyl amine in tetrahydrofuran was heated at   100  C    in a Parr bomb. The initial pressure was 75-80 psi and then remained at approximately 60 psi. After 18 hours, the reaction was cooled to room temperature, concentrated and dried to afford the crude product as a brown solid. Purification on silica gel using a gradient of 100: 0 to 95: 5 methylene chloride: methanol afforded the clean product (0.142 g, 92%). 1H NMR (300 MHz,   DMSO, d6) 8    10.20 (s,   1    H,
C (O) NH), 7.90 (d,   1 H, Jm-2. 7 Hz, Ar,-7.    69 (d,   2 H, Jo= 9. 0 Hz, ArH & .

   Hg-),    7.60 (s,   1   
H, ArH), 7. 41. (d, 1 H, Jm 2. 7 Hz, ArH7), 7.01 (d, 2 H, Jo=9.0 Hz, ArH3' &  H5'), 3.96 (s, 3
H, OCH), 3.75 (t, 4 H,   J= 4.    8 Hz,   OCH2CH2N),    3.10 (t, 4 H,   J= 4.    8 Hz,   OCH2CH2N),    3.08  (s, 6 H, N   (CH3)    2); Mass Spec.: calc. for   [C2lHlsBrClN303+H]    + Theor. m/z =   485,    487;

   Obs.   =    485,487
Reference Example 29
EMI73.1     

 Preparation of   6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-carboxylic    acid
Reference Example 29a: 8-Bromo-6-fluoro-4-methoxy-quinoline-2-carboxylic acid methyl ester
Into a 150 mL 3 neck round bottom flask equipped with a reflux condenser, magnetic stirrer and nitrogen inlet is placed 2.0 g (6.76 mmol, 1.0 equiv.) of 8-Bromo-6-fluoro-4-oxo  1,      4-dihydro-quinoline-2-carboxylic    acid methyl ester. This material is then dissolved in 50 mL of NMP. Then 300 mg (7.44 mmol, 1.1 equiv.) of a 60% dispersion of sodium hydride in oil is cautiously added portion-wise to the solution at room temperature. A yellow color then develops, indicating that formation of the anion has occurred, with hydrogen evolution.



  Stirring of the anion solution is continued for one hour, then 1.14 g, 500 pL (8.04 mmol, 1.2 equiv.) of iodomethane is added via syringe. The mixture is allowed to react for two hours additional, then is cautiously quenched with 20 mL of water. The solids, which precipitate upon dilution in 1L of water, are collected by filtration, then washed with water to give the pure O methylated material as 2.1 g (98%) of a colorless solid.



  Mass Spec.: calc. for   [Cl2HgBrFNO3+H] +    Theor. m/z = 314,316; Obs. = 314,316
Alternatively, into a 100 mL 3 neck round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is placed   350    mg (1.17 mmol, 1.0 equiv.) of 8  Bromo-6-fluoro-4-oxo-1,    4-dihydro-quinoline-2-carboxylic acid methyl ester and 242 mg (1.75 mmol, 1.5 equiv.)   of K2C03.    This material is suspended in 20 mL of DMSO then heated to 70    C    for 1 hr. The anion formation of the anion is apparent when the mixture becomes cloudy. The mixture is allowed to cool to 35    C    then 331 mg, 145   RL    (2.33 mmol,   2.    0 equiv.) of methyl iodide are added and stirring is continued for 2 hr.

   At the end of this time it is determined if the reaction is complete by LC/MS. Upon completion the mixture is poured into 200 mL of water and the solids which form are collected by filtration and washed with water to give 340 mg (93%) of the   Q-methylated    product after drying.



  Reference   Example 29b    :   6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-    carboxylic acid methyl ester
Into a 250mL, 3 neck round bottom flask equipped with a reflux condenser, magnetic stirrer and nitrogen inlet is added 2.1 g (6.68 mmol, 1.0 equiv.) of   8-Bromo-6-fluoro-4-    methoxy-quinoline-2-carboxylic acid methyl ester (Reference Example 29a) (122 mg, 0.134 mmol, 0.02 equiv.) of tris dibenzylidineacetone dipalladium, 499. mg (0.802 mmol, 0.12 equiv.) of racemic 2, 2'-bis   (diphenylphosphino)-1, 1'-binapthyl    and 1 g of 4 A molecular sieves and 80 mL of dry toluene.

   To the stirred suspension is then added 736 mg, 815   RL,    (7.35 mmol,   1.      1    equiv.) of   1-methylpiperazine,    followed by 3.05 g (9.35 mmol, 1.4 equiv.) of cesium carbonate. The mixture is then heated to 80    C    for 36 hr. At the end of this time completion was monitored by LC/MS analysis of an aliquot. When the reaction was determined to be complete it was cooled to room temperature then filtered through a plug of celite, with toluene washing to remove solid by products. Purification by flash chromatography using a gradient of 5 to 20% methanol in methylene chloride as eluent yielded 2.0 g, (90%) of the desired product.

   Mass Spec.: calc. for   [Cl7H20FN303+H]    + Theor. m/z = 334; Obs. =   334   
Reference Example 29c:   6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-    carboxylic acid
Into a 125 mL   erlenmeyer    flask containing 30 mL of THF and 30 mL of methanol is placed 2.1 g (6.3 mmol)   of 6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-    carboxylic acid methyl ester (Reference Example 29b). To this solution is added with stirring 30 mL of water in which is dissolved 291 mg (6.9 mmol, 1.1 equiv.) of lithium hydroxide monohydrate.

   This solution is allowed to react for 1 hr then is quenched with 10 mL   of 2N      HC1 solution.    The solution is then filtered and the solids washed with 10 mL of 0.5 N   HC1    solution. The combined filtrates are then concentrated to give 2.15 g, (95%) of the solid yellow product as the hydrochloride salt. Mass Spec.: calc. for   [C, 6HI8FN303+H] +    Theor.   m/z      = 320    ; Obs. = 320 
Example 1
EMI75.1     
    8-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl) phenyl]-4-oxo-4H-chromene-2-    carboxamide.



     8- (4-methyl-1-piperazinyl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 1) (400   mg, 1.    23 mmol) was suspended in anhydrous N, N   dimethylformamide    (20 ml) and triethylamine (0.69 ml, 4.92 mmol) was added to give a clear solution. The following were added in order: 1-hydroxybenzotriazole (HOBt (205 mg, mol)),   Q-      H-Benzotriazol-1-yl)-N,    N, N',   N'-pentamethylene-uronium    tetrafluoroborate (TBTU (435 mg, 3.1 mmol)) then   4- (dimethylamino)    pyridine (25 mg). After stirring for 5 min at room temperature,   4- (4-morpholinyl)    aniline (Reference Example 21) (220 mg, mmol). The reaction stirred overnight at room temperature.

   The solution was concentrated in vacuo, the remains were partitioned between   chloroform/saturated    sodium bicarbonate, extracted (x3) with chloroform, dried   (MgS04)    and concentrated in vacuo to give the crude product.



   Chromatography on silica (230-400 mesh ASTM) and eluting ethyl acetate followed by 2.5-5% methanol/chloroform gave 190 nig (% yield)   of 8-(4-methyl-1-piperazinyl)-N-      [4- (4-morpholinyl) phenyl]-4-oxo-4H-benzochromene-2-carboxamide    as a yellow solid (mp 217-218  decomposition and melt 244-247C). LC/MS. (M+1)   m/z = 449.    



  Example 2
EMI76.1     
   2-{1- [4- (2-Methoxy-phenyl)-piperazin-1-yl]-methanoyl}-8- (4-methyl-piperazin-1-yl)-    chromen-4-one.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 1- (2
Methoxy-phenyl)-piperazine (Aldrich) via the same procedure used in example 1, yielding a yellow solid. MS (M+H) m/z =   463.   



  Example 3
EMI76.2     
   2- {1- [4- (I-Acetyl-2, 3-dihydro-IH-indol-6-yl)-piperazin-1-yl]-methanoyl)-8- (4-methylpiperazin-1-yI)-chromen-4-one.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   1-(6-Piperazin-l-yl-2,    3-dihydroindol-1-yl)-ethanone (Reference Example 8) as prepared in Example 1, yielding a yellow solid. MS (M+H) m/z = 516. 



  Example 4
EMI77.1     

2-Chloro-5-(4-{1-[8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}  piperazin-1-yl)-benzonitrile.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and 2-chloro-5-piperazin-1-yl benzonitrile (Reference Example   9)    as prepared in Example 1, yielding a yellow solid. MS (M+H) m/z = 493.



  Example 5
EMI77.2     
   2-f 1- [4- (4-Methoxy-phenyl)-piperazin-1-yl]-methanoyll-8- (4-methyl-piperazin-l-yl)chromen-4-one.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available (Aldrich)   1- (4-Methoxy-phenyl)-piperazine    as prepared in example 1, yielding a yellow solid. MS (M+H) m/z = 463. 



  Example 6
EMI78.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (5-furan-2-yl-1H-pyrazol-    3-yl)-amide.



  This compound was prepared from 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2carboxylic acid hydrochloride (Reference Example 1) and commercially available 5-furan-2  yl-lH-pyrazol-3-ylamine (Maybridge)    as prepared in example   1,    yielding a yellow solid. MS (M+H) m/z   = 420.   



  Example 7
EMI78.2     
   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-imidazol-1-yl-phenyl)-    amide.



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 4  imidazol-1-yl-phenylamine    (Aldrich) as prepared in Example 1, yielding a yellow solid. MS (M+H) m/z = 430. 



  Example 8
EMI79.1     

   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (4- [1,    2,3] thiadiazol-5-ylphenyl)-amide.



   This   compound was, prepared from 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   4- [1,    2,3] thiadiazol-5-ylphenylamine (Reference Example 10) as prepared   in.    Example 1, yielding a yellow solid. MS   (M+H) m/z    =   448.   



  Example 9
EMI79.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   4- [1,    2,3] thiadiazol-5-ylbenzylamide.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available (Maybridge)   4-[1,    2,3] thiadiazol-5-yl-benzylamine as prepared in Example 1, yielding a yellow solid. MS (M+H) m/z = 462. 



  Example 10
EMI80.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (4-acetyl-piperazin-1-    yl)-phenyl]-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   1- [4- (4-amino-phenyl)-piperazin-    1-yl]-ethanone (Reference Example 11) as prepared in Example 1, yielding a yellow solid.



  MS (M+H) m/z = 499.



  Example 11
EMI80.2     
    8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4- (4-methanesulfonyl-    piperazin-1-yl)-phenyl]-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   4- (4-methanesulfonyl-piperazin-    1-yl)-phenylamine (Reference Example 12) as prepared in Example 1, yielding a yellow solid.



  MS (M+H)   m/z =    526. 



  Example 12
EMI81.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (2-methoxy-4-morpholin  4-yl-phenyl)-amide.   



     8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 1) (0.10 g, 0.35mmol), HOBt (0.10 g, 0.7mmol), TBTU (0.225 g, 0.7mmol),. 4- (dimethylamino) pyridine   (0, 01    g, catalytic amount), triethylamine (0.15   mL,.   



  1.04mmol), and commercially available 2-methoxy-4-morpholin-4-yl-phenylamine (SALOR) (0.08 g, 0.38mmol) were dissolved in   dimethylformamide    (2.5 mL) and stirred at room temperature overnight. Ethyl acetate (150 mL) was added and the resulting mixture was washed with water (3 x 50 mL), dried   (Na2S04),    filtered, concentrated under vacuum and triturated with ether to yield a yellow solid (85 mg,   54%).    LCMS: m/z = 480.3
Example 13
EMI81.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-chloro-4-morpholin-4  yl-phenyl)-amide.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 3-chloro4-morpholin-4-yl-phenylamine (Maybridge) as prepared in Example 12, yielding a yellow solid.   (110    mg =   73%),    LCMS-m/z = 483.5 
Example 14
EMI82.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-thiomorpholin-4-ylphenyl)-amide.



   This compound was prepared from 8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene2-carboxylic acid hydrochloride (Reference Example 1) and   4-thiomorpholin-4-yl-    phenylamine (Reference Example 13) as prepared in Example 12, yielding a yellow solid. (55   mg = 38%), LCMS-m/z =    465.5
Example 15
EMI82.2     
 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (2,5-diethoxy-4morpholin-4-yl-phenyl)-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 2,5diethoxy-4-morpholin-4-yl-phenylamine (Aldrich) as prepared in Example 12, yielding a yellow solid. (80 mg = 50%), LCMS-m/z = 537.6 
Example 16
EMI83.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-cyanomethyl-phenyl)amide.



   This compound was prepared from 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene2-carboxylic acid hydrochloride (Reference Example 1) and commercially available (4amino-phenyl)-acetonitrile (Aldrich) as prepared in Example 12, yielding a yellow solid.   (65    mg = 54%), LCMS-m/z = 403.5
Example 17
EMI83.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (1 H-indol-5-yl)-amide.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available   1H-    indol-5-ylamine (Aldrich) as prepared in Example 12, yielding a yellow solid. (35 mg =   29%),      LCMS-m/z = 401.    6
Example 18
EMI83.3     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (1-morpholin-4-ylmethanoyl)-phenyl]-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   1- (4-amino-phenyl)-1-    morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 12, yielding a yellow solid. (21 mg = 15%),   LCMS-m/z    = 477.6
Example   19   
EMI84.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (2,    6-dimethyl  morpholin-4-yl)-phenyl]-amide.   



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 4- (2, 6dimethyl-morpholin-4-yl)-phenylamine (Maybridge) as prepared in Example 12, yielding a yellow solid. (60 mg = 42%), LCMS-m/z = 477.6   Example 20   
EMI84.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (4-fluoro-phenoxy)-    phenyl]-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available   4- (4-    fluoro-phenoxy)-phenylamine (Maybridge) as prepared in Example 12, yielding a yellow solid. (110 mg = 77%), LCMS-m/z = 475.6
Example 21
EMI85.1     
    8-(4-Methyl-piperazin-1-yl)-2-(6-morpholin-4-yl-benzooxazol-2-yl)-chromen-4-one.   



   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride (Reference Example 1) (0.532 g,   1.      85mmol)    was placed in a 25 mL 3-neck flask under nitrogen and treated with PPA (6 g). The mixture was then treated with the prepared intermediate   4-amino-3-hydroxyphenylmorpholine    (0.43 g   of-85% pure,-2mmol).    The mixture was stirred and heated in an oil bath to   205 C    for 3 hours to give a dark liquid. The mixture was cooled to room temperature and treated with 10 mL of water to give a dark solution. The solution was slowly neutralized with IN aqueous sodium hydroxide to   pH-7    as a solid formed.

   The solid was collected, washed several times with water, air dried, and vacuum dried at room temperature to give 0.65 g of a black solid. TLC   (10% MeOH    in   CHC13    on   Si02)    showed 2 major components at   Rifs0.    5 and several lower Rf minor components. The solid was triturated with saturated aqueous sodium bicarbonate at room temperature. It was filtered off, washed several times with water, and air dried to give 0.65 g of a dark gray solid.



  TLC showed the same components seen previously. Mass spectral analysis showed m/e = 447 by positive ion CI and m/e = 446 by negative ion CI. The solid was dissolved in 2% methanol in chloroform and it was chromatographed on a Megabond Elute silica gel column (10 g of
Si02) using 2% methanol in chloroform. The slightly faster Rf yellow component was concentrated to give 0.0188 g of a yellow solid. CI mass spectral analysis showed m/e = 447 as the base peak by positive ion CI. The solid was recrystallized in methanol to give 0.0178 g of a yellow solid with a melting point of   158. 1-158. 8 C.    Proton NMR   (CDC13)    and CI mass spectral analyses were consistent for the desired product   (m/z    = 447 base peak by positive ion
CI and m/z = 446 base peak by negative ion CI). 



  Example 22
EMI86.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (2-hydroxy-4-morpholin-      4-yl-phenyl)-amide.   



     8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 1) (0.3768 g, 1.16 mmol) was placed in a 100 mL 3-neck flask under nitrogen and it was dissolved in 20 mL of DMF. The solution was treated with triethylamine   (0.      49mL,    3.5mmol) followed by HOBT hydrate (0.36g, 2.3mmol) followed by TBTU (0.74 g, 2.3mmol) and then followed by DMAP (0.020 g). The mixture was stirred for 10 minutes and then it was treated with 4-amino-3-hydroxyphenylmorpholine (Reference example 21) (0.228 g, 1.17   mmol). The    mixture was stirred for 15 minutes and then it was treated with triethylamine (0.17 mL, 1.2 mmol).

   The mixture was stirred at room temperature for 42 hours and then it was added to   a    solution of 50 mL of saturated aqueous sodium bicarbonate and 50 mL of water. The mixture was extracted 4 times with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to give 0.834 gram of a purple oil. The oil was dissolved in 2 percent methanol in chloroform and it was placed on a silica gel column (5.5 cm diameter by 10.5 cm long) and eluted with 2 percent methanol in chloroform followed by 5 percent methanol in chloroform. The yellow fraction was concentrated to give 0.2031 gram of an orange-yellow solid. The solid was dissolved in methanol, filtered through a medium sintered glass funnel, and concentrated to a few ml volume as a solid formed.

   The solid was filtered off, washed with methanol, and air dried to give 0.1613 gram of a tan solid with MP of 248.4-249. 6 C. Proton COSY NMR and CI mass spectral analyses were consistent for the desired product   (m/z    = 465 by positive ion CI and m/z = 463 by negative ion CI). 



  Example 23
EMI87.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (5-ethoxy-benzothiazol-2-      yl)-amide.   



   This compound was prepared from 8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene2-carboxylic acid hydrochloride (Reference Example   1)    and commercially available   5-ethoxy-    benzothiazol-2-ylamine (SALOR) as prepared in Example 12, yielding a yellow solid. (55 mg = 39%),   LCMS-m/z    = 465.3
Example 24
EMI87.2     
 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-bromo-phenyl)-amide.



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and commercially available 4-bromophenylamine (Aldrich) as prepared in Example 12, yielding a yellow solid. (1.0 g = 75%),
LCMS-m/z = 442.4 
Example 25
EMI88.1     
   8- (4-Methylpiperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   methyl- (4-morpholin-4-yl-    phenyl)amide.



     8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4yl-phenyl)-amide (Example 1) (0.1046 g, 0.2332 mmol) was placed in a 10 mL single neck round flask under nitrogen. The solid was dissolved in 2.8 mL of anhydrous DMF. The yellow solution was stirred at room temperature and treated with one portion of sodium hydride (0.011 g of 95%, 0.44   mmol).    The mixture evolved gas and became a red solution. It was stirred under nitrogen for 20 minutes and then it was treated with iodomethane (0.015 mL, 0.033 g, 0.233 mmol). The mixture was sealed and stirred at room temperature for 18 hours.



   The reaction mixture was concentrated to remove most of the DMF (35 C bath   &commat;    0.5   mm)    to give a dark semisolid. It was treated with a few drops of water followed by 10 mL of ethyl acetate. The mixture was dried over magnesium sulfate, filtered, and concentrated to give 0.0564 gram of a yellow glass. The glass was triturated with diethyl ether, filtered off, and dried under high vacuum to give 0.0302 g of a tan solid with MP of 245.0-246.8 C.



  Proton NMR and CI mass spectral analyses were consistent for the desired product   (m/z =    463 by positive ion CI).



  Example 26
EMI88.2     
   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-2-carboxylic acid    (3-morpholin-4-yl  phenyl)-amide..   



   This compound was prepared from 8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene2-carboxylic acid hydrochloride (Reference Example 1) and 3-morpholin-4-yl-phenylamine (Reference Example 18) as prepared in Example 12, yielding a yellow solid. (120 mg = 86%),
LCMS-m/z = 449.5
Example 27
EMI89.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-cyano-4-morpholin-4yl-phenyl)-amide.



   This compound was prepared   from 8-. (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and 5-amino-2-morpholin-4-ylbenzonitrile (Reference Example 15) as prepared in Example 12, yielding a yellow solid. (120 mg =   82%),    LCMS-m/z = 474.5
Example 28
EMI89.2     
   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-fluoro-4-morpholin-4  yl-phenyl)-amide.   



   This compound was prepared from   8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   3-fluoro-4-morpholin-4-yl-    phenylamine (Reference Example 16) as prepared in example 12, yielding a yellow solid.



  (120 mg = 83%),   LCMS-m/z    = 467.6 
Example 29
EMI90.1     
   4- [4- (f 1- [8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyll-amino)-phenyl]-      piperazine-1-carboxylic    acid tert-butyl ester.



   This compound was prepared from   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-    2-carboxylic acid hydrochloride (Reference Example 1) and   4- (4-amino-phenyl)-piperazine-    1-carboxylic acid ter-butyl ester (Reference Example 17) as prepared in example 12, yielding a yellow solid. (260 mg = 53%), LCMS-m/z = 548.6
Example 30
EMI90.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (4-piperazin-1-yl-    phenyl)-amide.



   4-[4-({1-[8-(4-Methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-amino)phenyl]-piperazine-l-carboxylic acid tert-butyl ester (Example 29) (160 mg, 0.3 mmol) was dissolved ethyl acetate (20 mL) and cooled to   0 C.      HC1    gas was bubbled in slowly for 2 minutes. A solid began to precipitate. Methanol (3-4 mL) was added to dissolve this solid and HCl gas was bubbled in for another 2 minutes.

   The mixture was concentrated under reduced pressure and triturated with ether and dried under vacuum to yield a tan solid (100 mg, 76%).   LCMS/m/z = 448.    6 
Example 31
EMI91.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin4-yl-phenyl)-amide:

      6-Methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 2) (3.0g, 8.5 mmol), TBTU   (5.      5g,    17 mmol),   1-    hydroxybenztriazole (2.6g, 17 mmol),   4-dimethylaminopyridine      (0.      05g,    catalytic) and commercially available 4-morpholin-4-yl-aniline (1.66g, 9.3 mmol) were dissolved in   dimethylformamide    (100 mL). Triethylamine (3.5 mL, 25 mmol was added and this mixture stirred at room temperature for 17 hours. The reaction mixture was concentrated under vacuum and the residue was partitioned between chloroform (400 mL) and saturated aqueous sodium bicarbonate (50 mL).

   The organic layer was separated, dried   (Na2S04),    vacuum-filtered and concentrated under vacuum. The residue was purified by chromatography on silica eluted with 25% methanol in chloroform and then triturated with ether to yield a yellow powder. (1.6 g = 39%)
LCMS-m/z = 479.5 mp =   234-236  C.   



  Example 32
EMI91.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4  methanesulfonyl-piperazin-1-yl)-phenyl]-amide.   



   This compound was prepared from   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and   4- (4-methanesulfonyl-    piperazin-1-yl)-phenylamine (Reference Example 12) as prepared in example   1,    yielding a yellow solid. GC/MS   (EI,    M+) m/z = 556
Example 33
EMI92.1     
   6-Methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-chloro-4  morpholin-4-yl-phenyl)-amide.   



   This compound was prepared from   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and commercially available   3-chloro-4-morpholin-4-yl-phenylamine    (Maybridge) as prepared in Example 12, yielding a yellow solid. (45mg   = 31 %)    LCMS-m/z = 513.5
Example 34
EMI92.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-fluoro-4morpholin-4-yl-phenyl)-amide.



   This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 3-fluoro-4-morpholin4-yl-phenylamine (Reference Example 16) as prepared in Example 12, yielding a yellow solid.   (SSmg = 61%), LCMS-m/z    = 497.5 
Example 35
EMI93.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (2-methoxy-4morpholin-4-yl-phenyl)-amide.



   This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and commercially available 2-methoxy-4-morpholin-4-yl-phenylamine (SALOR) as prepared in Example 12, yielding a yellow solid.   (55mg    = 38%), LCMS-m/z = 510.5
Example 36
EMI93.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4thiomorpholin-4-yl-phenyl)-amide.



   This compound was prepared from 6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4Hchromene-2-carboxylic acid hydrochloride (Reference Example 2) and 4-thiomorpholin-4-ylphenylamine (Reference Example 13) as prepared in Example 12, yielding a yellow solid.



  (99mg = 71%), LCMS-m/z = 495. 5 
Example 37
EMI94.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (2, 6dimethyl-morpholin-4-yl)-phenyl]-amide.



   This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and commercially available 4- (2, 6-dimethyl-morpholin-4-yl)-phenylamine (Maybridge) as prepared in Example 12, yielding a yellow solid. (70mg = 49%),   LCMS-m/z    = 507.5
Example 38
EMI94.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-morpholin4-yl-phenyl)-amide.



   This compound was prepared from 6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4Hchromene-2-carboxylic acid hydrochloride (Reference Example 2) and 3-morpholin-4-ylphenylamine (Reference Example 18) as prepared in Example   12,    yielding a yellow solid.



     (80mg =    60%),   LCMS-m/z    = 479.5 
Example 39
EMI95.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid f4- [4- (2  hydroxy-ethyl)-piperazin-1-yl]-phenyl}-amide.   



   This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-l-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and   2- [4- (4-amino-      phenyl)-piperazin-l-yl]-ethanol    (Reference Example 19) as prepared in Example 12, yielding a yellow solid. (80mg = 60%). mp = 211.5-212.2 (dec.), MS-base peak at m/z =492 by positive ion and   m/z    =490 by negative ion CI
Example 40
EMI95.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (l-      morpholin-4-yl-methanoyl)-phenyl]-amide.   



   . This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 2) and 1-(4-amino-phenyl)-1morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 12, yielding a yellow solid. (170mg   = 80%),    LCMS-m/z = 507.5 
Example 41
EMI96.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-cyano-4  morpholin-4-yl-phenyl)-amide.   



   This compound was prepared from   6-methoxy-8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid hydrochloride (Reference Example 2) and 5-amino-2-morpholin4-yl-benzonitrile (Reference Example 15) as prepared in Example 12, yielding a yellow solid.



  (120mg = 57%),   LCMS-m/z    = 504.5
Example 42
EMI96.2     
   4- [4- ( { 1- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-      amino)-phenyl]-piperazine-l-carboxylic    acid tert-butyl ester.



   The   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 2) (1.04 g, 2.93 mmol) was placed in a 250 ml 3-neck flask under nitrogen and it was dissolved in 50 ml of DMF. The solution was treated with triethylamine (1.22 mL, 8.79 mmol) followed by HOBT hydrate (0.90 g,   5.    9 mmol) followed by TBTU (1.88 g, 5.9 mmol) and then followed by DMAP (0.056 g, 0.46   mmol).    The mixture was stirred for 10 minutes and. then it was treated with 4- (4-Amino-phenyl)-piperazine-lcarboxylic acid ter-butyl ester (Reference Example 17) (0.81 g, 2.9 mmol). The mixture was stirred for 15 minutes and then it was treated with triethylamine (0.41 mL, 2.9 mmol).

   The mixture was stirred at room temperature for 18 hours and then it was concentrated   (1    mm Hg pressure, 45 C bath) to give a dark liquid. The concentrate was treated with 80 mL of saturated aqueous sodium bicarbonate and extracted with ethyl acetate forming a suspended yellow solid in the organic layer. The solid was filtered off, washed with diethyl ether, washed with water, and vacuum dried   (O.    lmm Hg pressure   &commat;    25C) to give 0.36 gram of a yellow solid, M. P. = 232.3-232.8   C.   



  Proton NMR and CI mass spectral analyses were consistent for the desired product (m/e = 578 by positive ion CI and   m/e    = 576 by negative ion CI).



  The aqueous layer was extracted twice with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to give 1.35 gram of a dark semisolid. It was triturated with diethyl ether and allowed to stand at room temperature as a solid formed. The solid was filtered off, washed with diethyl ether, and vacuum dried at room temperature to give 0.4816 gram of a yellow solid. CI mass spectral analyses was consistent for the desired product   (M/Z    =   578    BY positive ion CI AND M/Z = 576 by negative ion CI). 



  Example 43
EMI98.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-piperazin1-yl-phenyl)-amide.



   The   4- [4- ( { 1- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-      methanoyl}-amino)-phenyl]-piperazine-l-carboxylic    acid tert-butyl ester (Example 42) (0.792 gram, 1.37 mmol) was placed in a 50 ml round flask under nitrogen and it was dissolved in 15 ml of methylene chloride. The solution was treated with   15'ml of trifluoroacetic    acid (195 mmol) to give a dark solution and it was stirred at room temperature for 18 hours. It was concentrated to give a brown foam. The foam was treated with 30 ml of saturated aqueous sodium bicarbonate and it was stirred at room temperature as a yellow solid formed. The solid was filtered off, washed several times with water, air dried and dried under high vacuum (0.1 mm Hg pressure) to give 0.493 gram, of a yellow solid, M. P. = 203.6-204.7 C.



   Proton NMR and CI mass spectral analyses were consistent for the desired product (m/z = 478 by positive ion CI and m/z = 476 by negative ion CI).



  Example 44-54
The following examples were prepared in parallel by acylation of 6-methoxy-8- (4  methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   (4-piperazin-1-yl-phenyl)-    amide (Example 43) in an Argonaut Quest synthesizer.



   The piperazine side chain was derivatized in parallel fashion using eleven different commercially available acylating and sulfonating reagents. The resins used were Argonaut
Tech polystyrene amine resins. Each 5 ml Quest tube was charged with 0.010 gram (0.021 mmol) of the starting N-H piperazine and   3ml    of methylene chloride followed by 4 equivalents (0.08 mmol)   of PS-DIEA    resin (diisopropylbenzylamine PS resin) to scavenge   HC1.    Each tube was then treated with an acyl chloride, sulfonyl chloride, or isocyanate (2. equivalents of each) followed by a little more methylene chloride. The tubes were sealed under nitrogen, and stirred for 3 hours at room temperature.

   The mixtures were then opened and treated with about 4 equivalents (0.08 mmol) of PS-trisamine resin (primary amine PS resin) to scavenge any excess   acylating    or sulfonating reagent. The mixtures were sealed and stirred for 1.5 hours and then filtered directly into vials and concentrated to give the products.



  The products were characterized by HPLC mass spectral analysis and were found to be greater than 90% pure by HPLC. The compounds were submitted to the   5-HTlb    binding assay for determination of   5-HT    receptor binding affinities and selectivities.



  Example 44
EMI99.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4propionyl-piperazin-1-yl)-phenyl]-amide.



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available propionyl chloride (Aldrich) via the parallel synthesis described above.

   MS-base peak at m/z =534 by positive ion CI
Example 45
EMI99.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4- (4-ethane    sulfonyl-piperazin-1-yl)-phenyl]-amide.   MS-base    peak at m/z =570 by positive ion CI 
This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available ethanesulfonyl chloride (Aldrich) via the parallel synthesis described. above.



  Example 46
EMI100.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4dimethyl   sulfamoyl-piperazin-1-yl)-phenyl]-amide.   



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available dimethylsulfamoyl chloride (Aldrich) via the parallel synthesis described above. MS - base peak at m/z   =585    by positive ion CI
Example 47
EMI100.2     
   4- [4- ( 1- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-      amino)-phenyl]-piperazine-l-carboxylic    acid dimethylamide.



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and commercially available dimethylcarbamyl chloride (Aldrich) via the parallel synthesis described above. MS   - base    peak at   m/z    =549 by positive ion CI 
Example 48
EMI101.1     
   4- [4- ( { 1- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-      amino)-phenyl]-piperazine-l-carboxylic    acid ethylamide.



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and commercially available ethyl isocyanate (Aldrich) via the parallel synthesis described above.



  MS-base peak at m/z =549 by positive ion CI.



  Example 49
EMI101.2     
   4- [4- (11- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl)amino)-phenyl]-piperazine-l-carboxylic acid cyclohexylamide.   



   This compound was prepared from 6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4Hchromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and commercially available cyclohexyl isocyanate (Aldrich) via the parallel synthesis described above. MSbase peak at   m/z    =603 by positive ion CI 
Example 50
EMI102.1     
   4- [4- ( {1- [6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-      amino)-phenyl]-piperazine-l-carboxylic    acid cyclopentylamide.



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available cyclopentanecarbonyl chloride (Aldrich) via the parallel synthesis described above.



     MS-base    peak at m/z =574 by positive ion CI.



  Example 51
EMI102.2     
 6-Methoxy-S- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4- [4- (1  pyrrolidin-1-yl-methanoyl)-piperazin-1-yl]-phenyl}-amide.   



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available   1-pyrrolidinecarbonyl    chloride (Aldrich) via the parallel synthesis described above.



  MS-base peak at m/z =575 by positive ion CI. 



  Example 52
EMI103.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid {4- [4  (propane-2-sulfonyl)-piperazin-1-yl]-phenyl}-amide.   



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available isopropylsulfonylonyl chloride (Aldrich) via the parallel synthesis described above.



  *MS-base peak at   m/z    =584 by positive ion CI.



  Example 53
EMI103.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   {4- [4- (2-    methyl-propanoyl)-piperazin-1-yl]-phenyl}-amide.



   This compound was prepared from   6-methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid   (4-piperazin-1-yl-phenyl)-amide    (Example 43) and commercially available isobutyryl chloride (Aldrich) via the parallel synthesis described above. MS-base peak at m/z =548 by positive ion CI. 



  Example 54
EMI104.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4- [4- (1-    morpholin-4-yl-methanoyl)-piperazin-1-yl]-phenyl}-amide.



   This compound was prepared from   6-methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (Example 43) and commercially available morpholine-4-carbonyl chloride (Aldrich) via the parallel synthesis described above.



  MS-base peak at m/z =591 by positive ion CI.



  Example 55
EMI104.2     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4  yl-phenyl)-amide.   



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 4-morpholin-4-ylphenylamine (Reference Example 20) as prepared in Example 1, yielding a yellow solid. MS (M+H)   m/z    = 467 
Example 56
EMI105.1     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4  methanesulfonyl-piperazin-1-yl)-phenyl]-amide.   



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 4- (4-methanesulfonyl  piperazin-l-yl)-phenylamine (Reference    Example 12) as prepared in Example 1, yielding a yellow solid. MS   (M+H)      m/z    = 544
Example 57
EMI105.2     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4-acetyl  piperazin-1-yl)-phenyl]-amide.   



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid hydrochloride (Reference Example 3) and   1- [4- (4-amino-      phenyl)-piperazin-l-yl]-ethanone    (Reference Example 11) as prepared in Example   1,    yielding a yellow solid. MS (M+H) m/z = 508 
Example 58
EMI106.1     
   6-Fluoro-8-(4-methyl-piperazin-s1-yl)-4-oxo-4H-chromene-2-carboxylic acid (3-chloro-4-    morpholin-4-yl-phenyl)-amide.



     6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid hydrochloride (Reference Example 3) (150 mg, 0.43 mmol), 1-hydroxybenzotriazole (140 mg, 0.9 mmol),   0-      H-Benzotriazol-1-yl)-N,    N, N', N'-pentamethylene-uronium tetrafluoroborate (290 mg, 0.9 mmol),   4- (dimethylamino) pyridine    (10 mg, catalytic), triethylamine (0.2 mL, 1.5 mmol), and commercially available 3-chloro-4-morpholin-4-ylphenylamine (Maybridge) were dissolved in dimethylformamide (2.5 mL) and stirred at room temperature overnight. At 17 h, water (20 mL) was added and the resulting mixture was stirred for 15-30 min. The mixture was vacuum-filtered and the residue washed with water and air-dried to yield a yellow powder (220 mg = quantitative yield).

   LC/MS-m/z = 501.5
Example 59
EMI106.2     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-fluoro-4morpholin-4-yl-phenyl)-amide.



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 3-fluoro-4-morpholin  4-yl-phenylamine    (Reference Example 16) as prepared in Example 58, yielding a yellow solid   (210 mg = 99%). LC/MS-m/z =    485.5   Example 60   
EMI107.1     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-cyano-4morpholin-4-yl-phenyl)-amide.



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 3) and 5-amino-2-morpholin4-yl-benzonitrile (Reference Example 15) as prepared in Example 58, yielding a yellow solid   (210 mg = 99%). LC/MS-m/z =    492.5
Example 61
EMI107.2     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (1-      morpholin-4-yl-methanoyl)-phenyl]-amide.   



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 3) and   1- (4-amino-phenyl)-1-    morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 58, yielding a yellow solid (220 mg = quantitative yield). LC/MS-m/z = 495.5
Example 62
EMI107.3     
 
   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4 yl-phenyl)-amide.



   This compound was prepared from   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 4) and 4-morpholin-4-yl phenylamine (Reference Example 20) as prepared in Example   1,    yielding   a    yellow solid.



     LCMS-m/z = 463.    6
 Example 63
EMI108.1     
 6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid   [4- (1-    morpholin-4-yl-methanoyl)-phenyl]-amide.



   This compound was prepared from   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 4) and   1- (4-amino-phenyl)-1-    morpholin-4-yl-methanone (Reference Example 14) as prepared in Example 1, yielding a yellow solid. LCMS-m/z = 491.6
Example 64
EMI108.2     
   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (3-fluoro-4  morpholin-4-yl-phenyl)-amide.   



   This compound was prepared from   6-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 4) and 3-fluoro-4-morpholin 4-yl-phenylamine (Reference Example 16) as prepared in Example   1,    yielding a yellow solid.



  LCMS-m/z = 504. 5
Example 65
EMI109.1     
   6-Chloro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4  yl-phenyl)-amide.   



  This compound was prepared from   6-chloro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-      chromene-2-carboxylic    acid hydrochloride (Reference Example   5)    and 4-morpholin-4-ylphenylamine (Reference Example 20) as prepared in Example   1,    yielding a yellow solid.



     LCMS-m/z = 483.    3
Example 66
EMI109.2     
   5-Methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4yl-phenyl)-amide.



   This compound was prepared from 5-methyl-8- (4-methyl-piperazin-1-yl)-4-oxo-4H  chromene-2-carboxylic    acid hydrochloride (Reference Example 6) and 4-morpholin-4-ylphenylamine (Reference Example 20) as prepared in Example   1,    yielding a yellow solid (116 mg = 84%) LCMS-m/z = 463.5 
Example 67
EMI110.1     
   5-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin4-yl-phenyl)-amide.



   This compound was prepared from 5-methoxy-8-   n-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid hydrochloride (Reference Example 7) and 4-morpholin-4-ylphenylamine (Reference example 20) as prepared in Example 1, yielding a yellow solid (149   mg = 50%) LCMS-m/z = 479.    4
The following additional examples incorporate   4-substituted piperazine-l-yl-phenyl amides    similar in structure to Examples 44-54
Example 68
EMI110.2     
 6-Methoxy-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4-[4-(3  hydroxy-propanoyl)-piperazin-1-yl]-phenyl}-amide.   



     6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4piperazin-l-yl-phenyl)-amide (Example 43) (1.5 gram, 2.12 mmol) was placed in a 100 mL flask with 50 mL   of CH2C12.    This suspension was treated with triethylamine   (4    equivalents, 1.2   mL,    8.5 mmol) and   p-propionylactone    (0.2 mL, 3.2 mmol) and the reaction stirred at room temperature for 2 hours, then heated to   50 C    for 2 hours. Then 0.8 mL more ofbpropionylactone was added and the reaction heated for 4 hours more. The reaction was allowed to cool to room temperature and then concentrated (1 mm Hg pressure). The concentrate was treated with saturated aqueous sodium bicarbonate and the resulting solid collected by vacuum filtration.

   The residue was purified by chromatography on silica eluting with 2% methanol in chloroform, then concentrated   (lmm    Hg pressure). Then triturated with either to yield a yellow powder with was dried under high vacuum for 48 h at   50 C    (100 mg)
LCMS-m/z 550, mp =   195-197 C.   



  . Example 69
EMI111.1     
   4- [4- ( {l- [6-Fluoro-8- (4-methyl-piperazin-l-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-amino)-    phenyl]-piperazine-l-carboxylic acid tert-butyl ester.



   This compound was prepared from 6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4Hchromene-2-carboxylic acid hydrochloride (Reference Example 3) and   4- (4-Amino-phenyl)-    piperazine-l-carboxylic acid tert-butyl ester (Reference Example 17) according to the method of Example 42 to yield (1.65 grams, 64%) of a yellow powder LCMS-m/z = 556;   mp =      219-220 C.   



  Example 70
EMI111.2     
   4- [4- (11- [6-Fluoro-8- (4-niethyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4  piperazin-1-yl-phenyl)-amide.   



   This compound was prepared from   4- [4- (f 1- [6-Fluoro-8- (4-methyl-piperazin- 1-yl)-4-       oxo-4H-chromen-2-yl]-methanoyl}-amino)-phenyl]-piperazine-1-carboxylic acid tert-butyl    ester, as prepared in Example 69, using the method of Example 43 to yield a yellow solid
LCMS-m/z   = 466.   



  Example 71
EMI112.1     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (4-ethane      sulfohyl-piperazin-1-yl)-phenyl]-amide.   



     4- [4- ( { 1- [6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-piperazin-1-yl-phenyl)-amide ditrifluoroacetate (the free acid of which was prepared as in
Example 70) (4.0 grams, 5.77 mmol) was placed in a flask with 50 mL   of CH2C12    and triethylamine (3.2 mL and 23 mmol) and ethylsulfonyl chloride was added (0.6 mL, 6.35 mmol) portionwise (0.1 mL at a time)   over 15    minutes and allowed to stir at room temperature for 20 hours. The reaction was concentrated (1 mm Hg pressure) and then saturated aqueous sodium bicarbonate was added and extracted with CHC13.

   The organic fractions were combined, washed with saturated sodium chloride, dried   (MgSO4)    concentrated   (1    mm Hg pressure) to give a yellow solid which was recrystallized from methanol to give 1.33 grams of product LCMS-m/z = 558, mp =   233-234 C.   



  Example 72
EMI112.2     
   6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-propionyl-    piperazin-1-yl)-phenyl]-amide.



      4- [4- ( { 1- [6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid      (4-piperazin-1-yl-phenyl)-amide    ditrifluoroacetate (the free acid of which was prepared as in 
Example 70) (0.69 grams, 1,00 mmol) was placed in a flask with 25 mL   of CH2C12    and triethylamine (0.56 mL and 4 mmol) and propionyl chloride was added (0.95 mL, 1.1 mmol) and the reaction allowed to stir at room temperature for 20 hours. The residue was purified by chromatography on silica eluting with 2% methanol in chloroform, then concentrated   (lmm   
Hg pressure).

   The residue was triturated with either then digested with   CHC13    and the CHC13 concentrated to yield a yellow powder which was dried under high vacuum for 48 h at   45 C    (260 mg)   LCMS-m/z =    522.



  Example 73
EMI113.1     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid {4- [4- (3hydroxy-propanoyl)-piperazin-1-yl]-phenyl}-amide.   



   This compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-    chromene-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide and   p-propionylactone    using the method described above in Example 68 to yield 65 mg of a yellow powder   LCMS-m/z =    538,   mp = 195-199 C.   



  The following exemplifies   a.    substituted chromene-2-"reverse amide" (or substituted chromene-2-yl-benzamide).



  Example 74
EMI113.2     
   N- [8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-4-morpholin-4-yl-benzamide.   



   8- (4-Methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride
Reference Example 1 (227 mg, 0.69 mmol), triethylamine (2 equivalents, 1.389 mmol, 0.193 mL) and diphenylphosphoryl azide (0.69 mmol, 0.15 mL) were stirred in toluene (10 mL) at   65 C    for 30 minutes. The reaction was allowed to cool to   22 C    and   4-morpholinobenzonoic    acid (0.7 mmol, 145 mg), more triethylamine (0.051 mL, 0.7mmol), and CH3CN   (5    mL) were added and the reaction heated to reflux for 1 hour. The reaction was concentrated   (1    mm Hg pressure) the residue was partitioned between 1N   methanesufonic    acid and ether.

   The acid layer was then basified with solid   K2C03    and the product extracted in to   CHC13.    The organic layer was dried   (MgS04)    and concentrated under reduced pressure to leave a yellow solid which was further purified with silica chromatography using CHC13 to 4% CH30H in   CHC13.   



  Concentration of the fractions containing product yielded 13 mg of product LC/MS-m/z = 449.



   Enantiomers of   8- (4-Methyl-piperazin-1-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide.



  Example 75
EMI114.1     
   racemic-8- (4-Methyl-piperazin-1-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)amide.    racemic-8- (4-Methyl-1-piperazin-1-yl)-chroman-2-carboxylic    acid hydrochloride (Example 75a) (1.04 mmol) was dissolved in anhydrous   N, N-dimethylformamide    (40 ml) and the following were added in order: HOBt (0.17 g, 1.14 mmol), TBTU (0.37 g, 1.14 mmol) then triethylamine (0.6 ml, 4.2 mmol). After stirring for 5 min at room temperature,   4- (4-    morpholinyl) aniline (reference example 20) (0.185 g, 1.14 mmol) was added and the reaction stirred overnight at room temperature.



   The solution was concentrated in vacuo, the remains were partitioned between chloroform/ saturated sodium bicarbonate, extracted (x3) with chloroform, dried   (MgS04)    and concentrated in vacuo to give the crude product.



  The crude product was chromatographed on a Waters Delta Prep 4000 using 1 PrepPak cartridge (Porasil   37-55. m 125A)    eluting with 2.5 %   methanol/chloroform.    The product was collected to give a yellow oil. Ethyl acetate was added to the oil. The solution was refluxed then cooled the yellow solid was filtered to give 55 mg (12% yield) of racemic-8- (4  methyl-piperazin-l-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide (mp   215-216  C).    The mother liquor contained 76 mg that was used in the chiral separation described below. LC/MS   (M+1) m/z = 437.   



  Example 75a   racemic-8- (4-Methyl-1-piperazin-1-yl)-chroman-2-carboxylic    acid hydrochloride.



   Ethyl,   8- (4-methyl-1-piperazin-1-yl)-4-oxo-4H-chromen-2-carboxylate    (Reference
Example 1) (0.74 g, 2.3 mmol) was dissolved in glacial acetic acid (50 ml) and 10 % palladium on carbon (80 mg) was added. The mixture was hydrogenated on a Paar apparatus (50 psi) at   70  C    for 3 h. Then, concentrated   HC1    and 10 % palladium on carbon (100 mg) were added and the mixture was again subjected to hydrogenation (50 psi) at   70  C    for   lh.   



  The reaction was allowed to cool, the catalyst was filtered and the solution was concentrated in vacuo. Toluene was repeatedly added and the solution concentrated to give racemic-8- (4  Methyl-1-piperazin-l-yl)-chroman-2-carboxylic    acid hydrochloride as a foam that was used without further purification in the next reaction. LC/MS (M+1) m/z = 277.



  Example 76
EMI115.1     

   (+)-8- (4-Methyl-piperazin-1-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)amide.



   The enantiomers   of racemic-8- (4-Methyl-piperazin-1-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide (Example 75) (0.52 g, 1.19 mmol) were separated by the use of a chiral column (ChiralPak AD, 5 cm X 50 cm,   20      u).    The faster (+) isomer (example 76) was eluted with 45 % isopropanol/hexane and the slower (-) isomer (example 77) was eluted with 75 % isopropanol/hexane.



   The faster (+) isomer (example 76) was obtained as a white solid (250 mg, mp 206207    C,    aD + 92.66 in dichloromethane). LC/MS (M+1) m/z = 437. 



  Example 77
EMI116.1     
   (-)-8- (4-Methyl-piperazin-1-yl)-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide.



   The enantiomers   of racemic-8- (4-Methyl-piperazin-l-yl)-chroman-2-carboxylic    acid   (4-rriorpholin-4-yl-phenyl)-amide    (Example 75) (0.52 g, 1.19 mmol) were separated by the use of a chiral column (ChiralPak AD, 5 cm X 50 cm,   20      je.).    The faster (+) isomer (example 76) was eluted with 45 %   isopropanol/hexane and    the slower (-) isomer (example 77) was eluted with 75 % isopropanol/hexane.



   The slower (-) isomer (example 77) was obtained as obtained as a light purple solid (260 mg, mp 205.5-207    C,      aD-91.    08 in dichloromethane). LC/MS   (M+. 1)    m/z =   437.   



   Enantiomers of   8- (4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide.



  Example 78
EMI116.2     

   racemic-8- (4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic    acid (4-morpholin-4-ylphenyl)-amide.



   Racemic-8- (4-methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-carboxylic acid hydrochloride (Example 78a) (1.04 mmol) was dissolved in anhydrous   N, N-    dimethylformamide (40 ml) and the following were added in order: HOBt (0.17 g, 1.14 mmol), TBTU (0.37 g, 1.14 mmol) then triethylamine (0.6 ml,   4.    2 mmol). After stirring for 5 min at room temperature,   4- (4-morpholinyl) aniline    (reference example 20) (0.185 g, 1.14 mmol) was added and the reaction stirred overnight at room temperature. 



   The solution was concentrated in vacuo, the remains were partitioned between chloroform/ saturated sodium bicarbonate, extracted (x3) with chloroform, dried (MgSO4) and concentrated in vacuo to give the crude product.



   The crude product was chromatographed on a Waters Delta Prep 4000 using 1
PrepPak cartridge (Porasil   37-SS. m 125)    eluting with 2.5 %   methanol/chloroform.    The product was collected to give a yellow oil. Ethyl acetate was added to the oil. The solution was refluxed then cooled the yellow solid was filtered to give 55 mg   (12%    yield) of racemic  8- (4-methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)amide (mp 215-216    C).    The mother liquor contained 76 mg that was used in the chiral separation described below. LC/MS   (M+1)      m/z = 451.   



  Example 78a   racemic-8- (4-Methyl-l-piperazin-l-yl)- 4-oxo-chroman-2-carboxylic    acid hydrochloride.    racemic-Ethyl-8- (4-methyl-1-piperazinyl)- 4-oxo-chroman-2-carboxylate    (Example 78b) (0.33 g, 1.04 mmol) was dissolved in 6 M HCl (20 ml) and heated, to   100  C    for 1.5 h.



  The reaction was allowed to cool. The solution was concentrated in vacuo and anhydrous toluene was added (x3) and the solution was again concentrated in vacuo to give racemic-8  (4-Methyl-l-piperazin-l-yl)-4-oxo-chroman-2-carboxylic    acid hydrochloride as a yellow foam (0.44 g, quantitative yield) that was used as is in the next reaction. LC/MS (M+1) m/z   = 291.   



  Example 78b    racemic-Ethyl-8-(4-m thyl-1-piperazin-1-yl)-4-oxo-chroman-2-carboxylate.



   Racemic-Ethyl-8- (4-methyl-1-piperazin-1-yl)-4-hydroxy-chroman-2-carboxylate    (Example 78c) (0.43 g, 1.3 mmol) was dissolve in anhydrous dichloromethane (35 ml) and manganese dioxide (1.2 g, 13 mmol) was added. The reaction stirred at room temperature overnight.



   The reaction was filtered through diatomaceous earth and the solvent was removed in vacuo to give racemic-Ethyl-8-(4-methyl-1-piperazin-1-yl)- 4-oxo-chroman-2-carboxylate as a white solid (0.37 g, 86 % yield) that was used as is in the next reaction. GC/MS   (EI,    M+)   m/z = 318.   



  Example   78c    racemic-Ethyl-8-(4-methyl-1-piperazin-l-yl)-4-hydroxy-chroman-2-carboxylate.



   Ethyl   8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chroman-2-carboxylate    (reference example 1) (0.48 g, 1.5 mmol) was dissolved in glacial acetic acid (50 ml) and 10 % palladium on carbon (100 mg) was added. The mixture was hydrogenated on a Paar apparatus (50 psi) at   70  C    for 3 h.



   The reaction was allowed to cool, the catalyst was filtered and the solution was concentrated   in vacuo.    Ethyl acetate/saturated sodium bicarbonate was added to the remains and the mixture was extracted (x3) with ethyl acetate, dried   (MgS04)    and stripped to give   racemic-Ethyl-8- (4-methyl-1-piperazin-1-yl)- 4-hydroxy-chroman-2-carboxylate    (0.43 g, 90 % yield) as a yellow oil. GC/MS   (EI,    M+) m/z = 320.



  Example 79
EMI118.1     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic    acid   (4-morpholin-4-yl-phenyl)-    amide (faster running isomer).



   The enantiomers of the racemic-8-   (4-methyl-piperazin-1-yl)-4-oxo-chroman-2-    carboxylic acid (4-morpholin-4-yl-phenyl)-amide (Example 78) (100 mg, 0.22 mmol) were separated by the use of a chiral column (ChiralPak AD, 5 cm X 50 cm, 20   R).    The isomers were eluted with a gradient of 35-55 %   isopropanol/hexane.    The faster isomer was obtained as a light yellow solid (40 mg, mp   216  C    dec.)   LC/MS (M+l)    m/z =   451.   



  Example 80
EMI118.2     
   8- (4-Methyl-piperazin-1-yl)-4-oxo-chroman-2-carboxylic    acid (4-morpholin-4-yl-phenyl)amide (slower running isomer).



   The   enantiomers    of the   racemic-8- (4-methyl-piperazin-1-yl)-4-oxo-chroman-2-    carboxylic acid (4-morpholin-4-yl-phenyl)-amide (100 mg, 0.22 mmol) were separated by the use of a chiral column (ChiralPak AD, 5 cm X 50 cm,   20      jl).    The isomers were eluted with a gradient of 35-55 % isopropanol/hexane. The slower isomer was obtained as an off white solid   (32 mg,    mp   215  C    dec.)   LC/MS      (M+1)      m/z = 451.   



  Example 81
EMI119.1     
   4- [4- ( { 1- [6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromen-2-yl]-methanoyl}-amino)-    phenyl]-piperazine-l-carboxylic acid ethylamide: 6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-piperazin-1yl-phenyl)-amide (Example 71) (150 mg, 0.216 mmol) was placed in a 50 mL flask with 10 mL   of CH2C12.    This suspension was treated with triethylamine (0.1 mL, 0.67 mmol) and   ethylisocyanate    (0.21 mL, 18.7 mg, 0.26 mmol) and the reaction stirred at room temperature for 18 hours. The reaction was concentrated   (1    mm Hg pressure) and the concentrate purified by chromatography on silica eluting with   1 %    methanol in chloroform, then concentrated (lmm Hg pressure).

   Then triturated with either to yield a yellow powder with was dried under high vacuum for   48.    h at   50 C    (79 mg) LCMS-AP+ 537.4, mp =   236-238 C.   



  Example 82
EMI119.2     
   6-Methoxy-8- (4-methyl- [1,    4]   diazepan-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4morpholin-4-yl-phenyl)-amide:
Into a 100 mL round bottom flask equipped with a nitrogen inlet and magnetic stirrer is added 327 mg (0.89 mmol, 1.0 equiv.)   of 6-Methoxy-8- (4-methyl- [1,    4] diazepan-1-yl)-4  oxo-4H-chromene-2-carboxylic    acid hydrochloride salt (Reference Example 23). This material is dissolved in 20 mL of DMF and then 189 mg (1.06 mmol, 1.2 equiv.)   of 4-    morpholinoaniline is added.

   To the stirred solution is quickly added simultaneously added 568 mg (1.77 mmol, 2.0 equiv.) of TBTU and 239 mg (1.77 mmol, 2.0   equiv.) of HOBT.    At this point 457 mg, 577   tL    (25.2 mmol, 4.0 equiv.) is added via syringe over 5 minutes. The reaction is allowed to stir at room temperature for 18 hrs, then is concentrated on a rotary evaporator under high vacuum in order to remove the DMF. The residue is triturated with methanol and the crude solids are recovered by filtration. These residues are then purified by flash chromatography using a gradient of 5-10% methanol in methylene chloride as eluent.



  The eluted material, which is obtained from chromatography, is concentrated, dried under high vacuum, suspended in methylene chloride, dried over   K2CO3,    concentrated, then crystallized from methanol to give the free base of the pure product as 345 mg (79%) of a yellow solid. Mass Spec.: calc. for   [C27H32FN405+H]      +    Theor. m/z = 393; Obs. = 393
Example 83
EMI120.1     
   6-Ethoxy-8-   (4-methyl-piperazin-1-yl)-4-oxo-4g-chromene-2-carboxylic acid (4-morpholin-4yl-phenyl)-amide:
Into a 100 mL flask equipped with a nitrogen inlet and magnetic stirrer is placed 133 mg (. 748 mmol, 1.1 equiv.) of 4-morpholinoaniline, which is then dissolved in 20 mL of methylene chloride.

   To this mixture is then added 290 mg,   367 gel    (2.24 mmol, 3.3 equiv.) of ethyldiisopropyl amine, followed by addition of a solution of 250 mg (0.68 mmol, 1.0 equiv.) of   6-ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carbonyl    chloride (Reference
Example 23) which has been dissolved in 10 ml of methylene chloride. The reaction is allowed to stir for 4 hr, after which no further formation of product was seen by   LC/MS.    The crude reaction was concentrated on a rotary evaporator, then triturated with 10 mL of methanol. The crude solids were collected by filtration, then subjected to flash chromatography using a gradient of from 2 to 20% methanol in methylene chloride. 



  Recrystallization from methylene chloride and hexanes afforded 55 mg (16%) of the pure product as a yellow solid.



  Mass Spec.: calc. for   [C27H32N405+H]    + Theor. m/z = 493 ; Obs. = 493
Example 84
EMI121.1     
   6-Ethoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid   [4- (4-propionyl-      piperazin-1-yl)-phenyl]-amide    :
This compound was prepared from 250 mg (0.68 mmol, 1.0 equiv.) of 6-Ethoxy-8- (4  methyl-piperazin-l-yl)-4-oxo-4H-chromene-2-carbonyl    chloride (Reference Example 23) and 175 mg (0.748 mmol,   1.      1    equiv.) of   1- [4- (4-Amino-phenyl)-piperazin-1-yl]-propan-l-one    by an analogous procedure to that used to prepare the 4-morpholino aniline derivative, to give 45 mg (12%) of the desired product as a yellow solid.



  Mass Spec.: calc. for   [C3oH37N505+H]    + Theor. m/z = 548; Obs. = 548
Example 85
EMI121.2     
   6-Methoxy-4-oxo-8-piperazin-1-yl-4H-chromene-2-carboxylic    acid (4-morpholin-4-ylphenyl)-amide:
Into a 50 mL round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is placed 50 mg (0.115 mmol, 1.0 equiv.)   of 6-Methoxy-8- (4-methyl-      piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide (Example   31)    and 10 mL of   1,    2 dichloroethane.

   To this solution is then added via syringe 49 mg,   37 FL    (0.345 mmol, 3.0 equiv.) of   1-chloroethyl      chloroformate.    A precipitate forms, indicating formation of an intermediate. The reaction is heated to reflux for 3 days, whereupon an analysis of an aliquot by LC/MS indicates only a trace of product has formed.



  At this time 52 mg (0.345 mmol, 3.0 equiv.) of sodium iodide are added to the refluxing reaction. LC/MS analyses then progressively show formation of demethylated product over 5 additional days. The reaction is then cooled, concentrated on a rotary evaporator, then dried over   K2CO3    as a suspension in methylene chloride containing methanol, removal of solids by filtration, followed by flash chromatography of the solution, using a gradient of 5   to 20%    methanol in methylene chloride, gives 34 mg (64%) of the pure product as a reddish solid.



  Mass Spec.: calc. for   [C25H2gN4o5+H]    + Theor. m/z = 465; Obs. = 465
 Example 86
EMI122.1     
   6-Hydroxy-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid (4-morpholin4-yl-phenyl)-amide:
Into a 50 mL round bottom flask equipped with a reflux condenser, nitrogen inlet and magnetic stirrer is placed 50 mg (0.115 mmol, 1.0 equiv.)   of 6-Methoxy-8- (4-methyl-      piperazin-1-yl)-4-oxo-4H-clmomene-2-carboxylic    acid (4-morpholin-4-yl-phenyl)-amide (Example   31)    and 20 mL of methylene chloride. To this solution is added 1 mL of a 1N solution of boron tribromide in methylene chloride. The reaction is stirred at room temperature for 2.5 days at which time it is complete by LC/MS.

   The reaction is concentrated on a rotary evaporator, then methanol is added. The methanol is concentrated and readded 5 times, until the   BBr3    is removed as HBr and trimethyl borate. The solid hydrobromide salt residue, which is obtained, is  > 85% pure product by LC/MS. Mass Spec.: calc. for   [C2sH2SN4os+H]    + Theor. m/z = 465; obs. = 465 
Example 87 (Method 1)
EMI123.1     
   6-Methoxy-8- (4-methyl- [1,    4] diazepan-1-yl)-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   To a solution   of6-methoxy-8- (4-methyl- [l, 4] diazepan-l-yl)-4-oxo-l,    4-dihydro  quinoline-2-carboxylic    acid (2.10 mmol) (Reference Example 25b) and diisopropylethyl amine (1.4 mL, 8.6 mmol) in 34 mL dimethylformamide was added TBTU (1.40 g, 4.36 mmol) and HOBt (0.588 g, 4.35 mmol) followed by the addition of 4-morpholinoaniline (0.463 g, 2.60 mmol). The resulting dark brown solution was stirred at room temperature under nitrogen for 19 hours. The reaction was concentrated in vacuo and the resulting crude product was taken up in methylene chloride/methanol. Filtration of the resulting mixture afforded some product as a yellow solid. The filtrates were concentrated and partitioned between methylene chloride and saturated aqueous sodium bicarbonate.

   The organic layer was washed with saturated sodium bicarbonate, dried   (MgS04),    and concentrated under vacuum to afford a brown solid. This was suspended in methanol and filtered to afford the desired product as a yellow solid (0.714   g,      69%).'H    NMR (300 MHz, DMSO,   d6)    8 9.97 (bs,   1    H,   NID,    7.67 (d, 2 H, Jo= 8.8 Hz, ArH2' &  H6'), 7.47 (bs, 1 H,   ArH5),    7.00 (s, 1 H,   C=CH),    6.99 (d, 2 H,   Jo=    8.8 Hz,   ArH  &  H),    6.71 (bs, 1 H,   Ar¯7),    3.85 (s, 3 H,   OCH),    3.75 (t, 4 H,
J= 4.6 Hz, OCH2CH2N), 3.70 (bs, 2 H, ArNCH2CH2CH2NCH3), 3.55 (bs, 2 H,
ArNCH2CH2NCH3), 3.09 (t,

   4 H,   J= 4.    6 Hz, OCH2CH2N), 2.95 (bs, 2 H,
ArNCH2CH2NCH3), 2.73 (bs, 2 H,   ArNCH2CH2CH2NCH3),    2.36 (s, 3 H, NCH3), 2.07 (bs, 2
H   ArNCH2CH2CH2NCH3)    ; Mass Spec.: calc. for   [C27H33N504+H]    + Theor. m/z = 492; Obs.



  492. 



  Example 87 (Method 2)
EMI124.1     
   6-Methoxy-8- (4-methyl- [1,    4]   diazepan-1-yl)-4-oxo-1,    4-dihydro-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   A solution of   6-methoxy-8- (4-methyl- [1,    4]   diazepan-1-yl)-4- (2-trimethylsilanyl-      ethoxymethoxy)-quinoline-2-carboxylic    acid   (4-morpholin-4-yl-phenyl)-amide    (Reference
Example 27d) (0.989 g, 1.59 mmol) in 20 mL methanol was poured into 300 mL 0.05 N hydrochloric acid. The clear dark yellow solution became cloudy within 5 minutes. The mixture was stirred at room temperature for 45 minutes and then adjusted to pH 7 with 10% sodium hydroxide.

   The resulting yellow precipitate was isolated by filtration, washed with water, and dried under high vacuum to afford the desired product as a yellow solid (0.629 g, 80%). 1H NMR (300 MHz, DMSO, d6) 8 9.97 (bs, 1 H, C (O)   NH),    7.67 (d, 2 H, Jo=   8. 8    Hz,
ArH2' &  H6'), 7.47 (bs,   1    H,   ArH5),    7.00 (s,   1    H, C=CH), 6.99 (d, 2 H, Jo=   8.    8 Hz,   ArH3,  &       Hs),      6.    71 (bs, 1 H,   ArH7),    3.85 (s, 3   H,    OCH3), 3.75 (t, 4 H,   J= 4.    6 Hz,   OCH2CH2N),    3.70 (bs, 2 H, ArNCH2CH2CH2NCH3), 3.55 (bs, 2 H, ArNCH2CH2NCH3), 3.09 (t, 4 H, J= 4.

   6 Hz,   OCH2CH2N),    2.95 (bs, 2 H, ArNCH2CH2NCH3), 2.73 (bs, 2 H,   ArNCH2CH2CH2NCH3),    2.36 (s, 3 H,   NCH3),    2.07 (bs, 2 H   ArNCH2CH2CH2NCH3)    ; Mass Spec.: calc. for   [C27H33N504+H]''Theor. m/z    = 492; Obs.   = 492.    Analysis for   C27H33N504. 1. 0eqHCl.   



  0.3eqH20: Calculated C 60.79 H 6.54 N   13. 13.    Found C 60.82 H 6.53 N 13.17.



  Example 88
EMI124.2     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-1, 4-dihydro-quinoline-2-carboxylic    acid (4morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from 8-bromo-6-methoxy-4- (2-trimethylsilanyl  ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 1).   A    yellow solid was obtained. Mass Spec.: calc. for   [C26H31N504+H]    + Theor. m/z = 478; Obs.



  478.



  Example 89
EMI125.1     
   6-Methoxy-8- (4-methyl-piperazin-1-yl)-4-oxo-1,    4-dihydro-quinoline-2-carboxylic acid [4- (4  propionyl-piperazin-1-yl)-phenyl]-amide.   



   The title compound was prepared from   8-bromo-6-methoxy-4- (2-trimethylsilanyl-    ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 1), except that the amide was formed from   1- [4- (4-amino-phenyl)-piperazin-1-yl]-propan-1-one.    A yellow solid was obtained. Mass Spec.: calc. for   [C29H36N604+H] + Theor. m/z    = 533; Obs.



  533.



  Example 90
EMI125.2     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-1, 4-dihydro-quinoline-2-carboxylic acid    (4morpholin-4-yl-phenyl)-amide 
The title compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-      1,      4-dihydro-quinoline-2-carboxylic    acid hydrochloride salt (Reference Example 26) using the procedure described in Example 87 (Method 1). After chromatography, it is then crystallized from methanol to give the pure product as 150 mg (55%) of a yellow solid. Mass Spec.: calc. for   [C2sH28FN503+H]''Thcor. m/z    = 466 ; Obs. = 466.



  Example 91
EMI126.1     
   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-1,    4-dihydro-quinoline-2-carboxylic acid [4- (4propionyl-piperazin-1-yl)-phenyl]-amide.



   The title compound was prepared from   6-Fluoro-8- (4-methyl-piperazin-1-yl)-4-oxo-      1,    4-dihydro-quinoline-2-carboxylic acid hydrochloride salt (200 mg, 0.59 mmol) (Reference
Example 26) using the procedure described in Example 87 (Method 1). 31% yield. Mass
Spec.: calc. for   [C2sH33FN603+H] + Theor.    m/z = 521; Obs. = 521.



  Example 92
EMI126.2     
 8-[(2-Dimethylamino-ethyl)-methyl-amino]-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from   8-bromo-6-methoxy-4- (2-trimethylsilanyl-    ethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 2), using N, N, N'-trimethyl ethylenediamine for the Pd catalysed coupling. A yellow solid was obtained. Mass Spec.: calc. for   [C26H33N504+H] + Theor.    m/z = 480; Obs. = 480.



  Example 93
EMI127.1     
   8- [ (3-Dimethylamino-propyl)-methyl-amino]-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2-    carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from 8-bromo-6-methoxy-4- (2-trimethylsilanylethoxymethoxy)-quinoline-2-carboxylic acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 2), using N, N,   N'-trimethyl-1, 3-propanediamine    for the Pd catalysed coupling. A yellow solid was obtained. Mass Spec.: calc. for [C27H35N504+H] + Theor. m/z = 494; Obs. = 494.



  Example   94   
EMI127.2     
   8- ( (3R)- (+)-3-Dimethylamino-pyrrolidin-1-yl)-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2-    carboxylic acid   (4-morpholin-4-yl-phenyl)-amide.   



   The title compound was prepared from   8-bromo-6-methoxy-4- (2-trimethylsilanyl-      ethoxymethoxy)-quinoline-2-carboxylic    acid methyl (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example   87    (Method 2), using   (3R)- (+)-3- (dimethylamino)    pyrrolidine for the Pd catalysed coupling. A yellow solid was obtained. Mass Spec.: calc.   for [C27H33N504+H] +    Theor. m/z = 492; Obs. = 492. 



  Example 95
EMI128.1     
 8- ( (3S)- (-)-3-Dimethylamino-pyrrolidin-1-yl)-6-methoxy-4-oxo-1, 4-dihydro-quinoline-2carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from   8-bromo-6-methoxy-4- (2-trimethylsilanyl-      ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 2), using (3S)-(-)-3-(dimethylamino) pyrrolidine for the Pd catalysed coupling. A yellow solid was obtained. Mass Spec.: calc. for   [C27H33N504+H]      +    Theor. m/z = 492; Obs. = 492.



  Example 96
EMI128.2     
   6-Methoxy-8-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-4-oxo-1,4-dihydro-quinoline-2-    carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from 8-bromo-6-methoxy-4- (2-trimethylsilanyl  ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 2), using
N,   N'-dimethyl-3-aminopyrrolidine    for the Pd catalysed coupling. A yellow solid was obtained. Mass Spec.: calc. for   [Ci7H33N504+H] + Theor.    m/z = 492; Obs. = 492. 



  Example 97
EMI129.1     
   8-[Ethyl-(1-ethyl-pyrrolidin-3-yl)-amino]-6-methoxy-4-oxo-1,4-dihydro-quinoline-2-    carboxylic acid (4-morpholin-4-yl-phenyl)-amide.



   The title compound was prepared from 8-bromo-6-methoxy-4- (2-trimethylsilanyl  ethoxymethoxy)-quinoline-2-carboxylic    acid methyl ester (Reference Example 24c) according to the procedures described in Reference Example 25a and in Example 87 (Method 2), using   3-diethylaminopyrrolidine    for the Pd catalyzed coupling. A yellow solid was obtained. Mass
Spec.: calc. for   [C29H37N504+H]    + Theor. m/z = 520; Obs. = 520.



  Example 98
EMI129.2     
 4-Dimethylamino-6-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-carboxylic acid (4morpholin-4-yl-phenyl)-amide.



   To a suspension of 8-bromo-4-dimethylamino-6-methoxy-quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide (Reference Example 28b) (139.9 mg, 0.288 mmol), Nmethylpiperazine (48   iL,    0.43 mmol), and   4 A    sieves in 15 mL anhydrous toluene was added   Pd2    (dba) 2 (15.3 mg, 16.7   j-Lmol), BINAP    (63.0 mg, 0.101 mmol) and cesium carbonate (0.436 g, 1.345 mmol). The resulting wine colored mixture was heated at reflux under nitrogen for 20 hours. The reaction mixture was cooled to room temperature and concentrated.

   The crude mixture was purified by flash chromatography on silica gel using a gradient of 100: 0 to 95: 5 methylene chloride : methanol to afford the desired product as a yellow solid (96.9 mg,   67%).'H    NMR (300 MHz, DMSO, d6)   8    10.06 (s,   1    H, C (O) NH), 7.69 (d, 2 H, Jo= 9.0 Hz, ArH2' &  H6'), 7.58 (s, 1 H, ArH3), 7.58 (d, 2 H, Jo=9.0 Hz, ArH3' &  H5'),   6.      95      (d,    1 H, Jm= 2.7 Hz, ArH5), 6.76 (d, 1 H, Jm= 2.7 Hz, ArH7), 3.90 (s, 3 H, OCH3), 3.75 (t, 4 H, J= 4.8 Hz, OCH2CH2N), 3.

   37 (bs, 4 H,   ArNCH2CH2N),    3.10 (t, 4 H,   J= 4.    8 Hz,   OCH2CH2N),    3.01 (s, 6 H, N   (CH3)    2), 2.71 (bs, 4 H,   ArNCH2CH2N),    2.35 (s, 3 H,   R2NCH3)    ;
Mass Spec.: calc. for   [C2gH36N603+H]    + Theor.   milz = 505    ; Obs. = 505.5.



  Example 99
EMI130.1     
   6-Methoxy-4-methylamino-8- (4-methyl-piperazin-1-yl)-quinoline-2-carboxylic    acid (4  morpholin-4-yl-phenyl)-amide.   



   The title compound was prepared from   8-brormo-6-methoxy-4-oxo-1,    4-dihydroquinoline-2-carboxylic acid (Reference Example 27b) according to the procedure described for Example 98 using N-methyl amine to prepare 8-bromo-4-methylamino-6-methoxyquinoline-2-carboxylic acid   (4-molpholin-4-yl-phenyl)-amide.    A glassy orange solid was obtained. Mass Spec.: calc. for   [C27H34N603+H]    + Theor. m/z = 491; Obs. = 491.5.



  Example 100
EMI130.2     
   6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-quinoline-2-carboxylic    acid (4-morpholin-4  yl-phenyl)-amide.   



   Into a 250 mL round bottom flask equipped with a nitrogen inlet and magnetic stirrer is added 2. 01 g (6.3 mmol, 1.0 equiv.)   of 6-Fluoro-4-methoxy-8- (4-methyl-piperazin-1-yl)-    quinoline-2-carboxylic acid hydrochloride salt.. This material is dissolved in 20 mL   of DMF    and then 1.35 g (7.56 mmol, 1.2 equiv.) of 4-morpholinoaniline is added. To the stirred solution is quickly added simultaneously added 4.05g   (12.    6 mmol, 2.0 equiv.) of TBTU (2  (lH-benzotriazole-1-yl)-1,      1,    3,3tetramethyluroniumtetrafluoroborate) and 1.7 g (12.6 mmol, 2.0 equiv.) of HOBT (1-hydroxybenzotriaole hydrate). At this point 3.25 g, 4.11 mL (25.2 mmol, 4.0 equiv.) is added via syringe over 5 minutes.

   The reaction is allowed to stir at room temperature for 18 hrs, then is concentrated on a rotary evaporator under high vacuum   in.    order to remove the DMF. The residue is triturated with methanol and the crude solids are recovered by filtration. The material is then dissolved in methylene chloride and extracted with 10% sodium bicarbonate solution. The organic layer is dried and then concentrated.



  These residues are then purified by flash chromatography using a gradient of 5-10% methanol in methylene chloride as eluent. The material which is obtained from chromatography, is then crystallized from methanol to give the pure product as 2.83g (93%) of a yellow solid.



  Mass Spec.: calc. for   [C26H30FN503+H]    + Theor. m/z = 480; Obs. = 480
Example 101   6-Fluoro-4-oxo-8-piperazin-1-yl-4H-chromene-2-carboxylic    acid (4-morpholin-4-yl-phenyl)amide : made according to the general method of Howarth et. al. Tetrahedron, 1998,54, 10899-10914.



  Dry   6-flouro-8- (4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic    acid [4- (4  propionyl-piperazin-l-yl)-phenyl]-amide    (Example 72) (1 g 1.9 mmol) was added to 100 mL of rigorously dried   1,      2-dichloroethane    in a flask under N2 atmosphere and magnetic stirring.



  The mixture was cooled to   O6G    and freshly distilled   1-chloroethyl      chloroformate    (650 ul, 858 mg, 6 mmol, 3 eq) was added drop wise. The reaction was then heated under reflux for 5 hours at which time LC/MS revealed complete consumption of starting material. NaI   (lg,      leq)    was added and heating continued for 2 days more. The reaction was then allowed to cool and filtered and evaporated to dryness under reduced pressure.   MeOH    (100 mL) was added and heated to reflux for 4h, filtered hot and evaporated to dryness. The product was isolated by chromatography using silica gel and CHC13/5%   MeOH    as an eluent. This gave 700 mg of the product   HC1    salt as a yellow solid.

   LCMS-m/z = 508.

Claims

CLAIMS We claim: 1. A compound represented by the formula (I) : EMI132.1 wherein R'is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, thiomethoxy,-NHA,-NA2,-NHC (=O) A, aminocarbonyl, C (=O) NHA,-C (=O) NA2, halogen, hydroxy,-OA, cyano or aryl; A is optionally substituted allcyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl ; R2 is represented by (i), (ii), (iii), or (iv) below:
EMI132.2 R3 is independently at each position represented by-H, optionally substituted Cl 6alkyl, optionally substituted C2 6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-6cycloalkyl or AOH; n is 2, 3 or 4 ; a heterocyclic ring; R6 is-H or methyl ; Y is-C (=O) NH-,-C (=O) NA-,-C (=O) N (A)-,-NHC (=O)-,-C (=S) NH-,-CH2NH-,-C (=O) -C (=O) CH2-,-CH2C (=O)-,-C (=O)-piperazine-,,-NAC (=O)-,-C (=S) N (A)-, CH2NA, NACH2 or a 5-membered heterocyclic.
R7 is a monocyclic or bicyclic aromatic ring or a heterocycle optionally substituted by one or more substituents selected from R8-R9 and Rl ; wherein R7 is connected to Y either by a single bond or by a ring fusion; R8 is-CH2-,-C (=O)-,-S02-,-S02NH-,-C (=O) NH-,-0-,-S-,-S (=O)-, a single bond as tether from R to R, 5-membered heterocycle connected to R7 by a ring fusion or a single bond as tether;
R9 optionally substituted heterocycle, optionally substituted aryl, optionally substituted piperazinyl-Rl 1, optionally substituted morpholinyl-Rl 1, optionally substituted thiomorpholinyl, or-C (=O) A; Rl is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen,-C (=O) NH2-, methylthio,-NHA,-NA2,-NHC (=O) A, C (=O) NHA, C (=O) NA2, or OA; R"is-H, alkyl, AOH,-S02A,-S02NH2,-S02NHA,-S02NA2,-SO2NHAR9,-C (=O) R9, -alkyl9, C (=O) A, C (=O) NH2, C (=O) NHA, C (=O) NA2 or-C (=O) OA; or a pharmaceutically acceptable salt of said compound.
2. A compound recited in claim 1 for use in the treatment of migraine in a human or animal in need of such therapy.
3. A method of treatment of a human or animal suffering from migraine by administering to such animal an effective amount of a compound of Formula I or a pharmaceutically acceptable salt of said compound.
4. The use of the compound recited in claim 1 in the preparation of a medicament for the treatment of migraine.
5. A pharmaceutical composition comprising a compound as recited in Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
6. A compound of the Formula (VIe) : EMI134.1 Vle wherein Rl is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy,-NHA,-NA2,-NHC (=O) A, aminocarbonyl,-C (=O) NHA,-C (=O) NA2, halogen, hydroxy,-OA, cyano or aryl ; A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl ; R2 is represented by (i), (ii), (iii), or (iv) below: EMI134.2 and X is represented by O ; or a pharmaceutically acceptable salt of said compound.
7. The compound of Formula (VIfl) : EMI135.1 wherein R'is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy,-NHA,-NA2,-NHC (=O) A, aminocarbonyl,-C (=O) NHA,-C (=O) NA2, halogen, hydroxy,-OA, cyano or aryl; A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl ; R2 is represented by (i), (ii), (iii), or (iv) below: EMI135.2 and X is represented by 0, S, or N, or a pharmaceutically acceptable salt thereof.
8. A compound of Formula (VIgl) EMI135.3 wherein RI is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy,-NHA,-NA2,-NHC (=O) A, aminocarbonyl,-C (=O) NHA,-C (=O) NA2, halogen, hydroxy,-OA, cyano or aryl; A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl ; L represents a leaving group.
R2 is represented by (i), (ii), (iii), or (iv) below: EMI136.1 and X is represented by O ; or a pharmaceutically acceptable salt of said compound.
9. A compound of Formula (VIh) EMI136.2 VIh1 wherein R'is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy,-NHA,-NA2,-NHC (=O) A, aminocarbonyl,-C (=O) NHA,-C (=O) NA2, halogen, hydroxy,-OA, cyano or aryl; A is optionally substituted allcyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl; R2 is represented by (i), (ii), (iii), or (iv) below: EMI137.1 and X is represented by O ; or a pharmaceutically acceptable salt of said compound.
10. A process for preparing a compound of Formula (VIe) as recited in Claims 6 comprising reacting a compound of Formula (VId) : EMI137.2 <SEP> 0 <tb> <SEP> 0 <tb> <SEP> EX <tb> <SEP> il <tb> R, <SEP> I <SEP> 1: <SEP> x <SEP> I. <SEP> OR" <tb> <SEP> Halogen <SEP> O <tb> via with HR2 in the presence of a catalyst and a base.
11. A process for preparing a compound of Formula (VIfl) as recited in Claim 7 comprising heating a compound a of Formula (VIe) as recited in Claim 6 in the presence of an acid and water to form a mixture wherein the mixture is hydrogenated using a catalyst.
12. The process as recited in Claim 11 wherein the catalyst is palladium.
13. A process for preparing a compound of Formula (VIgl) as recited in Claim 8 comprising replacing the hydroxyl group of the carboxyl ate moiety of Formula (Vig) with a leaving group.
14. A process for preparing a compound of Formula (VIhl) as recited in Claim 9 comprising reacting a compound of (VIfl) as recited in Claim 7 with H2R7n wherein R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted by one or more substituents selected from R8-R9 and Rl ; wherein R7 is connected to Y either by a single bond or by a ring fusion; R8 is-CH2-,-C (=O)-,-SO2-,-SO2NH-,-C (=O) NH-,-O-,-S-,-S (=O)-, a five membered heterocyclic connected to R7 by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected from A, thiomorpholine, piperazin-RI 1, optionally substituted aryl, optionally substituted heterocyclic, or-C (=O) CA; Rl is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen,-C (=O) NH2-, methylthio,-NHA,-NA2,-NHC (=O) A,-C (=O) NHA,-C (=O) NA2, or OA; R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9, -alkyl9, C (=O) A, C (=O) NH2, C (=O) NHA, C (=O) NA2 or-C (=O) OA.
15. A process for preparing a compound of Formula (VIhl) as recited in Claim 9 comprising reacting a compound of Formula (VIgl) with H2R7 wherein R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted by one or more substituents selected from R8-R9 and R10 ; wherein R is connected to Y either by a single bond or by a ring fusion; R8 is -CH2-, -C (=O)-,-SO2-,-SO2NH-,-C (=O) NH-,-O-,-S-,-S (=O)-, a five membered heterocyclic connected to R by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected from A, thiomorpholine, piperazin-Ri, optionally substituted aryl, optionally substituted heterocyclic, or-C (=O) CA; Rl is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen,-C (=O) NH2-, methylthio, -NHA, -NA2, -NHC (=O) A,-C (=O) NHA,-C (=O) NA2, or OA; R"is-H, alkyl, AOH,-SO2A,-SO2NH2,-SO2NHA,-S02NA2,-SO2NHAR9,-C (=O) R9, -alkyl9, C (=O) A, C (=O) NH2, C (=O) NHA, C (=O) NA2 or-C (=O) OA.
EP02715919A 2001-01-16 2002-01-15 Therapeutic chroman compounds Withdrawn EP1353915A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26210801P 2001-01-16 2001-01-16
US262108P 2001-01-16
SE0103646 2001-11-01
SE0103646A SE0103646D0 (en) 2001-11-01 2001-11-01 Therapeutic chroman compounds
PCT/SE2002/000070 WO2002055014A2 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds

Publications (1)

Publication Number Publication Date
EP1353915A2 true EP1353915A2 (en) 2003-10-22

Family

ID=26655581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02715919A Withdrawn EP1353915A2 (en) 2001-01-16 2002-01-15 Therapeutic chroman compounds

Country Status (15)

Country Link
EP (1) EP1353915A2 (en)
JP (1) JP4280068B2 (en)
KR (1) KR20030070917A (en)
CN (1) CN100384833C (en)
AR (1) AR036327A1 (en)
AU (1) AU2002225551B8 (en)
BR (1) BR0206514A (en)
CA (1) CA2434015A1 (en)
IL (3) IL156601A0 (en)
MX (1) MXPA03006261A (en)
MY (1) MY138263A (en)
NO (1) NO20033205L (en)
NZ (1) NZ526699A (en)
SA (1) SA02220709B1 (en)
WO (1) WO2002055014A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530716B2 (en) 2008-08-14 2013-09-10 Bp Corporation North America Inc. Melt-crystallization separation and purification process
US8962906B2 (en) 2006-03-21 2015-02-24 Bp Corporation North America Inc. Apparatus and process for the separation of solids and liquids

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739132D1 (en) 1996-08-08 2009-01-08 Hitachi Chemical Co Ltd Graphite particles and lithium secondary cell in which they are used as a material of the negative electrode
SE0103649D0 (en) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515483A (en) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives for the treatment of stearoyl coa desaturase mediated diseases
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083992A (en) 2004-09-20 2007-12-05 泽农医药公司 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
BRPI0611187A2 (en) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
UY29892A1 (en) * 2005-11-04 2007-06-29 Astrazeneca Ab NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
AR059356A1 (en) * 2006-02-14 2008-03-26 Astrazeneca Ab NEW RADIOLIGANDS
WO2007097697A1 (en) * 2006-02-23 2007-08-30 Astrazeneca Ab Therapeutic quinoline compounds that are 5ht1b modulators
HUP0900281A2 (en) * 2009-05-05 2011-01-28 Univ Szegedi Kynurenc acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use for the treatment of headache
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
CN104262249A (en) * 2014-10-20 2015-01-07 云南民族大学 Environmental-friendly and efficient preparation method of quinolone compound
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
JP6997197B2 (en) 2017-01-23 2022-01-17 カデント セラピューティクス，インコーポレーテッド Potassium channel modulator
BR112021007552A2 (en) 2018-10-22 2021-07-27 Cadent Therapeutics, Inc. crystal forms of potassium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8515389D0 (en) * 1985-06-18 1985-07-17 Ici Plc Heterocyclic compounds
US5112856A (en) * 1986-08-15 1992-05-12 Hoffmann-La Roche Inc. Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
SE8904361D0 (en) * 1989-12-22 1989-12-22 Astra Ab NEW CHROMAN AND THIOCHROMAN DERIVATIVES
DE4140542A1 (en) * 1991-12-09 1993-06-17 Bayer Ag PIPERDYLMETHYL SUBSTITUTED CHORMANDERIVATE
FR2761358B1 (en) * 1997-03-27 1999-05-07 Adir NOVEL N-ARYL PIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE9703378D0 (en) * 1997-09-18 1997-09-18 Astra Ab New compounds
FR2782515B1 (en) * 1998-08-21 2000-09-22 Adir NEW INDANE-1-Ol DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02055014A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962906B2 (en) 2006-03-21 2015-02-24 Bp Corporation North America Inc. Apparatus and process for the separation of solids and liquids
US8530716B2 (en) 2008-08-14 2013-09-10 Bp Corporation North America Inc. Melt-crystallization separation and purification process

Also Published As

Publication number Publication date
IL156601A (en) 2009-06-15
AU2002225551B2 (en) 2008-04-03
CA2434015A1 (en) 2002-07-18
WO2002055014A3 (en) 2002-11-14
KR20030070917A (en) 2003-09-02
BR0206514A (en) 2004-01-06
MXPA03006261A (en) 2003-09-22
IL156601A0 (en) 2004-01-04
JP4280068B2 (en) 2009-06-17
JP2004517130A (en) 2004-06-10
AR036327A1 (en) 2004-09-01
NZ526699A (en) 2005-03-24
AU2002225551B8 (en) 2008-05-29
NO20033205D0 (en) 2003-07-15
IL183183A0 (en) 2007-08-19
SA02220709B1 (en) 2007-01-23
WO2002055014A2 (en) 2002-07-18
CN100384833C (en) 2008-04-30
MY138263A (en) 2009-05-29
NO20033205L (en) 2003-09-02
CN1524077A (en) 2004-08-25

Similar Documents

Publication Publication Date Title
AU2002217742B2 (en) Therapeutic heterocyclic compounds
AU2002217742A1 (en) Therapeutic heterocyclic compounds
AU2002225551B2 (en) Therapeutic chroman compounds
AU2002225551A1 (en) Therapeutic chroman compounds
US20050085457A1 (en) Therapeutic quinolone compounds with 5-ht-antagonistic properties
EP1353914A2 (en) Therapeutic chromone compounds
US20050096312A1 (en) Therapeutic quinolone compounds with 5-ht-antagonistic properties
US20040110745A1 (en) Therapeutic chroman compounds
AU2002219770A1 (en) Therapeutic chromone compounds
US20040082591A1 (en) Therapeutic heterocyclic compounds
US20060019947A1 (en) Therapeutic chromone compounds
NZ545374A (en) Process for the production of therapeutic heterocyclic compounds
AU2002348559A1 (en) Therapeutic quinolone compounds with 5-HT-antagonistic properties
AU2002348560A1 (en) Therapeutic quinoline compounds with 5-HT-antagonistic properties

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059933

Country of ref document: HK

17Q First examination report despatched

Effective date: 20060324

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120207

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1059933

Country of ref document: HK